Exploring the relevance and extent of small airways dysfunction in asthma (ATLANTIS):baseline data from a prospective cohort study by  et al.
  
 University of Groningen
Exploring the relevance and extent of small airways dysfunction in asthma (ATLANTIS)
ATLANTIS study group; Postma, Dirkje S; Brightling, Chris; Baldi, Simonetta; Van den Berge,
Maarten; Fabbri, Leonardo M; Gagnatelli, Alessandra; Papi, Alberto; Van der Molen, Thys;
Rabe, Klaus F
Published in:
The Lancet. Respiratory Medicine
DOI:
10.1016/S2213-2600(19)30049-9
IMPORTANT NOTE: You are advised to consult the publisher's version (publisher's PDF) if you wish to cite from
it. Please check the document version below.
Document Version
Final author's version (accepted by publisher, after peer review)
Publication date:
2019
Link to publication in University of Groningen/UMCG research database
Citation for published version (APA):
ATLANTIS study group, Postma, D. S., Brightling, C., Baldi, S., Van den Berge, M., Fabbri, L. M., ... Kraft,
M. (2019). Exploring the relevance and extent of small airways dysfunction in asthma (ATLANTIS):
baseline data from a prospective cohort study. The Lancet. Respiratory Medicine, 7(5), 402-416.
https://doi.org/10.1016/S2213-2600(19)30049-9
Copyright
Other than for strictly personal use, it is not permitted to download or to forward/distribute the text or part of it without the consent of the
author(s) and/or copyright holder(s), unless the work is under an open content license (like Creative Commons).
Take-down policy
If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately
and investigate your claim.
Downloaded from the University of Groningen/UMCG research database (Pure): http://www.rug.nl/research/portal. For technical reasons the
number of authors shown on this cover page is limited to 10 maximum.
Download date: 21-05-2020
                             Elsevier Editorial System(tm) for The Lancet 
Respiratory Medicine 
                                  Manuscript Draft 
 
 
Manuscript Number: THELANCETRM-D-18-00605R3 
 
Title: Exploring the relevance and extent of small airways dysfunction in 
asthma: AssessmenT of smalL Airways involvemeNT In aSthma, the ATLANTIS 
study  
 
Article Type: Article (Original Research) 
 
Keywords: Asthma, small airways disfunction, asthma severity, control, 
quality of life, and exacerbations 
 
Corresponding Author: Dr. Dirkje Postma, Ph.D. 
 
Corresponding Author's Institution: University of Groningen, University 
Medical Center Groningen 
 
First Author: Dirkje Postma, Ph.D. 
 
Order of Authors: Dirkje Postma, Ph.D.; Chris Brightling; Simonetta 
Baldi; Maarten van den Berge; Leonardo Fabbri; Alessandra Gagnatelli; 
Alberto Papi; Thys van der Molen; Klaus Rabe; Salman Siddiqui; Dave 
Singh; Gabriele Nicolini; Monica Kraft 
 
Manuscript Region of Origin: NETHERLANDS 
 
Abstract: Background  
Small airways dysfunction (SAD) is well-recognized in asthma, yet its 
role in severity and control is unclear.  
Methods 
This multinational observational study investigated participants without 
and with asthma (GINA 1-5). They underwent spirometry, body 
plethysmography, impulse oscillometry (IOS), Multiple Breath Nitrogen 
Washout (MBNW), computed tomography (CT) and questionnaires. Structural 
equation modeling in asthma, applied to the physiological and CT 
parameters, defined a clinical-SAD and CT-SAD score. Asthma subjects were 
classified in SAD groups using model-based clustering. Asthma severity, 
control and health care utilization in the past year were compared with 
the SAD scores and SAD groups.  
Findings  
We investigated 773 asthma and 99 control participants (median 
[interquartiles] age 46 [34, 54] and 41 [29, 52] years, 58% and 57% 
females, respectively). All physiologic measures contributed to the 
clinical SAD model; SAD prevalence was dependent on the measure used. IOS 
and spirometry contributed most to the Clinical-SAD score and SAD Groups. 
Clinical-SAD Group1 (n=452) had comparable MBNW Sacin values with 
controls. Group2 (n=312) had more abnormal physiologic SAD measures than 
Group1, particularly IOS and spirometry, and more severe asthma (asthma 
control, treatments, exacerbations, quality of life).  Clinical-SAD 
scores were higher in Group2 and related to asthma control, severity, and 
exacerbations. Clinical-SAD and CT-SAD scores did not significantly 
correlate.  
Interpretation 
SAD has multiple components, is present across all asthma severity and 
particularly in severe disease. The clinical classification of SAD, by 
the easy-to-conduct measures IOS and spirometry, is meaningful given its 
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Small airways dysfunction (SAD) is well-recognized in asthma, yet its role in asthma severity and 
asthma control is unclear. Our study aimed to assess which (combination of) biomarkers, 
physiological testing and imaging markers best measures the presence and extent of SAD in asthma. 
Methods 
This multinational observational study investigated participants without and with asthma (GINA 
severity stage 1-5). Asthma inclusion criteria were: 1) age 18-65 years; 2) clinical asthma diagnosis  
> 6 months, confirmed by a chest physician 2, supported by objective evidence of any of the 
following at the baseline visit or in the previous 5 years: a) positive airway hyperresponsiveness to 
methacholine, or b) positive reversibility (ΔFEV1≥ 12% and ≥ 200 mL within 30 minutes after 400 
μg of salbutamol pMDI with or without a spacer or c) PEF variability >20%, measured during 7 
days or d) documented reversibility after a cycle (e.g. 4 weeks) of maintenance anti-asthma 
treatment; 3) stable asthma on any previous regular asthma treatment (“rescue” β2-agonists alone 
included) at a stable dose for > 8 weeks before baseline; 4) lifetime smoking ≤ 10 pack-years. They 
underwent spirometry, body plethysmography, impulse oscillometry (IOS), Multiple Breath 
Nitrogen Washout (MBNW), computed tomography (CT) and questionnaires. Structural equation 
modeling (SEM) was applied in asthma to assess the contribution of all physiological and CT 
parameters to SAD. With SEM, we  defined a clinical-SAD and CT-SAD score. Asthma subjects 
were classified in SAD groups using model-based clustering. Asthma severity, control and health 
care utilization in the past year were compared with the SAD scores and SAD groups.  
Findings  
We investigated 773 asthma and 99 control participants (median [interquartiles] age 46 [34, 54] and 
41 [29, 52] years, 58% and 57% females, respectively). All physiologic measures contributed to the 
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clinical SAD model with SEM analysis. The prevalence of SAD in asthma was dependent on the 
measure used and lowest with MBNW Sacin that reflects ventilation heterogeneity in the most 
peripheral, pre-acinar/acinar airways. IOS and spirometry, reflecting dysfunction of small-to-mid-
sized airways, contributed most to the Clinical-SAD score and differentiated the two SAD Groups. 
Clinical-SAD Group1 (n=452) had “milder“ SAD, i.e. comparable MBNW Sacin with controls. 
Group2 (n=312) had more abnormal physiologic SAD measures than Group1, particularly IOS and 
spirometry, and more severe asthma (asthma control, treatments, exacerbations, quality of life). 
Clinical-SAD scores were higher in Group2 (“more severe” SAD) and related to asthma control, 
severity, and exacerbations. Clinical-SAD and CT-SAD scores did not significantly correlate.  
Interpretation 
SAD is a complex and silent signature of asthma, which is likely to be directly or indirectly 
captured  by combinations of physiologic tests: spirometry, body plethysmography, IOS, and 
MBNW. SAD is present across all asthma severity and particularly in severe disease. The clinical 
classification of SAD in two groups, i.e. a “milder” and “more severe” SAD group, by the easy-to-
conduct measures IOS and spirometry, is meaningful given its association with GINA asthma 
severity stages, asthma control, quality of life, and exacerbations. The longitudinal part of 
ATLANTIS will show the relevance of the SAD score for future risks in asthma, and additionally 
which parameter best associates with future asthma control. Moreover, we will report on 
development of a Small Airways Dysfunction Tool (SADT), a questionnaire as an easy measure to 
suggest SAD, and on the measures of inflammation that best discriminate between the large and 
small airways’ compartments, with bronchial and transbronchial biopsies, in a smaller subset of 
participants. 
 




Research in context 
Evidence before this study 
We searched PubMed for studies in asthma, including the terms asthma, adult, and small airways, 
and published between database inception and April 2018, using spirometry and any combination of 
body plethysmography, impulse oscillometry (IOS; including R5-R20 values) and Multiple Breath 
Nitrogen Washout (MBNW) measures, and similar terms in addition to CT scans. Small airways 
dysfunction (SAD) has been understudied, though it significantly contributes to airway obstruction, 
a hallmark of asthma. So far, studies on the role of SAD in asthma have been performed in small 
sample sizes and/or subgroups of asthma. Moreover, these studies investigated only a subset of 
available potential measurements of SAD and did not include both spirometry, body 
plethysmography, IOS, MBNW, CT scans and questionnaires.  
Added value of this study 
This is the largest study to date involving 773 evaluable asthma patients and 99 controls without 
airway obstruction specifically designed to determine the prevalence and impact of small airways 
dysfunction SAD in asthma. The study shows that SAD is present in asthma across all stages of 
severity, with highest prevalence in GINA 5. We were able to define a SAD score from a 
combination of lung function measurements that reflects the amount of physiological small airways 
impairment in asthma. The score associated significantly with measures of asthma control, history 
of exacerbations and disease severity. Model-based clustering delineated two clinical SAD groups 
that differed in age, duration of asthma, and disease severity. Of interest, values of Sacin, that 
measures ventilation heterogeneity in pre-acinar/acinar airways, were in the normal range in 
Group1. The difference between Clinical SAD Group1 and Group2 was particularly clear with 
clinically available SAD measurements, such as IOS and spirometry, followed by FEV1, while 
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differences were small with CT SAD parameters. In summary, we can cluster asthma patients in two 
subgroups based on SAD measured with easy-to-conduct, clinically applicable measures.  
 
Implications of all the available evidence 
Small airways dysfunction (SAD) has been understudied in asthma. Our results show the clinical 
relevance of SAD, which is present across all severity stages of asthma. It is particularly present in 
severe disease, likely reflecting structural lung changes that are not responsive to the use of oral 
corticosteroids and/or high dose inhaled corticosteroids. Moreover, SAD relates to asthma stability, 
severity, quality of life, exacerbation rates and health care utilization and can be delineated by easy-
to-conduct, clinically applicable measures such as IOS and spirometry. Therefore, this aspect of 




Asthma is a prevalent obstructive airway disease that affects the entire bronchial tree. The small 
airways, defined by a diameter <2 mm and referred to as the “silent zone” of the lungs, contribute to 
the resistance in the airways of patients with obstructive airways disease
1
. This is of clinical 
importance since small airways can be inflamed in asthma and hence narrowed
2-4
. Small airway 
narrowing can also occur due to smooth muscle contraction after inhaling allergic and non-allergic 




Small airways dysfunction (SAD) has been postulated to exist at all severities of asthma, whereas some 
studies suggest that the prevalence increases with asthma severity 6,1. However, it is not clear what 
proportion of asthma patients suffers from SAD, and which tests or combination of tests best defines it. 
Lack of best practice is due to the fact that published studies investigating the small airways in asthma 
included only small-sized and/or relatively homogeneous populations regarding asthma severity, or only 
tested one or a few physiologic SAD measures 6-8.  The ATLANTIS (AssessmenT of smalL Airways 
involvemeNT In aSthma) study is a multinational 1-year prospective cohort study, including people with 
asthma of all severities and controls without airway disease. In this paper we present the baseline, cross-
sectional data from ATLANTIS, aiming to identify which combination of biomarkers, physiologic testing and 
imaging approaches best measures the presence and extent of SAD in asthma, and their relationship with 
features of asthma. We assess SAD through a series of all available, clinically applicable, potential SAD tests, 
both for physiological and CT measures. The physiological tests may reflect abnormalities in different parts 
of the bronchial tree or different aspects of small airways dysfunction, providing different perspectives on 
SAD9,10. Lung imaging by CT scan can provide additional insight regarding SAD, but the relationship with 
physiologic measures of SAD in asthma has not been studied extensively and only in small groups; here we 
test both physiological and CT scan measures in a large cohort. 
In addition, we develop a score defining to what extent SAD is present in each individual patient and assess 
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its usefulness for prediction of asthma severity, control, quality of life and history of exacerbations. In 
future papers (not presented here), we will report the longitudinal data from ATLANTIS and aim to validate 
the SAD score over time, we will develop and validate a Small Airways Dysfunction Tool (SADT), a 
questionnaire as an easy measure to suggest SAD, and we will assess which direct and indirect measures of 
inflammation best discriminate between the large and small airways' compartments, with bronchial and 









Participants were recruited (first patient in June 30, 2014 and last patient out March 3, 2017)  from 
general practitioners, chest physician’s databases and by advertisements in 29 centers across 9 
countries worldwide. Inclusion criteria were: 1) age 18-65 years; 2) clinical asthma diagnosis  >6 
months, confirmed by a chest physician according to GINA 2012
11
 and supported by objective 
evidence of any of the following at the baseline visit or in the previous 5 years: a) positive airway 
hyperresponsiveness to methacholine, or b) positive reversibility, defined as ΔFEV1≥ 12% and ≥ 
200 mL over baseline FEV1 within 30 minutes after inhaling 400 μg of salbutamol pMDI with or 
without a spacer or c) Peak Expiratory Flow variability (i.e. highest - lowest value over the 
day/mean value of the two, ×100) >20%, measured during 7 days or d) documented reversibility 
after a cycle (e.g. 4 weeks) of maintenance anti-asthma treatment; 3) stable asthma on any previous 
regular asthma treatment (“rescue” β2-agonists alone included) at a stable dose for > 8 weeks before 
baseline; 4) lifetime smoking ≤ 10 pack-years. Main exclusion criteria were a COPD diagnosis 
confirmed by a chest physician and an asthma exacerbation during 8 weeks before baseline.  
Controls were included based on 1) age 18-65 years; 2) no respiratory symptoms compatible with 
asthma or COPD in the past 2 years; 3) normal spirometry: baseline FEV1≥ 80%predicted, 
FEV1/Forced Vital Capacity (FVC)> LLN (lower limit of normal); 4) normal airways 
responsiveness: PC20≥ 16 mg/mL, PD20≥ 1.4 mg; 5) lifetime smoking ≤ 10 pack-years. Diagnosed 
upper/lower respiratory tract diseases were exclusion criteria. The Medical Ethics Committee of 
each center approved the protocol; all patients gave written informed consent.  
Study design and procedures 
Participants were followed for 1 year with 6-month clinic and 3-month telephone follow-ups
9
. The 
clinical and CT tests were performed at 3-day baseline visits. The methods for spirometry, 
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hyperresponsiveness, MBNW, IOS, body plethysmography, CT, questionnaires, blood tests, and 
health care utilization are described in the Supplement. Medications during an eight-week period  
before evaluation were used to assess GINA severity
11
. The potential indices of SAD used with 
hypothetical location in the airways  and references between brackets are presented in Table 1 
12-19 
. 
These were  % fall in FVC during hyperresponsiveness testing; spirometry: Forced Expiratory Flow 
(FEF)25-75, FEF50, both corrected for FVC; body plethysmography: Residual Volume/Total Lung 
Capacity (RV/TLC), Functional Residual Capacity (FRC), IOS: R5-R20, AX, X5; MBNW: Scond, 
Sacin. Alveolar NO was not incorporated in this analysis since it was only available in a subset of 
participants (Supplement). Indices of “large airways dysfunction”, which may also capture small 
airways abnormalities, were FEV1%predicted, FEV1/FVC, IVC, FeNO, R20, PC20, PD20 and 3 
severity categories of airway hyperresponsiveness (Supplement).  
Computed tomography  
Volumetric whole lung scans were obtained at full inspiration (near total lung capacity) and at end 
of expiration, near FRC. Scans were analyzed by a single observer (SB) using semi-automated 
software, Apollo (VIDA Diagnostics, Iowa), with various quality control parameters
20,21
. The 
supplement describes CT acquisition, quantitative airway morphometry and lung densitometry. 
SAD parameters used (Table 1 
21,22
) were: ex- and inspiratory Mean Lung Density and their ratio 
(E/I MLD), ex- and inspiratory lung volume and their ratio (E/I LV), expiratory Voxel Index (VI-
856) and inspiratory VI-950 (% of Voxels with CT numbers <-856 and <-950 Hounsfield Units 
respectively, inspiratory Percentile15, Inspiratory median Lumen area, Wall area (WA) and Total 
area, these latter three divided by body surface area (BSA), inspiratory median percentage WA, and 
inspiratory Pi10 and Po20%WA (hypothetical airway with internal perimeter of 10 mm and outer 
perimeter of 20 mm respectively). 
Statistical analyses  
11 
 
Detailed statistical information, including power analysis
23
, is provided in the Supplement. The 
following variables reflecting SAD were used in the clinical SAD analysis: FEF50/FVC, FEF25-
75/FVC, FEV1%predicted, FEV1/FVC, IVC%predicted, % fall FVC at PC20 or PD20, RV/TLC 
%predicted, FRC%predicted, R5-R20, X5, AX, Scond, Sacin. For CT SAD analysis, variables 
were:  MLD ratio, Lung Volume ratio, VI-856, Pi10, Po20%WA. 
We used SEM analysis to assess clinical SAD, since this clarifies which SAD parameters, out of all 
the physiologic parameters measured, group together and weigh towards the presence of SAD in 
asthma (Supplement). Similarly we applied SEM analysis for CT SAD. Several steps were 
performed for clinical SAD and CT SAD SEM analysis separately
24
. A correlation matrix evaluated 
correlations among observed variables, high correlations indicating presence of underlying latent 
variables. An exploratory factor analysis for observed variables was performed to identify the 
underlying SAD factor structure. The final underlying SAD factor structure was tested by 
specifying a confirmatory factor model. Once the measurement model was set and fit the data 
properly, it was used to classify each patient into SAD groups, using model-based clustering. The 
SAD Groups and SAD scores from the clinical SAD and the CT-scan SAD model were compared, 
evaluating the rate of agreement, using Chi-square and Pearson’s correlation tests. The clinical SAD 
model was additionally tested in the subgroup with a CT scan, by adding the CT scan variables to 
the model. Full information maximum likelihood (FIML) method was used for dealing with missing 
data in SEM analysis
25
.  
Relationships of physiologic SAD variables with asthma severity, control and healthcare utilization  
were analyzed by Poisson regression. Continuous prediction equations, their lower- and upper limit 
of normal (LLN and ULN) from the literature
26 
and from formulas based on ATLANTIS controls 
are provided in Supplemental Table 1. Statistical analyses and data processing were performed 
using Statistical Analysis Systems (SAS®) Software (release 9.2) and Mplus Version 7.4 on a 
Windows 7 operating system. 
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The main reason for screening failure was not fulfilling inclusion/exclusion criteria (n=99, Figure 
1).  
Participants 
Baseline characteristics are shown in Table 2, Table 3 (asthma only) and Supplemental Table 2. 
Gender, age and smoking habits were comparable between asthma and control participants; the 
large majority of people included were of Caucasian descent (88% and 96% in asthma and control 
participants respectively). Asthma participants demonstrated higher BMI, heart rate, blood pressure, 
blood cell counts, and prevalence of atopy. Hyperresponsiveness was only present in asthma 
participants. All physiologic parameters were significantly worse in asthma. Asthma participants 
had lower MLD expiratory values, inspiratory airway lumen, wall, and total area, also when divided 
by BSA on CT. Asthma participants had a moderately severe health status impairment (Table 3) and 
lower lung-related quality of life (higher EuroQol-5Dim-5Levels score) than controls, median 
(Q1;Q3) being 95.0 (90.0;100.0) versus 80.0 (70.0;90.0). 
Association of physiologic parameters with asthma severity, control and health care 
utilization 
 X5, Scond, RV/TLC, R5-R20 and R5 values (Figure 2A) showed the highest positive correlations 
with GINA severity
11
. GINA severity was also associated, as expected, with lower FEV1, FEF50, 
and FEV1/FVC values. Table 4 shows that GINA5 had the highest SAD prevalence rate for every 
physiologic variable (measurements >ULN or <LLN). Sacin had the least SAD prevalence rate in 
all GINA stages, the lowest prevalence being with GINA1 (12%), rather similar, higher prevalences 
in GINA2-4 (18-19-20%), and highest in GINA5 (41%). This contrasts with other SAD variables, 
where prevalences either remain constant over the GINA stages (% fall FVC), continuously 
increase from GINA1-GINA5 (body plethysmography), or increase in steps, e.g. Scond and FEF25-
14 
 
75 showed lowest prevalences in GINA1-2, higher in GINA3-4 and highest in GINA5. R5-R20 and 
AX showed somewhat comparable rates in GINA1-3, higher in GINA4 and highest in GINA5 
(Table 4). Sacin also contrasted with <LLN prevalence distributions in FEV1, i.e. GINA1-GINA5 
26%-29%-36%-47%-72%. 
A lower Asthma Control Test (ACT) score was particularly associated with higher AX and R5 and 
lower FVC and FEV1 (Figure 2B).  
For exacerbations in the past year, highest positive correlations were with RV/TLC, R5-R20, AX 
and Sacin and highest negative correlations with FEV1, FVC, IVC, FEF25-75, FEF50 (Figure 2C). The 
number of exacerbations was independently predicted by SAD parameters from spirometry, IOS, 
body plethysmography, hyperresponsiveness severity, female gender and height (Table 5). There 
was also a negative association with Raw. Independent parameters for unscheduled consultation 
visits were FEV1, hyperinflation with body plethysmography, hyperresponsiveness severity, and 
female gender (Table 5). 
Prevalence of LAD and SAD in asthma 
Figure 3 (upper panel) shows the prevalence rates of large and small airways dysfunction, based on 
LLN and ULN. Sacin had the lowest SAD prevalence (19.2%), % fall FVC the highest (73.1%).  
SAD Model  
Figure 4 shows the final clinical SAD model based on cross-sectional data. It presents both the 
loadings to the three latent variables and the goodness of fit values (Supplemental methods), 
showing good coherence of this model to SAD. IOS parameters R5-R20, AX and X5 loaded to the 
first latent variable, FEF50 and FEF25-75 both corrected for FVC, to the second latent variable, while 
Sacin (MBNW) loaded both to the first and second latent variable. The lung volume parameter 
RV/TLC %predicted and Scond (MBNW) loaded to the third latent variable. Hyperresponsiveness 
was only tested at the first visit, hence could not be taken into account in the longitudinal design of 
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the SAD SEM model. Therefore, we also analyzed the clinical SAD model at baseline including 
hyperresponsiveness, and the % fall FVC loaded on the third latent variable without much change in 
goodness of fit values. The baseline model without and with % fall FVC correlated highly (r=0.99; 
Supplemental Figure 2A).  Since the cross-sectional SAD model with and without % fall FVC were 
almost identical, the model without % fall FVC was tested longitudinally; the same model structure 
was confirmed at all visits (Supplemental Figure 2B).  
Correlations of clinical SAD score with physiologic and clinical parameters  
A higher clinical SAD score reflects more severe SAD. The highest positive and negative 
correlations (r > 0.60 and r < -0.60) of the SAD score existed with physiologic parameters on which 
the score was based, i.e. IOS parameters AX, R5-R20, and R5 (positively) and X5, spirometric 
parameters FEF25-75 and FEF50 (negatively), next being FEV1 %predicted (Figure 5). The highest 
correlations of non-physiological parameters with the SAD score were duration of asthma, ACQ-6 
and number of exacerbations (positively), ACT, Mini AQLQ total and EQ-5D-5L (negatively). 
Clinical SAD scores increased with higher asthma severity, mean SAD score in GINA1-5 being -
0.143, -0.035, -0.048, +0.071 and +0.239 (ANOVA p <0.0001).  
Model-based clustering defined clinical SAD Groups 
Model-based clustering defined two clinical SAD groups, Group1 including 452 patients, Group2 
312 patients (Table 6 and Supplemental Table 3 present clinical characteristics). Overall, the 2 
clinical SAD Groups were similar regarding age of asthma onset, sex ratio, FeNO, atopy, and 
smoking habits, while duration of smoking was higher in Group2 (Table 6). Sacin values were 
comparable between Group1 and the controls, whereas Group2 had significantly higher values than 
both Group1 and controls. Clinical SAD Group2 was somewhat older, demonstrated higher blood 
pressure, heart rate and BMI, and a longer asthma duration. Additionally, Group2 had more severe 
asthma than Group1, according to GINA severity, ACT, ACQ, LABA/ICS use, 
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hyperresponsiveness, blood inflammation (eosinophils), quality of life and health care utilization. 
All physiologic parameters were worse in clinical SAD Group2; the two groups were best separated 
by SAD parameters from IOS followed by spirometry, and additionally FEV1 (Figure 3).  
CT scan factors in SAD 
CT scans were analyzed in 294 patients (with comparable asthma severity as the non-CT group, 
Supplemental Table 3). The SEM model provided three factors in CT that contributed to SAD: 
MLD inspiratory/expiratory ratio, Lung volume inspiratory/expiratory ratio and VI-856 
(Supplemental Figure 2D). The correlations of the CT SAD score with physiologic and clinical 
parameters, comparison of CT SAD groups, and additional Clinical SAD analysis in patients who 
had a CT scan are presented in the Supplement. 
Relationship between Clinical and CT SAD scores 
The Clinical SAD and CT SAD scores showed a significant, weak correlation (r=0.28). There was 







This large study shows the clinical relevance of small airway dysfunction for asthma, since SAD is 
present across all severities and particularly in more severe asthma. ATLANTIS was specifically 
designed to determine the prevalence and impact of SAD in asthma and has performed the most 
comprehensive evaluation of SAD to date using both physiological and imaging tools. We show 
that the prevalence of SAD depends on the physiologic measure used, i.e. localization and type of 
airway narrowing. Of importance, no single variable defines SAD, but IOS, MBNW, lung volumes 
and spirometry all contribute. For clinical practice, it is important to highlight that SAD associates 
with GINA severity and -independently- with history of exacerbations over time, particularly when 
measured by IOS, spirometry and body plethysmography. Moreover, the poorest asthma control 
was present in the group with the worst clinical SAD score.  
Of note, 91% of our asthma population expressed SAD, when defined as any abnormal physiologic 
parameter. This does not imply that patients Our data imply that they do have extensive SAD 
throughout all airway dimensions, since the prevalence varied with the type of physiologic measure. 
The lowest prevalence existed with Sacin (19%) and RV/TLC (22%), both reflecting dysfunction of 
the most peripheral small airways. The highest prevalence was with FEF25-75 (68%) and % fall FVC 
(73%), probably both reflecting obstruction in more small-to-mid-sized airways. Future work has to 
elucidate if these different prevalence rates define subtypes of SAD (consistent vs. variable, which 
level of airway is involved, and what percent of these airways are involved). We additionally 
compared our SAD prevalence with literature findings (Supplemental Table 7), yet no study 
compared all types of physiologic SAD methods. Anderson et al.
6
 used R5-R20 >0.03 kPa/L/s as 
cut-off for abnormality, concluding that abnormal R5-R20 values were present in all severities of 
asthma, i.e. 65% in British Thoracic Society step2, 64% in step3 and 70% in step4. Our overall 
prevalence with this cut-off was 70%; we extend their findings showing that prevalence rates of R5-
R20 >LLN  increase from GINA steps 1-5, being 54%, 65%, 70%, 77%, and 91% respectively. In 
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contrast, the prevalence of Sacin >LLN was lowest in GINA1, almost identical in GINA 2-4 and 
highest in GINA5, suggesting that mostly peripheral airway dysfunction, and likely structural 
changes, are present in most severe asthma. In summary, our data are comparable with published 
findings in smaller samples, yet expand these observations by providing information on all different 
SAD measurements at the same time in one group of asthma patients across all severities.  
Strengths of our study are the large group of asthma patients covering the full severity spectrum and 
the extensive work-up and quality and experience of the centers. ATLANTIS is a multi-center 
international study, therefore we feel our results are reliable and applicable to multiple populations. 
We also included smokers, a factor that by itself may induce some SAD. We felt it important that 
our study reflects the larger asthma and non-asthma population globally for generalizability, and 
thus not restricts the impact of our findings. The controls had comparable age, sex ratio and 
particularly smoking habits as the asthma population, which provided novel LLN and ULN values 
for physiological parameters infrequently studied, like IOS and MBNW. We acknowledge that a 
larger control group might have improved precision of these values, which will be partially 
overcome when we add the longitudinal data in the future.  
We recognize that a quality check of the maneuver to get optimal phase III slope in the MBNW 
test
27
 is key to validity of the measurements, which we have carefully ensured in the present study. 
The finding that some Sacin values were in the normal range does not contrast with the presence of 
airway dysfunction in Group1, as the body of the available literature on ventilation heterogeneity in 
adult asthma
21,28-34
 reveals a variable contribution of conducting versus acinar lung regions to 
treatment response, and consistency in the reversibility towards normal values after exacerbations
28
. 
Particularly, the persistent derangement of ventilation in conducting airways (Scond) seems more 
related to airway remodeling, exacerbations, and hyperresponsiveness, whereas the reversible 
derangement in acinar airway ventilation (Sacin) mainly reflects asthma severity
35
. Accordingly, the 
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worst clinical SAD score was present in the group with the poorest asthma control and higher 
prevalence in GINA 4 and 5. 
 
Another limitation is that CT scans were not available in all participants, limiting numbers for 
analyses. However, this allowed us to demonstrate that the clinical SAD model in the full asthma 
cohort could be replicated in the smaller group with CTs. Future work will expand our analyses by 
performing parametric response mapping (PRM)
36
, a CT voxel-based imaging biomarker tool to 
quantify 'functional small airways disease’. A potential limitation is that age was somewhat higher 
in the asthma than control participants, yet the difference  small  (median age (interquartile ranges) 
of 46 (34-54) vs 41 (29-52) years respectively) and likely not of clinical significance, and we 
adjusted for age in all analyses. We cannot put our clinical SAD score forward as a clinically 
applicable tool as yet, since this is a cross-sectional analysis. The score already significantly 
associates with number of exacerbations, asthma severity and control, and the longitudinal phase of 
the study will elucidate whether it also predicts future changes in these clinical outcomes. For the 
same reason we cannot put the “best parameters“ of SAD forward yet . Additionally, a Small 
Airways Dysfunction Tool (SADT) will be developed, a questionnaire as an easy measure to 
suggest SAD
9
, which may be easily applicable in the clinic as MBNW and body plethysmography 
are not available for all routine settings. Our article did not report on SAD with regard to the 
underlying pathology
9
. However, we will assess which direct and indirect measures of inflammation 
best discriminate between large and small airways’ compartments, with bronchial and 
transbronchial biopsies in a smaller subset of participants in the future.  
 
Large and small airways obstruction are important components of asthma pathophysiology
1-3
. Our 
focus is on the small airways and their specific impact upon asthma symptoms and exacerbations, 
an area of investigation that has been relatively neglected in our opinion (an overview of relatively 
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small-sized studies is presented in Supplemental Table 7). It would be of interest to analyze in the 
future subgroups with Large Airway Dysfunction (LAD) without SAD, or conversely, with SAD 
and without LAD. Finally, one would like to have a ‘gold standard’ for SAD, yet our study shows 
this is not feasible since many physiological parameters contribute to the SAD model. This likely 
reflects that they represent abnormalities in distinct parts of the bronchial tree and/or contrasting 
aspects of underlying mechanisms of SAD, thereby providing different information
9
.  
We were able to define a SAD score that reflects the amount of physiological small airways 
impairment and is significantly associated with asthma control, exacerbations and severity. We 
additionally observed two clinical SAD Groups that are comparable in e.g. gender, atopy, FeNO, 
ICS dose and smoking habits, while Group2 was somewhat older, had a longer asthma duration and 
more severe asthma according to all parameters tested. Interestingly, Sacin)
32
, which reflects 
dysfunction of the most peripheral small airways, was in the normal range in Group1 only and had a 
higher prevalence in Group2. The difference between the two clinical SAD groups was particularly 
clear with SAD measurements like IOS and spirometry (Figure 3). Clinical SAD Group 2 represents 
“more severe” SAD, given particularly the presence of more severe small-to-mid-sized airway 
obstruction (R5-R20, FEF25-75) and less airway distensibility (AX). In summary, we can detect 
asthma subtypes based on presence and extent of SAD measured with easy-to-conduct, clinically 
applicable tools.  
Similarly, with regard to the clinical SAD score, we developed a CT-SAD score. The CT-SAD 
score significantly associated with GINA severity, but less well than the clinical SAD score. CT 
SAD Group2 had more severe asthma and the physiologic parameters were significantly different 
from controls and from Group1. However, the CT SAD Groups had similar levels of small-to-mid-
sized airway obstruction (R5-R20) and conducting airway ventilation heterogeneity (Scond), 
reflective of dysfunction in small-medium size conducting airways, while Group2 had significantly 
higher air trapping (RV/TLC) and acinar airway ventilation heterogeneity (Sacin) values, reflective 
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of the most peripheral small airways. This suggests that CT scan-derived SAD captures regional 
differences in mechanisms of airway dysfunction due to air trapping as a surrogate for peripheral 
airways impairment. They become apparent in supine position, when airway closure and 
compliance reduction develop as consequence of severe hyperinflation and expiratory reserve 
volume reduction
37
 in more severe asthma. Notably, we observed a difference in airway 
distensibility (AX) in participants undergoing CT scan, in comparison to those who did not ( 
Supplemental Table 3). It is thus understandable that the Clinical SAD score and the CT SAD score 
were not concordant (r=0.28). Where CT scans (performed in supine position) provide information 
on SAD particularly by changes driven from increased residual static lung volumes and air 
trapping
38
, the physiologic parameters measured in the sitting position provide information on air 
trapping (body plethysmography RV/TLC), small airway obstruction (IOS and FEF25-75) and 
heterogeneity of both conducting and acinar airway ventilation (MBNW). This potentially explains 
why the CT SAD score, in contrast to the clinical SAD score, did not associate with health status or 
asthma control. 
 
Asthma control is lacking in 50-60% of patients despite guideline-based management
39
 and 
untreated SAD has been proposed as a contributing factor
1
. Drivers of asthma control include 
treatment adherence and appropriate use of inhalers, psychological factors and environmental 
trigger exposures. The current study suggests that asthma control is also determined by the presence 
of SAD, since ACT was significantly associated with the clinical SAD score and specifically 
abnormal in clinical SAD Group2 (most severe SAD). Moreover, a lower ACT score was associated 
with higher IOS parameters R5 and AX values. Hence asthma control may be partially driven by 
SAD, but also obstruction in larger airways given its association with FEV1, the gold standard for 




Of interest, asthma participants had higher blood pressure than our controls. We did not find 
literature reporting this observation. Comorbidities are thus not only present in COPD, another 
obstructive pulmonary disease 
40,41
, but also occur in asthma patients with a median age of 46 
(34;54) years. This is in agreement with previous studies indicating systemic inflammation as one 
underlying mechanism linking reduced lung function to cardiovascular mortality
42
 and a positive 
association between lower FEV1 and systemic arterial hypertension, while lower ICS doses 
attenuated the likelihood for hypertension in a population with comparable age to ours
43
. 
Alternatively, hyperinflation could have a role via its contribution to changes in intrathoracic 




In conclusion, our data in a large asthma population covering the full spectrum of asthma severity 
show the complexity of SAD. Notwithstanding this, the clinical classification of Small Airways 
Dysfunction is meaningful given its association with asthma severity, control and exacerbations. 
Results show that SAD can be present across all GINA severity stages. Depending on the type of 
physiologic parameter used, the prevalence rate changes considerably, but is consistently highest in 
GINA5. SAD prevalence rates were lowest with Sacin, reflecting pre-acinar/acinar airway 
abnormalities, and this prevalence was quite comparable over GINA2-4 but again highest in 
GINA5, suggesting structural abnormalities in severe asthma. In contrast, other physiologic 
parameters showed either increasing prevalence rates with severity (RV/TLC) or a stepwise 
increase (FEF25-75, R5-R20, AX, X5). Clinical SAD and CT SAD scores did not significantly 
correlate. SAD derived from the CT scan provides particularly data on air trapping and ventilation 
impairment in more peripheral airways, while the physiologic measures show results from both 
small-medium size conducting airways and peripheral airways. For clinical practice it is important 
that physiological, easy-to-conduct measures like IOS and spirometry, delineate two asthma SAD 
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Legend to Figure 2. Correlations are presented for GINA severity ( top panel), ACT score (middle panel), and Number 
of exacerbations in the past year (lowest panel). Darkest red is highest positive correlation between parameters. Darkest 
blue is the lowest negative correlation between parameters.  All abbreviations are presented in Table 1.  
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Figure 3. Prevalence rates of airways dysfunction in the full asthma cohort and in the 2 SAD subgroups  
  
 
Legend to Figure 3. Prevalence rates of Large Airways abnormalities, and Small Airways abnormalities in the full 
cohort of asthma participants (upper Figure), and according to Clinical SAD Group1 and Group2 (lower Figure).  
Prevalences are based on LLN (Lower Limit of Normal) and ULN (Upper Limit of Normal) values derived from the 
literature or from ATLANTIS controls without airway disease, noted with*. For abbreviations see Table 2. 
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Figure 4. Cross-Sectional Clinical SEM analyses of small airway function 
 
 
Legend to Figure 4. SAD=Small Airway Dysfunction.  
The figure shows the results of Structural Equation Modeling (SEM). The model uses the measured variables presented 
in squares to define the three latent variables (Lung1, Lung2 and Lung3). The strength of the relationship of each 
measured variable to the underlying factor is expressed by the factor loading, presented in the Figure in dashed squares. 
Moreover, the numbers that are not presented in squares are the measured variable variances. The variable SAD is then 
constructed by a structural model that imputes the relations between these three latent variables (Lung1 loading 0.617, 
Lung2 loading 0.518 and Lung3 loading 0.981). Thus SEM modeling  showed that SAD was built up by three latent 
variables, represented in circles ( Lung1 loading 0.617, Lung2 loading 0.518 and Lung3 loading 0.981). The measured 
variables are presented in squares . IOS parameters R5-R20, X5 and AX (reflecting small-to-mid-sized airway 
obstruction/distensibility) loaded to the first latent variable (Lung1), FEF50 and FEF25-75 both corrected for FVC 
(reflecting small-to-mid-sized airway obstruction), to the second latent variable, while MBNW parameter Sacin 
(reflecting dysfunction in the most peripheral airways) loaded both to the first and second latent variable. The lung 
volume parameter RV/TLC % predicted (most peripheral airways dysfunction) and MBNW parameter Scond 
(dysfunction in small-medium size conducting airways) loaded to the third latent variable (Lung3). Please Note that 
Sacin loaded equally with 0.285 and 0.291 to latent variable Lung1 and Lung2 respectively. Please Note that Sacin 
loaded equally with 0.285 and 0.291 to latent variable Lung1 and Lung2 respectively. The numbers on the right hand 
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side represent the variance of the measures, i.e. variance in AX is 0.009, contrasting with the variance in RV/TLC % 
predicted being 0.738.  Goodness of fit of the SEM model was evaluated through the following fit indices: Root Mean 
Square Error of Approximation (RMSEA), Comparative Fit Index (CFI), Tucker-Lewis Index (TLI).  The closer CFI 
and TLI are to 1 and the closer RMSEA is to 0 the better is the model fit. The goodness of fit values (Supplemental 
methods) show there is good coherence of this model to SAD. Fall in FVC during hyperresponsiveness testing 
contributed to the model when analyzed in the subgroup of asthmatic participants who had undergone 





Figure 5.  Correlations of the Clinical SAD score of asthma participants with all parameters measured
 
 






Table 1. Parameters of SAD as presented in the SEM analyses of the study and their hypothetical location  
Physiologic parameters Interpretation 
Spirometry  




FEF50 (corrected for FVC), L/s/L
 13
 
FEFs at 25-75% interval, or at 50% of expired lung volumes are 
measurements of airflow obstruction in small-to-mid-caliber 
airways taken at low/mid expiratory lung volumes. 
When corrected for FVC, they are surrogate measures of the 
sizes of small-to-mid caliber airways relative to lung size, called 
dysanapsis. Dysanapsis is a characteristic favoring airways 
hyperresponsiveness. 
Body plethysmography  
RV/TLC ratio, L/L 
14




 Respiratory system resting volume as main determinant of 




 Respiratory Resistance of small-to-mid-sized conductive and 
peripheral airways  
X5, kPa/L/s 
15
 Respiratory System Reactance reflecting inertance and elasticity 
(capacitance), including small peripheral airways 
AX, kPa/L 
15




-1   16
 Index of convectional ventilation heterogeneity in peripheral 
conducting airways 
Sacin*VT, L
-1   17
 Index of diffusive ventilation heterogeneity in most peripheral 
pre-acinar/acinar airways 
Hyperresponsiveness  
Fall in FVC at PC20 or PD20, %
18,19
 Air trapping due to excessive bronchoconstriction or closure of 
small airways 
CT scan parameters  
MLD ratio, E/I 
25
 Ratio of mean lung density for inspiratory versus expiratory 
scans- a measure of air-trapping due to lung parenchyma 
inspiratory distension in the supine position 




 Ratio of CT-derived lung volume for inspiratory versus 
expiratory scans- a measure of air-trapping due to obstruction in 




 The voxel index < -856 Hounsfield Units from the expiratory 
scans, an index of expiratory air trapping 
 Legend to Table 1. Numbers in superscript refer to references used. IOS= impulse oscillometry; MBNW= Multiple 






Table 2: Baseline clinical, physiologic and CT characteristics of asthma participants and controls without airway 
disease 
Parameter Asthma  Controls P - value 
    
  n=773 n=99   
Clinical characteristics    
Age, years 46 (34 ; 54) 41 (29 ; 52) 0.01 
Gender, female N (%) 450 (58) 56 (57) 0.75 
Heart rate, bpm 71 (65 ; 78) 68 (61 ; 75) 0.01 
BP syst, mmHg 123 (114 ; 131) 120 (110 ; 130) 0.01 
BP diast, mmHg  80 (70 ; 84) 75 (68 ; 83) 0.06 
BMI, kg/m
2
 26 (23 ; 30) 24 (21 ; 27) <0.001 
Atopy (Phadiatop), N (%) 454 (81) 39 (46) <0.001 
FeNO, ppb 25 (16 ; 38) 18 (11 ; 26) <0.001 
Ex-smoker, N (%) 156 (20) 19 (19) 0.39 
Current Smoker, N (%) 27 (4) 1(1)  
Eosinophils, 10⁹ /L 0.2 (0.1 ; 0.4) 0.1 (0.1 ; 0.2) <0.001 
Neutrophils, 10⁹ /L 3.7 (3.0 ; 4.7) 3.3 (2.7 ; 4.4) 0.01 
PC20, mg/mL 1.25 (0.4 ; 4.2) 15.23 (16.0 ; 16.0) <0.001 
PD20, mg 0.11 (0.0 ; 0.6) 1.86 (2.0 ; 2.0) <0.001 
Moderate-severe hyperresponsiveness, N (%) 271 (48.4) 0 (0.0) <0.001 
Fall in FVC, % 17 (12 ; 22) 4 (1 ; 8) <0.001 
Lung Physiology characteristics (%predicted)    
FEV1, %predicted 82.7 (69.9 ; 93.8) 100.4 (91.6 ; 107.3) <0.001 
Change FEV1, %predicted 7.6 (4.1 ; 12.7)   
FEV1/FVC, %predicted 85.8 (76.5 ; 93.9) 98.2 (93.8 ; 102.7) <0.001 
IVC, %predicted 99.0 (18.21) 109.7 (15.28) <0.001 
FEF50, %predicted 62.0 (43.2 ; 84.1) 102.0 (84.8 ; 117.3) <0.001 
FEF25-75, %predicted  56.6 (37.6 ; 75.6) 90.7 (75.6 ; 108.1) <0.001 
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RV, %predicted 117.1 (98.4 ; 138.9) 95.6 (87.0 ; 115.7) <0.001  
TLC, %predicted 104.9 (95.9 ; 115.5) 104.8 (96.7 ; 112.5) 0.62 
RV/TLC, %predicted 106.1 (91.6 ; 125.8) 92.5 (80.6 ; 109.6) <0.001 
FRC, %predicted 108.7 (93.4 ; 126.7) 107.6 (91.9 ; 121.4) 0.42 
Raw, %predicted 143.0 (91.4 ; 231.1) 77.6 (62.9 ; 99.5) <0.001 
sGaw, %predicted 60.5 (42.5 ; 94.7) 85.0 (61.3 ; 124.6) <0.001 
R20, %predicted 114.6 (97.4 ; 134.9) 96.5 (84.7 ; 110.2) <0.001 
R5-R20, %predicted 278.6 (91.2 ; 640.9) 69.5 (0.0 ; 161.7) <0.001 
X5, %predicted 130.4 (94.4 ; 184.7) 94.6 (77.6 ; 119.7) <0.001 
AX, %predicted 209.3 (95.0 ; 510.0) 66.1 (49.9 ; 108.0) <0.001 
Scond*VT, %predicted 180.5 (100.7 ; 305.3) 95.6 (44.8 ; 149.6) <0.001 
Sacin*VT, %predicted 107.2 (76.7 ; 154.8) 94.1 (61.6 ; 129.8) 0.01 
CT Scan characteristics    
MLD Inspiratory, HU -837.93 (-856.95 ; -811.97) -839.89 (-853.81 ; -812.76) 0.65 
MLD Ratio E/I  0.83 (0.77 ; 0.88) 0.80 (0.73 ; 0.87) 0.08 
VI-856 7.82 (2.5; 19.5) 7.83 (1.5; 15.5) 0.35 
Lung Volume Ratio 0.50 (0.43 ; 0.60) 0.47 (0.38 ; 0.56) 0.16 
Percentile 15 Inspiratory -921 (-935;-904) -929 (-940;-899) 0.46 
Median LA/BSA Inspiratory 10.4 (2.93) 11.4 (2.83) 0.03 
Median LA Inspiratory 19.0 (15.7 ; 23.3) 21.3 (18.5 ; 25.6) 0.01 
Pi10   Inspiratory 7.21 (6.59 ; 7.77) 6.70 (6.28 ; 7.84) 0.07 
Po20 %WA Inspiratory 7.41 (6.67 ; 8.50) 7.33 (6.42 ; 9.02) 0.73 
Legend to Table 2: All parameters are presented as Mean (standard deviation), Median (Quartile1 - Quartile 3), or N 
(%) as appropriate. BP= Blood Pressure, Syst=Systolic, BMI= Body Mass Index, FeNO=Fraction of exhaled Nitric 
Oxide, WBC=White Blood Cell, RV= Residual Volume, FRC=Functional Residual Capacity, PC=Provocative 
Concentration, PD=Provocative Dose, PC20 and PD20 = the provocative concentration and dose, respectively, that cause 
a 20% fall in FEV1 from baseline FEV1 during methacholine challenge, Fall in FVC, % fall in FVC at PC20 or PD20; 
FEV1=Forced Expiratory Volume in the 1
st
 second, FVC= Forced Vital Capacity, FEF50=Forced Expiratory Flow at 
50% of FVC, IVC=Inspiratory Vital Capacity, FEF25-75= Forced Expiratory Flow at 25%-75% of FVC,RV= Residual 
Volume, TLC=Total Lung Capacity, FRC= Functional residual Capacity, Raw- airway resistance, sGaw= specific 
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airway conductance,  R5-R20= Peripheral Airway Resistance, X5= Resistance at 5 Hz, AX= Area of Reactance, 
Scond*VT=  ventilation inhomogeneity in the conductive zone of the lungs, Sacin*VT= Ventilation inhomogeneity of 
the acinar zone of the lungs, CT= Computed tomography, MLD Ratio E/I= Mean Lung Density Expiratory to 
Inspiratory ratio, E=Expiratory, I=Inspiratory, LA= Lumen Area (mm2), BSA= Body Surface Area (m2), VI-856= 




Table 3 Characteristics of asthma participants  
Parameter  
  
GINA 1, N (%) 135 (17.5) 
GINA 2, N (%) 85 (11.0) 
GINA 3, N (%) 207 (26.8) 
GINA 4, N (%) 300 (38.8) 
GINA 5, N (%) 46 (6.0) 
Medication use  
SABA, N (%) 671 (86.8) 
Short acting anticholinergics, N (%) 9 (1.2) 
LABA, N (%) 86 (11.1) 
ICS, uncombined N (%),  183 (23.9) 
        Extra-fine ICS, N (%) 58 (7.5) 
        Non-extra-fine ICS, N (%) 127 (16.4) 
ICS mean daily dose ( BDP equivalent), µg 669 (446) 
ICS/LABA, N (%) 460 (59.5) 
ICS/LABA mean daily dose (BDP-equivalent), µg 882 (634) 
          Extra-fine ICS/LABA, N (%) 124 (16.0) 
          Non-extra-fine ICS/LABA, N (%) 336 (43.5) 
Oral corticosteroids, N (%) 22 (2.8) 
Oral corticosteroids mean daily dose, mg 7.5 (5.0 ; 20.0) 
Montelukast, N (%) 144 (18.6) 
LAMA, N (%) 29 (3.8) 
Biologics, N (%) 32 (4.1) 
Duration of disease, years 16.7 (5.6 ; 29.3)   
Age 1st diagnosis <18 years, % 39 
Unscheduled consultations past 12 months, N 0.3 (1.4) 
Exacerbations past 12 months, N 0.2 (0.6) 
>1 exacerbation past 12 months, % 14 
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 ACT, total score 21.0 (18.0 ; 24.0) 
 ACT < 15, % 13 
 ACQ-6, total score 0.8 (0.3;1.5) 
 ACQ-6 > 1.25, % 33 
 EQ-5D-5L, VAS score 80.0 (70.0 ; 90.0) 
 Mini AQLQ, total score 5.6 (4.7 ; 6.3) 
Legend to Table 3. Data are presented as N (%) or Median (Q1 to Q3 ranges) as appropriate. ACT=Asthma Control 
Questionnaire, ACQ-6= Asthma Control Questionnaire-6, EQ-5D-5L= Standardized measure of health status 
descriptive system, Mini AQLQ= Mini Asthma Quality of Life Questionnaire. Number of exacerbations and 
unscheduled consultations are based on the past 12 months. The daily dose of ICS (inhaled corticosteroids) is expressed 
in BDP equivalents, µg/day  
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Table 4. Prevalence rates (%) of abnormal SAD parameters (>ULN or <LLN) according to GINA stages 
 
Legend to Table 3. for abbreviations see Table 2. GINA severity was based on past treatment used.  Note that the 
highest prevalence of SAD is always in GINA5, the lowest prevalence across all GINA stages is with Sacin. 
 
  
Parameter, % GINA 1 GINA 2 GINA 3 GINA 4 GINA 5 
FEF25-75 41.4 43.0 50.5 54.5 80.4 
FEF50 37.3 49.4 54.1 55.3 75.0 
% fall FVC 71.7 67.9 75.2 72.7 84.2 
RV/TLC 14.0 16.3 19.3 28.1 31.1 
FRC 16.2 23.4 19.1 24.5 27.3 
R5-R20 29.9 40.0 36.5 50.5 70.6 
AX 32.4 34.4 35.4 49.2 67.7 
X5 22.8 31.8 28.5 33.2 53.1 
Scond  20.5 20.0 30.0 33.3 63.6 




Table 5. Relationship of lung physiology variables with number of exacerbations and unscheduled consultations  
Number of exacerbations   




  FEF25-75, L/s corrected for FVC -1.226 0.034  
  R5-R20, kPa/L/s 2.894 0.01  
  Raw, kPa*s/L -2.286 0.01  
  RV/TLC, ratio 2.773 0.04  
  sGaw, 1/kPa*s -0.316 0.03  
  Height, cm -0.053 <.001  
  PC20 and PD20 categories – very mild vs normal -1.058 0.02 0.006 
  PC20 and PD20 categories - mild vs normal -1.624 <.001  
  PC20 and PD20 categories - moderate-severe vs normal -1.212 0.01  
  Sex - Female vs Male 0.717 0.03  
 
Number of unscheduled consultations due to worsening symptoms  




  FEV1 , L 0.647 <.001  
  FRC , L -0.425 0.01  
  RV/TLC, ratio 4.659 0.01  
  sGaw , 1/kPa*s) -0.466 <.001  
  PC20 and PD20 categories – very mild vs normal -0.999 0.01 0.02 
  PC20 and PD20 categories - mild vs normal -0.888 0.01  
  PC20 and PD20 categories - moderate-severe vs normal -0.792 0.01  
  Sex (male/female) - Female vs Male 0.647 0.02  
Legend to Table 4. MBNW parameters were not used, since this would restrict the number of asthmatics to be analyzed 
(see Methods). P-value type 3 assesses the statistical difference in hyperresponsiveness severity stages. The coefficients 
are per 1 unit increase in each parameter. As example: the estimate of R5-R20 (kPa/L/s) for exacerbations is 2.894, one 
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needs to calculate exp(2.894) = 18.065 and this means that for 1-unit increase of R5-R20 the mean number of 
exacerbations will increase by a factor of 18.07, holding other variables constant. Mild hyperresponsiveness means a 
higher PD20 or PC20 value. Patients with more severe hyperresponsiveness have more frequent exacerbations and 




Table 6. Clinical characteristics of asthma participants in Clinical SAD Group1 and Clinical SAD Group2  
Parameter Group1 (n=452)  Group2 (n=312) P-value  
    
Clinical SAD score -0.256 (-0.34;-0.16) 0.284 (0.12;0.56) <0.001 
Age, years  43 (30;53) 50 (40;58) <0.001 
Gender, female N (%) 257 (57) 186 (60) 0.45 
Heart rate, bpm 70 (64;77) 72 (65;80) 0.02 
BP syst, mmHg 120 (110;130) 125 (117;135) <0.001 
BP diast, mmHg  78 (70;82) 80 (72;87) <0.001 
BMI, kg/m
2
 25 (22;28) 28 (25;32) <0.001 
Atopy, N (%) 262 (81) 187 (79) 0.53 
FeNO, ppb 24 (16;37) 25 (16;39) 0.42 
Ex-smoking, N (%) 90 (20) 65 (21)  0.47 
Duration smoking, years 10 (5.1;16.7) 14 (8.0;20.0) 0.02 
GINA 1/2, N (%) 157 (35) 60 (9) <0.001 
GINA 3, N (%) 135 (30) 70 (22) <0.001 
GINA 4/5, N (%) 160 (35) 182 (58) <0.001 
ICS uncombined, N (%) 98 (22) 83 (27) 0.12 
ICS/LABA, N (%) 254 (56) 202 (65) 0.02 
ICS dose, BDP equivalence 603.2 (384.9) 739.9 (482.5) 0.08 
ICS/LABA dose, BDP equivalence 818.8 (563.1) 959.6 (710.8) 0.08 
Oral corticosteroids, N (%) 8 (1.8) 14 (4.5) 0.03 
Eosinophils, 10⁹ /L 0.21 (0.12;0.35) 0.26 (0.16;0.40) <0.001 
Neutrophils, 10⁹ /L 3.50(2.88;4.47) 3.90(3.07;4.91) <0.001 
FEV1, %predicted 90.2 (80.1 ; 98.4) 70.1 (58.8 ; 81.8) <0.001 
Change FEV1, %predicted 6.5 (3.6 ; 9.9) 10.2 (5.5 ; 14.9) <0.001 
FEV1/FVC, %predicted 90.1 (83.4 ; 96.6) 78.3 (70.5 ; 86.0) <0.001 
FEF50, %predicted 75.2 (59.1 ; 94.8) 44.4 (31.5 ; 59.7) <0.001 
IVC, %predicted 103.3 (18.0) 93.1 (17.0) <0.001 
FEF25-75, %predicted, N (%) 66.6 (51.7 ; 86.9) 37.7 (27.8 ; 52.2) <0.001 
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RV, %predicted 108.9 (92.7 ; 127.2) 134.2 (110.9 ; 158.8) <0.001 
TLC, %predicted 104.3 (95.7 ; 114.0) 105.9 (95.9 ; 116.9) 0.24 
FRC, %predicted 107.3 (91.7 ; 123.0) 111.2 (94.8 ; 129.9) 0.01 
Raw, %predicted 110.1 (81.4 ; 167.8) 192.3 (139.6 ; 309.3) <0.001 
sGaw, %predicted 66.5 (47.4 ; 105.1) 47.0 (33.9 ; 72.4) <0.001 
R20, %predicted 107.8 (92.2 ; 125.7) 126.3 (109.7 ; 147.9) <0.001 
R5-R20, %predicted 129.6 (29.0 ; 304.0) 636.3 (378.2 ; 1065.0) <0.001 
X5, %predicted 109.1 (80.9 ; 140.5) 199.0 (151.6 ; 254.6) <0.001 
AX, %predicted 115.3 (65.3 ; 198.3) 613.6 (384.7 ; 868.3) <0.001 
Scond*VT, %predicted 144.6 (75.9 ; 239.7) 245.2 (161.7 ; 392.1) <0.001 
Sacin*VT, %predicted 93.1 (70.6 ; 127.0) 140.8 (95.8 ; 190.5) <0.001 
No. unscheduled consultations , N 0.15 (0.57) 0.50 (2.08) 0.001 
No. exacerbations, N 0.16 (0.52) 0.29 (0.76) 0.002 
 >= 1 exacerbation, N (%) 50 (11.1) 59 (18.9) 0.002 
Duration of disease, years 11.6 (4.4 ; 24.5) 21.5 (9.4 ; 35.0) <0.001 
Age at 1
st
 Diagnosis, years 25 (10 ; 41) 22 (7 ; 41) 0.13 
Age at 1
st
 Diagnosis < 18 years, N(%) 162 (36.2) 134 (42.9) 0.06 
ACT, total score 22.0 (19.0 ; 24.0) 20.0(17.0 ; 23.0) <0.001 
ACT score < 15, N (%) 40 (8.9) 60 (19.2) <0.001 
ACQ-6, total mean score 0.66 (0.2 ; 1.3) 1.00 (0.5 ; 1.8) <0.001 
ACQ-6 score > 1.25, N (%) 124 (27.4) 126 (40.4) <0.001 
EQ-5D-5L, VAS score 83.0 (75.0 ; 90.0) 80.0 (70.0 ; 90.0) <0.001 
Mini-AQLQ, total score 5.7 (4.8;6.4) 5.5(4.5;6.3)  
CT Scan characteristics    
MLD Inspiratory, HU -844.53(-859.56 ; -815.71) -831.65(-854.46 ; -808.68) 0.09 
MLD Ratio E/I 0.82 (0.76 ; 0.87) 0.84 (0.78 ; 0.90) 0.01 
VI-856 6.96 (1.92 ; 18.27) 9.54 (3.18 ; 21.30) 0.07 
Lung Volume Ratio 0.49 (0.41 ; 0.56) 0.51 (0.45 ; 0.62) 0.008 
Percentile 15 Inspiratory -922.33 (-937.51 ; -906.97) -917.72 (-930.20 ; -900.38) 0.05 
Median LA/BSA Inspiratory 10.95 (2.66) 9.67 (3.08) <0.001 
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Median LA Inspiratory 20.37 (17.32 ; 23.47) 17.82 (14.59 ; 22.08) <0.001 
Pi10   Inspiratory 7.12 (6.54 ; 7.77) 7.28 (6.59 ; 7.78) 0.64 
Po20 %WA Inspiratory 7.49 (6.71 ; 8.52) 7.27 (6.57 ; 8.41) 0.46 
Legend to Table 6. Data are presented as N (%), Mean (SD) and Median (interquartile ranges) as appropriate; for 
abbreviations see Table 2 and Table3. 
1 
 
Exploring the relevance and extent of small airways dysfunction in asthma: : baseline data 
from the AssessmenT of smalL Airways involvemeNT In aSthma, the (ATLANTIS) 
prospective cohort study  
Postma DS
1
, MD Prof, Brightling C
2
, MD Prof,  Baldi S
2,11





, MD Prof, Gagnatelli A
5
, PhD, Papi A
6
, MD Prof, Van der Molen T
7
, MD, Prof, Rabe 
KF
8




, MD Prof, Nicolini G
5
, PhD,  Kraft M
10
 , MD Prof, and 
the ATLANTIS study group*Postma DS
1


























 and the ATLANTIS study group* 
 
Collaborators 
* Badorrek P, Boersma W, Broeders M, Chetta A, Cukier A, D’Amato M, Djukanovic R, Foschino 
MP, Gessner C, Hanania N, Martin R, Milleri S, Olivenstein R, Paggiaro P Pizzichini E, Plaza 
Moral V, Scichilone N, Schilz R, Spanevello A, Stelmach R, Vroegop J, Usmani OS, Zhang Q. 
Author Information 
1. University of Groningen, University Medical Center Groningen, Department of 
Pulmonology, Groningen Research Institute for Asthma and COPD, Groningen, The 
Netherlands University of Groningen, University Medical Center Groningen, Department of 
Pulmonology, Groningen Research institute for Asthma and COPD, Groningen, The 
Netherlands 
2. Institute for Lung Health, NIHR Biomedical Research Centre, University of Leicester, UK; 
Department of Global Clinical Development, Chiesi SAS, Bois Colombes, France 




4. COPD Centre, Sahlgrenska University Hospital, Gothenburg 
5. Department of Global Clinical Development, Chiesi Farmaceutici SpA, Parma, Italy  
6. Research Centre on Asthma and COPD, University of Ferrara, Ferrara, Italy  
7. University of Groningen, University Medical Center Groningen, Department of General 
Practice, Groningen Research Institute for Asthma and COPD, Groningen, The Netherlands  
8. Lungen Clinic, Grosshansdorf, and Department of Medicine, Christian Albrechts University, 
Kiel, Germany. Airway Research Center North in the German Center for Lung Research 
(DZL), Germany. 
9. Centre for Respiratory Medicine and Allergy, University of Manchester, University Hospital 
of South Manchester, Manchester, UK. 
10. University of Arizona College of Medicine, Department of Medicine, Tucson, Arizona, 
United States   
11. Department of Global Clinical Development, Chiesi SAS, Bois Colombes, France 
 
 






Summary Background  
Small airways dysfunction (SAD) is well-recognized in asthma, yet its role in asthma severity and 
asthma control is unclear.  
Methods 
This multinational observational study investigated participants without and with asthma (GINA 
severity stage 1-5). They underwent spirometry, body plethysmography, impulse oscillometry 
(IOS), Multiple Breath Nitrogen Washout (MBNW), computed tomography (CT) and 
questionnaires. Structural equation modeling (SEM) was applied in asthma to assess the 
contribution of all physiological and CT parameters to SAD. With SEM, we  defined a clinical-
SAD and CT-SAD score. Asthma subjects were classified in SAD groups using model-based 
clustering. Asthma severity, control and health care utilization in the past year were compared with 
the SAD scores and SAD groups.  
Findings  
We investigated 773 asthma and 99 control participants (median [interquartiles] age 46 [34, 54] and 
41 [29, 52] years, 58% and 57% females, respectively). All physiologic measures contributed to the 
clinical SAD model with SEM analysis. The prevalence of SAD in asthma was dependent on the 
measure used and lowest with MBNW Sacin that reflects ventilation heterogeneity in the most 
peripheral, pre-acinar/acinar airways. IOS and spirometry, reflecting dysfunction of small-to-mid-
sized airways, contributed most to the Clinical-SAD score and differentiated the two SAD Groups. 
Clinical-SAD Group1 (n=452) had “milder“ SAD, i.e. comparable ventilation heterogeneity in pre-
acinar/acinar airways values (MBNW Sacin) with controls. Group2 (n=312) had more abnormal 
physiologic SAD measures than Group1, particularly IOS and spirometry, and more severe asthma 
(asthma control, treatments, exacerbations, quality of life). Clinical-SAD scores were higher in 
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Group2 (“more severe” SAD) and related to asthma control, severity, and exacerbations. Clinical-
SAD and CT-SAD scores did not significantly correlate.  
Interpretation 
SAD has multiple components and physiologic parameters from spirometry, body 
plethysmography, IOS and MBNW contribute to SAD. SAD is present across all asthma severity 
and particularly in severe disease. The clinical classification of SAD in two groups, i.e. a “milder” and 
“more severe” SAD group, by the easy-to-conduct measures IOS and spirometry, is meaningful given its 
association with GINA asthma severity stages, asthma control, quality of life, and exacerbations. Further 
work is needed 
 
Background  
Small airways dysfunction (SAD) is well-recognized in asthma, yet its role in asthma severity and 
asthma control is unclear. Our study aimed to assess which (combination of) biomarkers, 
physiological testing and imaging markers best measures the presence and extent of SAD in asthma. 
Methods 
This multinational observational study investigated participants without and with asthma (GINA 
severity stage 1-5). Asthma inclusion criteria were: 1) age 18-65 years; 2) clinical asthma diagnosis  
> 6 months, confirmed by a chest physician 2, supported by objective evidence of any of the 
following at the baseline visit or in the previous 5 years: a) positive airway hyperresponsiveness to 
methacholine, or b) positive reversibility (ΔFEV1≥ 12% and ≥ 200 mL within 30 minutes after 400 
μg of salbutamol pMDI with or without a spacer or c) PEF variability >20%, measured during 7 
days or d) documented reversibility after a cycle (e.g. 4 weeks) of maintenance anti-asthma 
treatment; 3) stable asthma on any previous regular asthma treatment (“rescue” β2-agonists alone 
included) at a stable dose for > 8 weeks before baseline; 4) lifetime smoking ≤ 10 pack-years. They 
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underwent spirometry, body plethysmography, impulse oscillometry (IOS), Multiple Breath 
Nitrogen Washout (MBNW), computed tomography (CT) and questionnaires. Structural equation 
modeling (SEM) was applied in asthma to assess the contribution of all physiological and CT 
parameters to SAD. With SEM, we  defined a clinical-SAD and CT-SAD score. Asthma subjects 
were classified in SAD groups using model-based clustering. Asthma severity, control and health 
care utilization in the past year were compared with the SAD scores and SAD groups.  
Findings  
We investigated 773 asthma and 99 control participants (median [interquartiles] age 46 [34, 54] and 
41 [29, 52] years, 58% and 57% females, respectively). All physiologic measures contributed to the 
clinical SAD model with SEM analysis. The prevalence of SAD in asthma was dependent on the 
measure used and lowest with MBNW Sacin that reflects ventilation heterogeneity in the most 
peripheral, pre-acinar/acinar airways. IOS and spirometry, reflecting dysfunction of small-to-mid-
sized airways, contributed most to the Clinical-SAD score and differentiated the two SAD Groups. 
Clinical-SAD Group1 (n=452) had “milder“ SAD, i.e. comparable MBNW Sacin with controls. 
Group2 (n=312) had more abnormal physiologic SAD measures than Group1, particularly IOS and 
spirometry, and more severe asthma (asthma control, treatments, exacerbations, quality of life). 
Clinical-SAD scores were higher in Group2 (“more severe” SAD) and related to asthma control, 
severity, and exacerbations. Clinical-SAD and CT-SAD scores did not significantly correlate.  
Interpretation 
SAD is a complex and silent signature of asthma, which is likely to be directly or indirectly 
captured  by combinations of physiologic tests: spirometry, body plethysmography, IOS, and 
MBNW. SAD is present across all asthma severity and particularly in severe disease. The clinical 
classification of SAD in two groups, i.e. a “milder” and “more severe” SAD group, by the easy-to-
conduct measures IOS and spirometry, is meaningful given its association with GINA asthma 
6 
 
severity stages, asthma control, quality of life, and exacerbations. The longitudinal part of 
ATLANTIS will show the relevance of the SAD score for future risks in asthma, and additionally 
which parameter best associates with future asthma control. Moreover, we will report on 
development of a Small Airways Dysfunction Tool (SADT), a questionnaire as an easy measure to 
suggest SAD, and on the measures of inflammation that best discriminate between the large and 
small airways’ compartments, with bronchial and transbronchial biopsies, in a smaller subset of 
participants. 
 
Funding: Chiesi Farmaceutici SpA. 
 
Research in context 
Evidence before this study 
We searched PubMed for studies in asthma, including the terms asthma, adult, and small airways, 
and published between database inception and April 2018, using spirometry and any combination of 
body plethysmography, impulse oscillometry (IOS; including R5-R20 values) and Multiple Breath 
Nitrogen Washout (MBNW) measures, and similar terms in addition to CT scans. Small airways 
dysfunction (SAD) has been understudied, though it significantly contributes to airway obstruction, 
a hallmark of asthma. So far, studies on the role of SAD in asthma have been performed in small 
sample sizes and/or subgroups of asthma. Moreover, these studies investigated only a subset of 
available potential measurements of SAD and did not include both spirometry, body 
plethysmography, impulse oscillometry (IOS), Multiple Breath Nitrogen Washout (MBNW), CT 
scans and questionnaires.  
Added value of this study 
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This is the largest study to date involving 773 evaluable asthma patients and 99 controls without 
airway obstruction specifically designed to determine the prevalence and impact of small airways 
dysfunction SAD in asthma. The study shows that SAD is present in asthma across all stages of 
severity, with highest prevalence in GINA 5. We were able to define a SAD score from a 
combination of lung function measurements that reflects the amount of physiological small airways 
impairment in asthma. The score associated significantly with measures of asthma control, history 
of exacerbations and disease severity. Model-based clustering delineated two clinical SAD groups 
that differed in age, duration of asthma, and disease severity. Of interest, values of Sacin, that 
measures ventilation heterogeneity in pre-acinar/acinar airways, were in the normal range in 
Group1. The difference between Clinical SAD Group1 and Group2 was particularly clear with 
clinically available SAD measurements, such as IOS and spirometry, followed by FEV1, while 
differences were small with CT SAD parameters. In summary, we can cluster asthma patients in two 
subgroups based on SAD measured with easy-to-conduct, clinically applicable measures.  
 
Implications of all the available evidence 
Small airways dysfunction (SAD) has been understudied in asthma. Our results show the clinical 
relevance of SAD, which is present across all severity stages of asthma. It is particularly present in 
severe disease, likely reflecting structural lung changes that are not responsive toe the use of oral 
corticosteroids and/or high dose inhaled corticosteroids. Moreover, SAD relates to asthma stability, 
severity, quality of life, exacerbation rates and health care utilization and can be delineated by easy-
to-conduct, clinically applicable measures such as IOS and spirometry. Therefore, this aspect of 




Asthma is a prevalent obstructive airway disease that affects the entire bronchial tree. The small 
airways, defined by a diameter <2 mm and referred to as the “silent zone” of the lungs, contribute to 
the resistance in the airways of patients with obstructive airways disease
1
. This is of clinical 
importance since small airways can be inflamed in asthma and hence narrowed
2-4
. Small airway 
narrowing can also occur due to smooth muscle contraction after inhaling allergic and non-allergic 




Small airways dysfunction (SAD) has been postulated to exist at all severities of asthma, whereas 
some studies suggest that the prevalence increases with asthma severity 
6,1
. However, it is still not 
clear what proportion of asthma patients suffers from SAD, and which tests or combination of tests 
best defines it. Lack of best practice is due to the fact that published studies investigating the small 
airways in asthma included only small-sized and/or relatively homogeneous populations regarding 
asthma severity, or only tested one or a few physiologic SAD measures 
6-8
. The ATLANTIS 
(AssessmenT of smalL Airways involvemeNT In aSthma) study subjected a large asthma cohort to 
all available, clinically applicable, potential SAD tests, including spirometry, body 
plethysmography (e.g. residual volume), impulse oscillometry (IOS), and Multiple Breath Nitrogen 
Washout (MBNW) and CT scan.  The physiological tests may reflect abnormalities in different 
parts of the bronchial tree or different aspects of small airways dysfunction, providing different 
perspectives on SAD
9,10
. Lung imaging by CT scan can provide additional insight regarding SAD, 
but the relationship with physiologic measures of SAD in asthma has not been studied extensively 
and only in small groups.  
The ATLANTIS study assessed which (combination of) biomarkers, physiological testing and 
imaging markers best measures the presence and extent of SAD in asthma. It builds on both a 
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baseline and 1-year follow-up phase. We assessed SAD through a series of baseline measurements 
using published criteria defining small airways dysfunction for each test, both for physiological and 
CT measures. The final result of the model-building process is a score defining to what extent SAD 
is present in each individual patient, a score that was built from baseline data and validated at 
follow-up. With this score, its usefulness for prediction of asthma severity, asthma control, quality 
of life and history of exacerbations was evaluated  
Here we present the clinical baseline data of the ATLANTIS study. The main aim is to identify 
which combination of biomarkers, physiologic testing and imaging approaches best measures the 
presence and extent of SAD in asthma cross-sectionally and their relationship with asthma severity, 
control, quality of life and history of exacerbations over time
9
.  The study allowed us to develop 
novel predicted, upper limit of normal (ULN) and lower limit of normal (LLN) values of 
physiological parameters infrequently studied (e.g. IOS). The ATLANTIS (AssessmenT of smalL 
Airways involvemeNT In aSthma) study is a multinational 1-year prospective cohort study, 
including people with asthma of all severities and controls without airway disease. In this paper we 
present the baseline, cross-sectional data from ATLANTIS, aiming to identify which combination 
of biomarkers, physiologic testing and imaging approaches best measures the presence and extent of 
SAD in asthma, and their relationship with features of asthma. We assess SAD through a series of 
all available, clinically applicable, potential SAD tests, both for physiological and CT measures. 
The physiological tests may reflect abnormalities in different parts of the bronchial tree or different 
aspects of small airways dysfunction, providing different perspectives on SAD
9,10
. Lung imaging by 
CT scan can provide additional insight regarding SAD, but the relationship with physiologic 
measures of SAD in asthma has not been studied extensively and only in small groups; here we test 
both physiological and CT scan measures in a large cohort. 
In addition, we develop a score defining to what extent SAD is present in each individual patient 
and assess its usefulness for prediction of asthma severity, control, quality of life and history of 
10 
 
exacerbations. In future papers (not presented here), we will report the longitudinal data from 
ATLANTIS and aim to validate the SAD score over time, we will develop and validate a Small 
Airways Dysfunction Tool (SADT), a questionnaire as an easy measure to suggest SAD, and we 
will assess which direct and indirect measures of inflammation best discriminate between the large 













Participants were recruited (first patient in June 30, 2014 and last patient out March 3, 2017) (2014-
2016) from general practitioners, chest physician’s databases and by advertisements in 29 centers 
across 9 countries worldwide. Inclusion criteria were: 1) age 18-65 years; 2) clinical asthma 
diagnosis  >6 months, confirmed by a chest physician according to GINA 2012
11
 and supported by 
objective evidence of any of the following at the baseline visit or in the previous 5 years: a) positive 
airway hyperresponsiveness to methacholine, or b) positive reversibility, defined as ΔFEV1≥ 12% 
and ≥ 200 mL over baseline FEV1 within 30 minutes after inhaling 400 μg of salbutamol pMDI 
with or without a spacer or c) Peak Expiratory Flow variability (i.e. highest - lowest value over the 
day/mean value of the two, ×100) >20%, measured during 7 days or d) documented reversibility 
after a cycle (e.g. 4 weeks) of maintenance anti-asthma treatment; 3) stable asthma on any previous 
regular asthma treatment (“rescue” β2-agonists alone included) at a stable dose for > 8 weeks before 
baseline; 4) lifetime smoking ≤ 10 pack-years. Main exclusion criteria were a COPD diagnosis 
confirmed by a chest physician and an asthma exacerbation during 8 weeks before baseline.  
Controls were included based on 1) age 18-65 years; 2) no respiratory symptoms compatible with 
asthma or COPD in the past 2 years; 3) normal spirometry: baseline FEV1≥ 80%predicted, 
FEV1/Forced Vital Capacity (FVC)> LLN (lower limit of normal); 4) normal airways 
responsiveness: PC20≥ 16 mg/mL, PD20≥ 1.4 mg; 5) lifetime smoking ≤ 10 pack-years. Diagnosed 
upper/lower respiratory tract diseases were exclusion criteria. The Medical Ethics Committee of 
each center approved the protocol; all patients gave written informed consent.  
Study design and procedures 
Participants were followed for 1 year with 6-month clinic and 3-month telephone follow-ups
9
. The 
clinical and CT tests were performed at 3-day baseline visits. The methods for spirometry, 
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hyperresponsiveness, MBNW, IOS, body plethysmography, CT, questionnaires, blood tests, and 
health care utilization are described in the Supplement. Medications during an eight-week period  
before evaluation were used to assess GINA severity
11
. The potential indices of SAD used with 
hypothetical location in the airways  and references between brackets are presented in Table 1 
12-1922 
. These were  % fall in FVC during hyperresponsiveness testing; spirometry: Forced Expiratory 
Flow (FEF)25-75, and FEF50, both corrected for FVC;, body plethysmography: Residual 
Volume/Total Lung Capacity (RV/TLC), and Functional Residual Capacity (FRC), IOS: R5-R20, 
AX, and X5;  MBNW: Scond, and Sacin. Alveolar NO was not incorporated in this analysis since it 
was only available in a subset of participants (See Supplement). Indices of “large airways 
dysfunction”, which may also capture small airways abnormalities, were FEV1%predicted, 
FEV1/FVC, IVC, FeNO, R20, PC20, PD20 and 3 severity categories of airway hyperresponsiveness 
(Supplement).  
Computed tomography  
Volumetric whole lung scans were obtained at full inspiration (near total lung capacity) and at end 
of expiration, near FRC. Scans were analyzed by a single observer (SB) using semi-automated 
software, Apollo (VIDA Diagnostics, Iowa), with various quality control parameters
203,214
. The 
supplement describes CT acquisition, quantitative airway morphometry and lung densitometry. 
SAD parameters used (see also Table 1 
214,225
) were: ex- and inspiratory Mean Lung Density and 
their ratio (E/I MLD), ex- and inspiratory lung volume and their ratio (E/I LV), expiratory Voxel 
Index (VI-856) and inspiratory VI-950 (% of Voxels with CT numbers <-856 and <-950 Hounsfield 
Units respectively, inspiratory Percentile15, Inspiratory median Lumen area, Wall area (WA) and 
Total area, these latter three divided by body surface area (BSA), inspiratory median percentage 
WA, and inspiratory Pi10 and Po20%WA (hypothetical airway with internal perimeter of 10 mm 
and outer perimeter of 20 mm respectively). 
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Statistical analyses  
Detailed statistical information, including power analysis
263
, is provided in the Supplement. The 
following variables reflecting SAD were used in the clinical SAD analysis: FEF50/FVC, FEF25-
75/FVC, FEV1%predicted, FEV1/FVC, IVC%predicted, % fall FVC at PC20 or PD20, RV/TLC 
%predicted, FRC%predicted, R5-R20, X5, AX, Scond, Sacin. For CT SAD analysis, variables 
were:  MLD ratio, Lung Volume ratio, VI-856, Pi10, Po20%WA. 
We used SEM analysis to assess clinical SAD, since this clarifies which SAD parameters, out of all 
the physiologic parameters we measured , group together and weigh towards the presence of SAD 
in asthma (see Supplement). Similarly we applied SEM analysis for CT SAD. Several steps were 
performed for clinical SAD and CT SAD SEM analysis separately
274
. A correlation matrix 
evaluated correlations among observed variables, high correlations indicating presence of 
underlying latent variables. An exploratory factor analysis for observed variables was performed to 
identify the underlying SAD factor structure. The final underlying SAD factor structure was tested 
by specifying a confirmatory factor model. Once the measurement model was set and fit the data 
properly, it was used to classify each patient into SAD groups, using model-based clustering. The 
SAD Groups and SAD scores from the clinical SAD and the CT-scan SAD model were compared, 
evaluating the rate of agreement, using Chi-square and Pearson’s correlation tests. The clinical SAD 
model was additionally tested in the subgroup with a CT scan, by adding the CT scan variables to 
the model. Full information maximum likelihood (FIML) method was used for dealing with missing 
data in SEM analysis
258
.  
Relationships of physiologic SAD variables with asthma severity, control and healthcare utilization  
were analyzed by Poisson regression. Continuous prediction equations, their lower- and upper limit 
of normal (LLN and ULN) from the literature
296 
and from formulas based on ATLANTIS controls 
are provided in Supplemental Table 1. Statistical analyses and data processing were performed 
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using Statistical Analysis Systems (SAS®) Software (release 9.2) and Mplus Version 7.4 on a 
Windows 7 operating system. 
Role of Funding Source 
Chiesi Farmaceutici SpA financed the study, contributed to the set-up of the study which was 
designed by DP, MK, CB, MvdB, LF, AP, TvdM, KR, SS and DS. Chiesi Farmaceutici SpA 
contributed to interpretation of the study and approved the submitted manuscript. Data collection 
and management was done by Cromsource and data were analysed by CROS NT. All co-authors 
discussed and interpreted the data. The first draft of the report was written by DP, CB and MK; DP 
collated input from all co-authors. DP and MK had access to raw data. The corresponding author 











The main reason for screening failure was not fulfilling inclusion/exclusion criteria (n=99, Figure 
1).  
Participants 
Baseline characteristics are shown in Table 2, Table 3 (asthma only) and Supplemental Table 2. 
Gender, age and smoking habits were comparable between asthma and control participants; the 
large majority of people included were of Caucasian descent (88% and 96% in asthma and control 
participants respectively). Asthma participants demonstrated higher BMI, heart rate, blood pressure, 
blood cell counts, and prevalence of atopy. Hyperresponsiveness was only present in asthma 
participants. All physiologic parameters were significantly worse in asthma. Asthma participants 
had lower MLD expiratory values, inspiratory airway lumen, wall, and total area, also when divided 
by BSA (body surface area) on CT. Asthma participants had a moderately severe health status 
impairment (Table 3) and lower lung-related quality of life (higher EuroQol-5Dim-5Levels score) 
than controls, median (Q1;Q3) value ofbeing 95.0 (90.0;100.0) versus 80.0 (70.0;90.0). 
Association of physiologic parameters with asthma severity, control and health care 
utilization 
 X5, Scond, RV/TLC, R5-R20 and R5 values (Figure 2A) showed the highest positive correlations 
with GINA severity
11
. GINA severity was also associated, as expected, with lower FEV1, FEF50, 
and FEV1/FVC values. Table 4 shows that GINA5 had the highest SAD prevalence rate for every 
physiologic variable (measurements >ULN or <LLN). Sacin had the least SAD prevalence rate in 
all GINA stages, the lowest prevalence being with GINA1 (12%), rather similar, higher prevalences 
in GINA2-4 (18-19-20%), and highest in GINA5 (41%). This contrasts with other SAD variables, 
where prevalences either remain constant over the GINA stages (% fall FVC), continuously 
increase from GINA1-GINA5 (body plethysmography), or increase in steps, e.g. Scond and FEF25-
17 
 
75 showed lowest prevalences in GINA1-2, higher in GINA3-4 and highest in GINA5. R5-R20 and 
AX showed somewhat comparable rates in GINA1-3, higher in GINA4 and highest in GINA5 
(Table 4). Sacin also contrasted with <LLN prevalence distributions in FEV1, i.e. GINA1-GINA5 
26%-29%-36%-47%-72%. 
A lower Asthma Control Test (ACT) score was particularly associated with higher AX and R5 and 
lower FVC and FEV1 (Figure 2B).  
For exacerbations in the past year, highest positive correlations were with RV/TLC, R5-R20, AX 
and Sacin and highest negative correlations with FEV1, FVC, IVC, FEF25-75, FEF50 (Figure 2C). The 
number of exacerbations was independently predicted by SAD parameters from spirometry, IOS, 
body plethysmography, hyperresponsiveness severity, female gender and height (Table 5). There 
was also a negative association with Raw. Independent parameters for unscheduled consultation 
visits were FEV1, hyperinflation with body plethysmography, hyperresponsiveness severity, and 
female gender (Table 5). 
Prevalence of LAD and SAD in asthma 
Figure 3 (upper panel) shows the prevalence rates of large and small airways dysfunction, based on 
LLN and ULN. Sacin had the lowest SAD prevalence (19.2%), % fall FVC the highest (73.1%).  
SAD Model  
Figure 4 shows the final clinical SAD model based on cross-sectional data. It presents both the 
loadings to the three latent variables, and the goodness of fit values (Supplemental methods), 
showing good coherence of this model to SAD. IOS parameters R5-R20, AX and X5 loaded to the 
first latent variable, FEF50 and FEF25-75 both corrected for FVC, to the second latent variable, while 
Sacin (MBNW) loaded both to the first and second latent variable. The lung volume parameter 
RV/TLC %predicted and Scond (MBNW) loaded to the third latent variable. Hyperresponsiveness 
was only tested at the first visit, hence could not be taken into account in the longitudinal design of 
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the SAD SEM model. Therefore, we also analyzed the clinical SAD model at baseline including 
hyperresponsiveness, and the % fall FVC loaded on the third latent variable without much change in 
goodness of fit values. The baseline model without and with % fall FVC correlated highly (r=0.99; 
Supplemental Figure 2A).  Since the cross-sectional SAD model with and without % fall FVC were 
almost identical, the model without % fall FVC was tested longitudinally; the same model structure 
was confirmed at all visits (Supplemental Figure 2B).  
Correlations of clinical SAD score with physiologic and clinical parameters  
A higher clinical SAD score reflects more severe SAD. The highest positive and negative 
correlations (r > 0.60 and r < -0.60) of the SAD score existed with physiologic parameters on which 
the score was based, i.e. IOS parameters AX, R5-R20, and R5 (positively) and X5, spirometric 
parameters FEF25-75 and FEF50 (negatively), next being FEV1 %predicted (Figure 5). The highest 
correlations of non-physiological parameters with the SAD score were duration of asthma, ACQ-6 
and number of exacerbations (positively), ACT, Mini AQLQ total and EQ-5D-5L (negatively). 
Clinical SAD scores increased with higher asthma severity, mean SAD score in GINA1-5 being -
0.143, -0.035, -0.048, +0.071 and +0.239 (ANOVA p <0.0001).  
Model-based clustering defined clinical SAD Groups 
Model-based clustering defined two clinical SAD groups, Group1 including 452 patients, Group2 
312 patients (Table 6 and Supplemental Table 3 present clinical characteristics). Overall, the 2 
clinical SAD Groups were similar regarding age of asthma onset, sex ratio, FeNO, atopy, and 
smoking habits, while duration of smoking was higher in Group2 (Table 6). Sacin values were 
comparable between Group1 and the controls, whereas Group2 had significantly higher values than 
both Group1 and controls. Clinical SAD Group2 was somewhat older, demonstrated higher blood 
pressure, heart rate and BMI, and a longer asthma duration. Additionally, Group2 had more severe 
asthma than Group1, according to GINA severity, ACT, ACQ, LABA/ICS use, 
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hyperresponsiveness, blood inflammation (eosinophils), quality of life and health care utilization. 
All physiologic parameters were worse in clinical SAD Group2; the two groups were best separated 
by SAD parameters from IOS followed by spirometry, and additionally FEV1 (Figure 3).  
CT scan factors in SAD 
CT scans were analyzed in 294 patients (with comparable asthma severity as the non-CT group, 
Supplemental Table 3). The SEM model provided three factors in CT that contributed to SAD: 
MLD inspiratory/expiratory ratio, Lung volume inspiratory/expiratory ratio and VI-856 
(Supplemental Figure 2D). The correlations of the CT SAD score with physiologic and clinical 
parameters, comparison of CT SAD groups, and additional Clinical SAD analysis in patients who 
had a CT scan are presented in the Supplement. 
Relationship between Clinical and CT SAD scores 
The Clinical SAD and CT SAD scores showed a significant, weak correlation (r=0.28). There was 
no significant overlap between the clinical SAD and CT SAD Groups (p=0.103, Supplemental 






This large clinical study shows the clinical relevance of small airway dysfunction for asthma, since 
SAD is present across all severities and particularly in more severe asthma. ATLANTIS was 
specifically designed to determine the prevalence and impact of SAD in asthma and has performed 
the most comprehensive evaluation of SAD to date using both physiological and imaging tools. We 
show that the prevalence of SAD depends on the physiologic measure used, i.e. localization and 
type of airway narrowing. Of importance, no single variable defines SAD, but IOS, MBNW, lung 
volumes and spirometry all contribute. For clinical practice, it is important to highlight that SAD 
associates with GINA severity and -–independently- with history of exacerbations over time, 
particularly when measured by IOS, spirometry and body plethysmography. Moreover, the poorest 
asthma control was present in the group with the worst clinical SAD score.  
Of note, 91% of our asthma population expressed SAD, when defined as any abnormal physiologic 
parameter. This does not imply that patients Our data imply that they do have extensive SAD 
throughout all airway dimensions, since the prevalence varied with the type of physiologic measure. 
The lowest prevalence existed with Sacin (19%) and RV/TLC (22%), both reflecting dysfunction of 
the most peripheral small airways. The highest prevalence was with FEF25-75 (68%) and % fall FVC 
(73%), probably both reflecting obstruction in more small-to-mid-sized airways. Future work has to 
elucidate if these different prevalence rates define subtypes of SAD (consistent vs. variable, which 
level of airway is involved, and what percent of these airways are involved). We additionally 
compared our SAD prevalence with literature findings (Supplemental Table 7), yet no study 
compared all types of physiologic SAD methods. Anderson et al.
6
 used R5-R20 >0.03 kPa/L/s as 
cut-off for abnormality, concluding that abnormal R5-R20 values were present in all severities of 
asthma, i.e. 65% in British Thoracic Society step2, 64% in step3 and 70% in step4. Our overall 
prevalence with this cut-off was 70%; we extend their findings showing that prevalence rates of R5-
R20 >LLN  increase from GINA steps 1-5, being 54%, 65%, 70%, 77%, and 91% respectively. In 
21 
 
contrast, the prevalence of Sacin >LLN was lowest in GINA1, almost identical in GINA 2-4 and 
highest in GINA5, suggesting that mostly peripheral airway dysfunction, and likely structural 
changes, are present in most severe asthma. In summary, our data are comparable with published 
findings in smaller samples, yet expand these observations by providing information on all different 
SAD measurements at the same time in one group of asthma patients across all severities.  
Strengths of our study are the large group of asthma patients covering the full severity spectrum and 
the extensive work-up and quality and experience of the centers. ATLANTIS is a multi-center 
international study, therefore we feel our results are reliable and applicable to multiple populations. 
We also included smokers, a factor that by itself may induce some SAD. We felt it important that 
our study reflects the larger asthma and non-asthma population globally for generalizability, and 
thus not restricts the impact of our findings. The controls had comparable age, sex ratio and 
particularly smoking habits as the asthma population, which provided novel LLN and ULN values 
for physiological parameters infrequently studied, likesuch as IOS and MBNW. We acknowledge 
that a larger control group might have improved precision of these predicted, LLN and ULN values, 
whichand this will be also partially overcome when we add the longitudinal data in the future.  
We recognize that a quality check of the maneuver to get optimal phase III slope in the MBNW 
test
3027
 is key to validity of the measurements, which we have carefully ensured in the present study. 
The finding that of some measurements of ventilation heterogeneity in pre-acinar/acinar airways 
(Sacin values were) in the normal range doesis not in contrast with the presence of airway 
dysfunction in Group1, as the body of the available literature on ventilation heterogeneity in adult 
asthma
214,2831-384
 reveals a variable contribution of conducting versus acinar lung regions to 
treatment response, and consistency in the reversibility towards normal values after 
exacerbations
3281
. Particularly, the persistent derangement of ventilation in conducting airways 
(Scond) seems more related to airway remodeling, exacerbations, and hyperresponsiveness, 





. Accordingly, the worst clinical SAD score was present in the group with the poorest 
asthma control and higher prevalence in GINA 4 and 5. 
 
Another limitation of the study is that CT scans were not available in all participants, limiting 
numbers for analyses. However, this allowed us to demonstrate that the clinical SAD model in the 
full asthma cohort could be replicated in the smaller group with CTs. Future work will expand our 
analyses by performing parametric response mapping (PRM)
4036
, a CT voxel-based imaging 
biomarker tool which uses dynamic image registration between paired inspiratory and expiratory 
scans to quantify 'functional small airways disease’. A potential limitation is that agethere was a 
was somewhat higher age in the asthma than control participants, yet the difference is was  a small 
difference  (median age (interquartile ranges) of 46 (34-54) vs 41 (29-52) years respectively) 
andthat is  likely not of clinical significance, and we adjusted for age in all analyses. We cannot put 
our clinical SAD score forward as a clinically applicable tool as yet, since this is a cross-sectional 
analysisstudy. The score already significantly associates with number of exacerbations, asthma 
severity and control, and the longitudinal phase of the study will elucidate whether it also predicts 
future changes in these clinical outcomes. For the same reason we cannot put the “best parameters“ 
of SAD forward yet, since this also needs prospective data that will follow in the future. 
Additionally, a Small Airways Dysfunction Tool (SADT) will be developed, a questionnaire as an 
easy measure to suggest SAD
9
, which may be easily applicable in the clinic, as MBNW and body 
plethysmography are not available for all routine settings. Our article did not report on SAD with 
regard to the underlying pathology
9
. It was not feasible to perform bronchial and transbronchial 
biopsies in all participants. However, we will assess which direct and indirect measures of 
inflammation best discriminate between the large and small airways’ compartments, with bronchial 




Large and small airways obstruction are important components of asthma pathophysiology
1-3
. Our 
focus in this study is on the small airways and their specific impact upon asthma symptoms and 
exacerbations, an area of investigation that has been relatively neglected in our opinion (an 
overview of relatively small-sized studies is presented in Supplemental Table 7). It would be of 
interest to analyze in the future data in individualssubgroups with Large Airway Dysfunction 
(LAD) without SAD, or conversely, individuals with SAD and without LAD. Finally, one would 
like to have a ‘gold standard’ for SAD, yet our study shows this is not feasible since many 
physiological parameters contribute to the SAD model. This likely reflects that they represent 
abnormalities in distinct parts of the bronchial tree and/or contrasting aspects of underlying 
mechanisms of SAD, thereby providing different information
9
.  
We were able to define a SAD score that reflects the amount of physiological small airways 
impairment and is significantly associated with measures of asthma control, exacerbations and 
severity. We additionally observed two clinical SAD Groups that are comparable in e.g. gender, 
atopy, FeNO, ICS dose and smoking habits, while Group2 was somewhat older, had a longer 
asthma duration and more severe asthma according to all parameters tested. InterestinglyOf interest, 
ventilation heterogeneity in pre-acinar/acinar airways measured as Sacin)
32
, which reflectsive of 
dysfunction of the most peripheral small airways, was in the normal range in Group1 only and had a 
higher prevalence in Group2. The difference between the two clinical SAD gGroups1 and Group2 
was particularly clear with SAD measurements like IOS and spirometry (Figure 3). Clinical SAD 
Group 2 represents “more severe” SAD, given particularly the presence of more severe small-to-
mid-sized airway obstruction (R5-R20, FEF25-75) and less airway distensibility (AX). In summary, 
we can detect asthma subtypes based on presence and extent of SAD measured with easy-to-
conduct, clinically applicable tools.  
Similarly, with regard to the clinical SAD score, we developed a CT-SAD score. The CT-SAD 
score significantly associated with GINA severity, but less well than the clinical SAD score. CT 
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SAD Group2 had more severe asthma and the physiologic parameters were significantly different 
from controls and from Group1. However, the CT SAD Groups had similar levels of small-to-mid-
sized airway obstruction (R5-R20) and conducting airway ventilation heterogeneity (Scond), 
reflective of dysfunction in small-medium size conducting airways, while Group2 had significantly 
higher air trapping (RV/TLC) and acinar airway ventilation heterogeneity (Sacin) values, reflective 
of the most peripheral small airways. This suggests that CT scan-derived SAD captures regional 
differences in mechanisms of airway dysfunction due to air trapping and small airways as a 
surrogate for peripheral airways impairment
41
. They become apparent in supine position, when 
airway closure and compliance reduction develop as consequence of severe hyperinflation and 
expiratory reserve volume reduction
4237
 in participants with more severe asthma. Notably, we 
observed a difference in airway distensibility (AX) in participants undergoing CT scan, in 
comparison to those who did not (see Supplemental Table 3). It is thus understandable that the 
Clinical SAD score and the CT SAD score were not concordant (r=0.28). Where CT scans 
(performed in supine position) provide information on SAD particularly by changes driven from 
increased residual static lung volumes and air trapping
4338
, the physiologic parameters measured in 
the sitting position provide information on air trapping (body plethysmography RV/TLC), small 
airway obstruction (IOS and FEF25-75) and heterogeneity of both conducting and acinar airway 
ventilation (MBNW). This potentially explains why the CT SAD score, in contrast to the clinical 
SAD score, did not associate with health status or asthma control. 
 
Asthma control is lacking in 50-60% of patients despite guideline-based management
4439
 and 
untreated SAD has been proposed as a contributing factor
1
. Drivers of asthma control include 
treatment adherence and appropriate use of inhalers, psychological factors and environmental 
trigger exposures. The current study suggests that asthma control is also determined by the presence 
of SAD, since ACT was significantly associated with the clinical SAD score and was specifically 
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abnormal in clinical SAD Group2 (most severe SAD). Moreover, a lower ACT score was associated 
with higher IOS parameters R5 and AX values. These data suggest thatHence asthma control may 
be partially driven by SAD, but also obstruction in larger airways given its association with FEV1, 
the gold standard for diagnosis and severity in clinical practice.  
Of note, 91% of our asthma population expressed SAD when defined as any abnormal physiologic 
parameter. Our data imply that they do not all have extensive SAD throughout all airway 
dimensions, since the prevalence varied with the type of physiologic measure. The lowest 
prevalence existed with Sacin (19%) and RV/TLC (22%), both reflecting dysfunction of the most 
peripheral small airways
41
. The highest prevalence was with FEF25-75 (68%) and % fall FVC (73%), 
probably both reflecting obstruction in more small-to-mid-sized airways. Future work will have to 
elucidate if these different prevalence rates define subtypes of SAD (consistent vs. variable, which 
level of airway is involved, and what percent of these airways are involved). We additionally 
compared our SAD prevalence with literature findings (Supplemental Table 7), yet no study 
compared all types of physiologic SAD methods. Anderson et al.
6
 used R5-R20 >0.03 kPa/L/s as 
cut-off for abnormality, concluding that abnormal R5-R20 values were present in all severities of 
asthma, i.e. 65% in British Thoracic Society step2, 64% in step3 and 70% in step4. Our overall 
prevalence with this cut-off was 70%, while our data extend their findings showing that the 
prevalence rates of R5-R20 >LLN  increase from GINA steps 1-5, being 54%, 65%, 70%, 77%, and 
91% respectively. In contrast, the prevalence of Sacin >LLN was lowest in GINA1, almost identical 
in GINA 2-4 and highest in GINA5, suggesting that mostly peripheral airway dysfunction, and 
likely structural changes are present in most severe asthma. In summary, our data are comparable 
with published findings in smaller samples, yet extend these observations by providing information 





Of interest, asthma participants had higher blood pressure than our controls. We did not find 
literature reporting this observation. Comorbidities are thus not only present in COPD, another 
obstructive pulmonary disease 
45.4640,41
, but also occur in asthma patients with a mediann average 
age of 46 (34;54) years. Thise findingis is in agreement with previous studies indicating systemic 
inflammation as one underlying mechanism linking reduced lung function to cardiovascular 
mortality
4742
 and a positive association between lower FEV1 and systemic arterial hypertension, 
while lower ICS doses attenuated the likelihood for hypertension in a population with comparableof 
the same age toas ours
438
. Alternatively, hyperinflation could be also considered to have a role via 
its contribution to changes in intrathoracic pressure that increase left ventricular wall stress, similar 




In conclusion, our data in a large asthma population covering the full spectrum of asthma severity 
show the complexity of SAD. Notwithstanding this, the clinical classification of Small Airways 
Dysfunction is meaningful given its association with asthma severity, control and exacerbations. 
Results show that SAD can be present across all GINA severity stages. Depending on the type of 
physiologic parameter used, the prevalence rate changes considerably, but is consistently the 
highest in GINA5. SAD prevalence rates were lowest with Sacin, reflecting pre-acinar/acinar 
airway abnormalities, and this prevalence was quite comparable over GINA2-4 but again highest in 
GINA5, suggesting structural abnormalities in severe asthma. In contrast, other physiologic 
parameters showed either increasing prevalence rates with severity (RV/TLC) or a stepwise 
increase (FEF25-75, R5-R20, AX, X5). Clinical SAD and CT SAD scores did not significantly 
correlate. SAD derived from the CT scan provides particularly data on air trapping and ventilation 
impairment in more peripheral airways, while the physiologic measures show results from both 
small-medium size conducting airways  and peripheral airways. For clinical practice it is important 
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that physiological, easy-to-conduct measures such aslike IOS and spirometry, delineate two asthma 
SAD subtypes that differ in exacerbation rates, quality of life, asthma severity and control.   
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Legend to Figure 2. Correlations are presented for GINA severity ( top panel), ACT score (middle panel), and Number 
of exacerbations in the past year (lowest panel). Darkest red is highest positive correlation between parameters. Darkest 
blue is the lowest negative correlation between parameters.  All abbreviations are presented in Table 1.  
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Figure 3. Prevalence rates of airways dysfunction in the full asthma cohort and in the 2 SAD subgroups  
  
 
Legend to Figure 3. Prevalence rates of Large Airways abnormalities, and Small Airways abnormalities in the full 
cohort of asthma participants (upper Figure), and according to Clinical SAD Group1 and Group2 (lower Figure).  
Prevalences are based on LLN (Lower Limit of Normal) and ULN (Upper Limit of Normal) values derived from the 
literature or from ATLANTIS controls without airway disease, noted with*. For abbreviations see Table 2. 
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Figure 4. Cross-Sectional Clinical SEM analyses of small airway function 
 
 
Legend to Figure 4. SAD=Small Airway Dysfunction.  
The figure shows the results of Structural Equation Modeling (SEM). The model uses the measured variables presented 
in squares to define the three latent variables (Lung1, Lung2 and Lung3). The strength of the relationship of each 
measured variable to the underlying factor is expressed by the factor loading, presented in the Figure in dashed squares. 
Moreover, the numbers that are not presented in squares are the measured variable variances. The variable SAD is then 
constructed by a structural model that imputes the relations between these three latent variables (Lung1 loading 0.617, 
Lung2 loading 0.518 and Lung3 loading 0.981). Thus SEM modeling  showed that SAD was built up by three latent 
variables, represented in circles ( Lung1 loading 0.617, Lung2 loading 0.518 and Lung3 loading 0.981). The measured 
variables are presented in squares . IOS parameters R5-R20, X5 and AX (reflecting small-to-mid-sized airway 
obstruction/distensibility) loaded to the first latent variable (Lung1), FEF50 and FEF25-75 both corrected for FVC 
(reflecting small-to-mid-sized airway obstruction), to the second latent variable, while MBNW parameter Sacin 
(reflecting dysfunction in the most peripheral airways) loaded both to the first and second latent variable. The lung 
volume parameter RV/TLC % predicted (most peripheral airways dysfunction) and MBNW parameter Scond 
(dysfunction in small-medium size conducting airways) loaded to the third latent variable (Lung3). Please Note that 
Sacin loaded equally with 0.285 and 0.291 to latent variable Lung1 and Lung2 respectively. Please Note that Sacin 
loaded equally with 0.285 and 0.291 to latent variable Lung1 and Lung2 respectively. The numbers on the right hand 
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side represent the variance of the measures, i.e. variance in AX is 0.009, contrasting with the variance in RV/TLC % 
predicted being 0.738.  Goodness of fit of the SEM model was evaluated through the following fit indices: Root Mean 
Square Error of Approximation (RMSEA), Comparative Fit Index (CFI), Tucker-Lewis Index (TLI).  The closer CFI 
and TLI are to 1 and the closer RMSEA is to 0 the better is the model fit. The goodness of fit values (Supplemental 
methods) show there is good coherence of this model to SAD. Fall in FVC during hyperresponsiveness testing 
contributed to the model when analyzed in the subgroup of asthmatic participants who had undergone 





Figure 5.  Correlations of the Clinical SAD score of asthma participants with all parameters measured
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Table 2: Baseline clinical, physiologic and CT characteristics of asthma participants and controls without airway 
disease 
Parameter Asthma  Controls P - value 
    
  n=773 n=99   
Clinical characteristics    
Age, years 46 (34 ; 54) 41 (29 ; 52) 0.0107 
Gender, female N (%) 450 (58) 56 (57) 0.754 
Heart rate, bpm 71 (65 ; 78) 68 (61 ; 75) 0.0104 
BP syst, mmHg 123 (114 ; 131) 120 (110 ; 130) 0.0109 
BP diast, mmHg  80 (70 ; 84) 75 (68 ; 83) 0.0655 
BMI, kg/m
2
 26 (23 ; 30) 24 (21 ; 27) <0.001 
Atopy (Phadiatop), N (%) 454 (81) 39 (46) <0.001 
FeNO, ppb 25 (16 ; 38) 18 (11 ; 26) <0.001 
Ex-smoker, N (%) 156 (20) 19 (19) 0.393 
Current Smoker, N (%) 27 (4) 1(1)  
Eosinophils, 10⁹ /L 0.2 (0.1 ; 0.4) 0.1 (0.1 ; 0.2) <0.001 
Neutrophils, 10⁹ /L 3.7 (3.0 ; 4.7) 3.3 (2.7 ; 4.4) 0.010 
PC20, mg/mL 1.25 (0.4 ; 4.2) 15.23 (16.0 ; 16.0) <0.001 
PD20, mg 0.11 (0.0 ; 0.6) 1.86 (2.0 ; 2.0) <0.001 
Moderate-severe hyperresponsiveness, N (%) 271 (48.4) 0 (0.0) <0.001 
Fall in FVC, % 17 (12 ; 22) 4 (1 ; 8) <0.001 
Lung Physiology characteristics (%predicted)    
FEV1, %predicted 82.7 (69.9 ; 93.8) 100.4 (91.6 ; 107.3) <0.001 
Change FEV1, %predicted 7.6 (4.1 ; 12.7)   
FEV1/FVC, %predicted 85.8 (76.5 ; 93.9) 98.2 (93.8 ; 102.7) <0.001 
IVC, %predicted 99.0 (18.21) 109.7 (15.28) <0.001 
FEF50, %predicted 62.0 (43.2 ; 84.1) 102.0 (84.8 ; 117.3) <0.001 
FEF25-75, %predicted  56.6 (37.6 ; 75.6) 90.7 (75.6 ; 108.1) <0.001 
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RV, %predicted 117.1 (98.4 ; 138.9) 95.6 (87.0 ; 115.7) <0.001  
TLC, %predicted 104.9 (95.9 ; 115.5) 104.8 (96.7 ; 112.5) 0.6216 
RV/TLC, %predicted 106.1 (91.6 ; 125.8) 92.5 (80.6 ; 109.6) <0.001 
FRC, %predicted 108.7 (93.4 ; 126.7) 107.6 (91.9 ; 121.4) 0.4219 
Raw, %predicted 143.0 (91.4 ; 231.1) 77.6 (62.9 ; 99.5) <0.001 
sGaw, %predicted 60.5 (42.5 ; 94.7) 85.0 (61.3 ; 124.6) <0.001 
R20, %predicted 114.6 (97.4 ; 134.9) 96.5 (84.7 ; 110.2) <0.001 
R5-R20, %predicted 278.6 (91.2 ; 640.9) 69.5 (0.0 ; 161.7) <0.001 
X5, %predicted 130.4 (94.4 ; 184.7) 94.6 (77.6 ; 119.7) <0.001 
AX, %predicted 209.3 (95.0 ; 510.0) 66.1 (49.9 ; 108.0) <0.001 
Scond*VT, %predicted 180.5 (100.7 ; 305.3) 95.6 (44.8 ; 149.6) <0.001 
Sacin*VT, %predicted 107.2 (76.7 ; 154.8) 94.1 (61.6 ; 129.8) 0.014 
CT Scan characteristics    
MLD Inspiratory, HU -837.93 (-856.95 ; -811.97) -839.89 (-853.81 ; -812.76) 0.651 
MLD Ratio E/I  0.83 (0.77 ; 0.88) 0.80 (0.73 ; 0.87) 0.081 
VI-856 7.82 (2.5; 19.5) 7.83 (1.5; 15.5) 0.3547 
Lung Volume Ratio 0.50 (0.43 ; 0.60) 0.47 (0.38 ; 0.56) 0.156 
Percentile 15 Inspiratory -921 (-935;-904) -929 (-940;-899) 0.463 
Median LA/BSA Inspiratory 10.4 (2.93) 11.4 (2.83) 0.0327 
Median LA Inspiratory 19.0 (15.7 ; 23.3) 21.3 (18.5 ; 25.6) 0.013 
Pi10   Inspiratory 7.21 (6.59 ; 7.77) 6.70 (6.28 ; 7.84) 0.073 
Po20 %WA Inspiratory 7.41 (6.67 ; 8.50) 7.33 (6.42 ; 9.02) 0.732 
Legend to Table 2: All parameters are presented as Mean (standard deviation), Median (Quartile1 - Quartile 3), or N 
(%) as appropriate. BP= Blood Pressure, Syst=Systolic, BMI= Body Mass Index, FeNO=Fraction of exhaled Nitric 
Oxide, WBC=White Blood Cell, RV= Residual Volume, FRC=Functional Residual Capacity, PC=Provocative 
Concentration, PD=Provocative Dose, PC20 and PD20 = the provocative concentration and dose, respectively, that cause 
a 20% fall in FEV1 from baseline FEV1 during methacholine challenge, Fall in FVC, % fall in FVC at PC20 or PD20; 
FEV1=Forced Expiratory Volume in the 1
st
 second, FVC= Forced Vital Capacity, FEF50=Forced Expiratory Flow at 
50% of FVC, IVC=Inspiratory Vital Capacity, FEF25-75= Forced Expiratory Flow at 25%-75% of FVC,RV= Residual 
Volume, TLC=Total Lung Capacity, FRC= Functional residual Capacity, Raw- airway resistance, sGaw= specific 
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airway conductance,  R5-R20= Peripheral Airway Resistance, X5= Resistance at 5 Hz, AX= Area of Reactance, 
Scond*VT=  ventilation inhomogeneity in the conductive zone of the lungs, Sacin*VT= Ventilation inhomogeneity of 
the acinar zone of the lungs, CT= Computed tomography, MLD Ratio E/I= Mean Lung Density Expiratory to 
Inspiratory ratio, E=Expiratory, I=Inspiratory, LA= Lumen Area (mm2), BSA= Body Surface Area (m2), VI-856= 




Table 3 Characteristics of asthma participants  
Parameter  
  
GINA 1, N (%) 135 (17.5) 
GINA 2, N (%) 85 (11.0) 
GINA 3, N (%) 207 (26.8) 
GINA 4, N (%) 300 (38.8) 
GINA 5, N (%) 46 (6.0) 
Medication use  
SABA, N (%) 671 (86.8) 
Short acting anticholinergics, N (%) 9 (1.2) 
LABA, N (%) 86 (11.1) 
ICS, uncombined N (%),  183 (23.9) 
        Extra-fine ICS, N (%) 58 (7.5) 
        Non-extra-fine ICS, N (%) 127 (16.4) 
ICS mean daily dose ( BDP equivalent), µg 669 (446) 
ICS/LABA, N (%) 460 (59.5) 
ICS/LABA mean daily dose (BDP-equivalent), µg 882 (634) 
          Extra-fine ICS/LABA, N (%) 124 (16.0) 
          Non-extra-fine ICS/LABA, N (%) 336 (43.5) 
Oral corticosteroids, N (%) 22 (2.8) 
Oral corticosteroids mean daily dose, mg 7.5 (5.0 ; 20.0) 
Montelukast, N (%) 144 (18.6) 
LAMA, N (%) 29 (3.8) 
Biologics, N (%) 32 (4.1) 
Duration of disease, years 16.7 (5.6 ; 29.3)   
Age 1st diagnosis <18 years, % 39 
Unscheduled consultations past 12 months, N 0.3 (1.4) 
Exacerbations past 12 months, N 0.2 (0.6) 
>1 exacerbation past 12 months, % 14 
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 ACT, total score 21.0 (18.0 ; 24.0) 
 ACT < 15, % 13 
 ACQ-6, total score 0.8 (0.3;1.5) 
 ACQ-6 > 1.25, % 33 
 EQ-5D-5L, VAS score 80.0 (70.0 ; 90.0) 
 Mini AQLQ, total score 5.6 (4.7 ; 6.3) 
Legend to Table 3. Data are presented as N (%) or Median (Q1 to Q3 ranges) as appropriate. ACT=Asthma Control 
Questionnaire, ACQ-6= Asthma Control Questionnaire-6, EQ-5D-5L= Standardized measure of health status 
descriptive system, Mini AQLQ= Mini Asthma Quality of Life Questionnaire. Number of exacerbations and 
unscheduled consultations are based on the past 12 months. The daily dose of ICS (inhaled corticosteroids) is expressed 
in BDP equivalents, µg/day  
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Table 43. Prevalence rates (%) of abnormal SAD parameters (>ULN or <LLN) according to GINA stages 
 
Legend to Table 3. for abbreviations see Table 2. GINA severity was based on past treatment used.  Note that the 
highest prevalence of SAD is always in GINA5, the lowest prevalence across all GINA stages is with Sacin. 
 
  
Parameter, % GINA 1 GINA 2 GINA 3 GINA 4 GINA 5 
FEF25-75 41.4 43.0 50.5 54.5 80.4 
FEF50 37.3 49.4 54.1 55.3 75.0 
% fall FVC 71.7 67.9 75.2 72.7 84.2 
RV/TLC 14.0 16.3 19.3 28.1 31.1 
FRC 16.2 23.4 19.1 24.5 27.3 
R5-R20 29.9 40.0 36.5 50.5 70.6 
AX 32.4 34.4 35.4 49.2 67.7 
X5 22.8 31.8 28.5 33.2 53.1 
Scond  20.5 20.0 30.0 33.3 63.6 




Table 54. Relationship of lung physiology variables with number of exacerbations and unscheduled consultations  
Number of exacerbations   




  FEF25-75, L/s corrected for FVC -1.226 0.034  
  R5-R20, kPa/L/s 2.894 0.010  
  Raw, kPa*s/L -2.286 0.014  
  RV/TLC, ratio 2.773 0.0438  
  sGaw, 1/kPa*s -0.316 0.0327  
  Height, cm -0.053 <.001  
  PC20 and PD20 categories – vVery mild vs nNormal -1.058 0.0217 0.006 
  PC20 and PD20 categories - mMild vs nNormal -1.624 <.001  
  PC20 and PD20 categories - mModerate-severe vs nNormal -1.212 0.0104  
  Sex - Female vs Male 0.717 0.0326  
 
Number of unscheduled consultations due to worsening symptoms  




  FEV1 , L 0.647 <.001  
  FRC , L -0.425 0.0107  
  RV/TLC, ratio 4.659 0.0101  
  sGaw , 1/kPa*s) -0.466 <.001  
  PC20 and PD20 categories – very mild vs normal -0.999 0.0104 0.023 
  PC20 and PD20 categories - mild vs normal -0.888 0.0108  
  PC20 and PD20 categories - moderate-severe vs normal -0.792 0.012  
  Sex (male/female) - Female vs Male 0.647 0.023  
Legend to Table 4. MBNW parameters were not used, since this would restrict the number of asthmatics to be analyzed 
(see Methods). P-value type 3 assesses the statistical difference in hyperresponsiveness severity stages. The coefficients 
are per 1 unit increase in each parameter. As example: the estimate of R5-R20 (kPa/L/s) for exacerbations is 2.894, one 
needs to calculate exp(2.894) = 18.065 and this means that for 1-unit increase of R5-R20 the mean number of 
exacerbations will increase by a factor of 18.07, holding other variables constant. Mild hyperresponsiveness means a 
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higher PD20 or PC20 value. Patients with more severe hyperresponsiveness have more frequent exacerbations and 














Table 6. Clinical characteristics of asthma participants in Clinical SAD Group1 and Clinical SAD Group2  
Parameter Group1 (n=452)  Group2 (n=312) P-value  
    
Clinical SAD score -0.256 (-0.34;-0.16) 0.284 (0.12;0.56) <0.001 
Age, years  43 (30;53) 50 (40;58) <0.001 
Gender, female N (%) 257 (57) 186 (60) 0.4548 
Heart rate, bpm 70 (64;77) 72 (65;80) 0.023 
BP syst, mmHg 120 (110;130) 125 (117;135) <0.001 
BP diast, mmHg  78 (70;82) 80 (72;87) <0.001 
BMI, kg/m
2
 25 (22;28) 28 (25;32) <0.001 
Atopy, N (%) 262 (81) 187 (79) 0.531 
FeNO, ppb 24 (16;37) 25 (16;39) 0.424 
Ex-smoking, N (%) 90 (20) 65 (21)  0.474 
Duration smoking, years 10 (5.1;16.7) 14 (8.0;20.0) 0.020 
GINA 1/2, N (%) 157 (35) 60 (9) <0.001 
GINA 3, N (%) 135 (30) 70 (22) <0.001 
GINA 4/5, N (%) 160 (35) 182 (58) <0.001 
ICS uncombined, N (%) 98 (22) 83 (27) 0.1216 
ICS/LABA, N (%) 254 (56) 202 (65) 0.0218 
ICS dose, BDP equivalence 603.2 (384.9) 739.9 (482.5) 0.0879 
ICS/LABA dose, BDP equivalence 818.8 (563.1) 959.6 (710.8) 0.0788 
Oral corticosteroids, N (%) 8 (1.8) 14 (4.5) 0.0327 
Eosinophils, 10⁹ /L 0.21 (0.12;0.35) 0.26 (0.16;0.40) <0.001 
Neutrophils, 10⁹ /L 3.50(2.88;4.47) 3.90(3.07;4.91) <0.001 
FEV1, %predicted 90.2 (80.1 ; 98.4) 70.1 (58.8 ; 81.8) <0.001 
Change FEV1, %predicted 6.5 (3.6 ; 9.9) 10.2 (5.5 ; 14.9) <0.001 
FEV1/FVC, %predicted 90.1 (83.4 ; 96.6) 78.3 (70.5 ; 86.0) <0.001 
FEF50, %predicted 75.2 (59.1 ; 94.8) 44.4 (31.5 ; 59.7) <0.001 
IVC, %predicted 103.3 (18.0) 93.1 (17.0) <0.001 
FEF25-75, %predicted, N (%) 66.6 (51.7 ; 86.9) 37.7 (27.8 ; 52.2) <0.001 
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RV, %predicted 108.9 (92.7 ; 127.2) 134.2 (110.9 ; 158.8) <0.001 
TLC, %predicted 104.3 (95.7 ; 114.0) 105.9 (95.9 ; 116.9) 0.2439 
FRC, %predicted 107.3 (91.7 ; 123.0) 111.2 (94.8 ; 129.9) 0.011 
Raw, %predicted 110.1 (81.4 ; 167.8) 192.3 (139.6 ; 309.3) <0.001 
sGaw, %predicted 66.5 (47.4 ; 105.1) 47.0 (33.9 ; 72.4) <0.001 
R20, %predicted 107.8 (92.2 ; 125.7) 126.3 (109.7 ; 147.9) <0.001 
R5-R20, %predicted 129.6 (29.0 ; 304.0) 636.3 (378.2 ; 1065.0) <0.001 
X5, %predicted 109.1 (80.9 ; 140.5) 199.0 (151.6 ; 254.6) <0.001 
AX, %predicted 115.3 (65.3 ; 198.3) 613.6 (384.7 ; 868.3) <0.001 
Scond*VT, %predicted 144.6 (75.9 ; 239.7) 245.2 (161.7 ; 392.1) <0.001 
Sacin*VT, %predicted 93.1 (70.6 ; 127.0) 140.8 (95.8 ; 190.5) <0.001 
No. unscheduled consultations , N 0.15 (0.57) 0.50 (2.08) 0.001 
No. exacerbations, N 0.16 (0.52) 0.29 (0.76) 0.002 
 >= 1 exacerbation, N (%) 50 (11.1) 59 (18.9) 0.002 
Duration of disease, years 11.6 (4.4 ; 24.5) 21.5 (9.4 ; 35.0) <0.001 
Age at 1
st
 Diagnosis, years 25 (10 ; 41) 22 (7 ; 41) 0.131 
Age at 1
st
 Diagnosis < 18 years, N(%) 162 (36.2) 134 (42.9) 0.0659 
ACT, total score 22.0 (19.0 ; 24.0) 20.0(17.0 ; 23.0) <0.001 
ACT score < 15, N (%) 40 (8.9) 60 (19.2) <0.001 
ACQ-6, total mean score 0.66 (0.2 ; 1.3) 1.00 (0.5 ; 1.8) <0.001 
ACQ-6 score > 1.25, N (%) 124 (27.4) 126 (40.4) <0.001 
EQ-5D-5L, VAS score 83.0 (75.0 ; 90.0) 80.0 (70.0 ; 90.0) <0.001 
Mini-AQLQ, total score 5.7 (4.8;6.4) 5.5(4.5;6.3)  
CT Scan characteristics    
MLD Inspiratory, HU -844.53(-859.56 ; -815.71) -831.65(-854.46 ; -808.68) 0.0986 
MLD Ratio E/I 0.82 (0.76 ; 0.87) 0.84 (0.78 ; 0.90) 0.0107 
VI-856 6.96 (1.92 ; 18.27) 9.54 (3.18 ; 21.30) 0.0768 
Lung Volume Ratio 0.49 (0.41 ; 0.56) 0.51 (0.45 ; 0.62) 0.008 
Percentile 15 Inspiratory -922.33 (-937.51 ; -906.97) -917.72 (-930.20 ; -900.38) 0.054 
Median LA/BSA Inspiratory 10.95 (2.66) 9.67 (3.08) <0.001 
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Median LA Inspiratory 20.37 (17.32 ; 23.47) 17.82 (14.59 ; 22.08) <0.001 
Pi10   Inspiratory 7.12 (6.54 ; 7.77) 7.28 (6.59 ; 7.78) 0.641 
Po20 %WA Inspiratory 7.49 (6.71 ; 8.52) 7.27 (6.57 ; 8.41) 0.4658 
Legend to Table 6. Data are presented as N (%), Mean (SD) and Median (interquartile ranges) as appropriate; for 
abbreviations see Table 21 and Table 3. 
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Supplement belonging to  
Exploring the relevance and extent of small airways dysfunction in asthma: AssessmenT 
of smalL Airways involvemeNT In aSthma, the ATLANTIS study 
Postma DS,  Brightling C, Baldi S, Van den Berge M, Fabbri L, Gagnatelli A, Papi A, 
Van der Molen T, Rabe K,  Siddiqui S, Singh D, Nicolini G, Kraft M and the 
ATLANTIS study group* 
 
Collaborators 
* Badorrek P, Boersma W, Broeders M, Chetta A, Cukier A, D’Amato M, Djukanovic R, 
Foschino MP, Gessner C, Hanania N, Martin R, Milleri S, Olivenstein R, Paggiaro P 
Pizzichini E, Plaza Moral V, Scichilone N, Schilz R, Spanevello A, Stelmach R, Vroegop J, 




Participants were recruited in 29 worldwide sites: Brazil (3), Canada (1), China (1), Germany 
(3), Italy (8), the Netherlands (4), Spain (1), UK (4), USA (4). Participants gave informed 
consent separately for the full study and the optional measurements (e.g. Computed 
Tomography (CT) scan, bronchial biopsies). All measurements were performed according to 
international guidelines, if available (e.g. spirometry, body plethysmography), or pre-
specified, standardized procedures in references or as described in detail below. Some 
measurements were performed in a subgroup of patients in selected sites (e.g. Fraction of 
exhaled Nitric Oxide (FeNO), oscillometry system (IOS), CT). 
Papers in press and other supporting documentation
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The baseline visit was divided into three days to allow all the different tests being performed 
without conflict. Day 1 included measurements in the following order: healthcare resource 
consumption assessments (asthma participants only); Asthma Control Test (ACT), 6-items 
Asthma Control Questionnaire (ACQ-6) and mini-Asthma Quality of Life Questionnaire 
(mini-AQLQ); Small Airways Dysfunction Tool (SADT) and EuroQol-5D-5L (EuroQol-5 
dimensions-5Levels); bronchial hyperresponsiveness questionnaire (BHQ); FeNO; 
Methacholine challenge test; nasal brushing. Day 2 included measurements in the following 
order: pre-bronchodilator IOS; pre-bronchodilator Multiple Breath Nitrogen Washout test 
(MBNW); pre-bronchodilator lung volumes measurement with body box; pre-bronchodilator 
spirometry; only in asthma participants the following: administration of 4 puffs (4 × 100 µg) 
of salbutamol by pressured metered dose inhaler plus spacer; post-bronchodilator IOS; post-
bronchodilator MBNW; Post-bronchodilator lung volumes measurement with body box; Post-
bronchodilator spirometry; CT scan. Sites performing bronchoscopy with endobronchial and 
transbronchial biopsies had a further separate third visit. 
 
Pulmonary function tests  
Lung function measurements and daily calibration of the equipment was performed according 
to the recommendation of the Official Statement of the European Respiratory Society and 
American Thoracic Society
1
. Predicted values, where available, were calculated according to 
the formulas reported by Quanjer et al.
2
. Throughout the study, the clinic visits and the lung 
function measurements started in the morning, approximately at the same time of the day for 
each patient and after appropriate washout from bronchodilators, i.e. 6 hours for short acting 
β2-agonists (SABA); 12 hours (8 hours in patients with severe asthma defined as step 4 or 5 
of treatment according to GINA 2014 www.ginasthma.org) for short acting antimuscarinic 
agents (SAMA);  12 hours for long acting β2-agonists twice daily (LABA); 72 hours (24 
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hours in patients with severe asthma defined as step 4 or 5 of treatment according to GINA 
2014 www.ginasthma.org) for long-acting β2-agonists once daily (LABA) and long-acting 
antimuscarinic agents (LAMA) once daily.  
Airway hyperresponsiveness was measured with the two-minute tidal breathing method or 5-
breath dosimeter method according to the published international guidelines
(3,4)
. As example, 
the tidal breathing method consists of the inhalation of increasing concentrations of 
methacholine by using a nebulizer with a two-way valve that allows a controlled amount of 
material to be delivered during continuous nebulization while the patient breathes quietly 
(tidal breathing) for two minutes. This procedure is repeated with increasing concentrations of 
methacholine until the Forced Expiratory Volume in one second (FEV1) decreases by at least 
20% from baseline value or until the highest concentration of methacholine (16 mg/mL) has 
been delivered. At the same time, the corresponding fall in Forced Vital Capacity (FVC) is 
recorded. Positive airway hyperresponsiveness to methacholine was defined as the 
provocative concentration or provocative dose when the FEV1 falls with 20% from baseline 
FEV1, i.e. PC20 < 8 mg/mL or PD20< 0.7 mg for those subjects not using inhaled 
corticosteroids (ICS) and PC20 < 16 mg/mL or PD20 < 1.4 mg for subjects using  ICS 
respectively.  
For analyses, we stratified asthma patients for severity of airway hyperresponsiveness as 
follows: 1) normal PC20 and PD20 > 16 mg/ml and >1 mg respectively, 2) very mild 4-16 
mg/ml and 0.6-0.10 mg,  3) mild 1-4 mg/ml and 0.6-1.0 mg, and 4) moderate-severe < 1 
mg/ml and < 0.3 mg respectively.  
Body plethysmography was performed according to standard procedures
2
. Residual Volume 
(RV), RV divided by Total Lung Capacity (RV/TLC), Functional Residual Capacity (FRC), 




Impulse oscillometry system (IOS) was performed according to the standard procedures
5
 only 
if the instrument was locally available at the site (n= 22 out of 29 centers). 
MBNW was performed with a standardized instrument provided to all sites: EXHALYZE-R 
D, according to previously published standard procedures
6
. In short, ventilation distribution 
inhomogeneity was assessed during tidal breathing from FRC, by examining inert gas 
clearance over a series of breaths. The indices of ventilation heterogeneity in the peripheral 
regions of the lung, where gas transport occurs predominantly across a pressure gradient 
through convection [ventilation heterogeneity in convection-dependent airways (Scond)] and 
across a concentration gradient through diffusion [ventilation heterogeneity in diffusion-
dependent airways (Sacin)], were derived.  
Questionnaires  
Asthma control was measured with the ACT and the ACQ-6, whereas asthma-related quality 
of life was assessed with the mini-AQLQ
7,8





Healthcare resource consumption  
Healthcare resource consumption in the past 12 months was assessed by the numbers of 1) 
unscheduled consultations for asthma (without hospitalization) defined as: the need for a visit 
(medical specialist or general practitioner) due to symptoms requiring treatment and 2) 
exacerbations  defined by the use of an antibiotic and/or systemic corticosteroid course (> 3 
days). The other health care utilization questions were not analyzed, due to very low 
prevalences (asthma-specific hospital admissions (number and length), asthma-specific 





Blood was collected for total and differential cell counts as performed in the local 
laboratories.  
FeNO 
FeNO was performed only if the instrument was locally available at the site (22 sites out of 
29). Depending on the specific equipment available at the site, FeNO was measured as 
standard single flow (50ml/s) or multiple flows. FeNO measurements were performed, 
according to international guidelines before spirometry, at constant flow (50 mL/s) in 
triplicate by using an electrochemical/chemiluminescent analyzer. Exhaled NO levels were 
expressed as parts per billion (ppb). The mean of 3 values obtained within 10% of each other 
was used to calculate FeNO result. 
If available, measurements at multiple constant flows (50, 100, 150, and 350 mL/s) was 
performed. At each flow, the mean of 3 values obtained within 10% of each other was used to 
calculate bronchial (JNO) and alveolar NO (Calv). The contributions of the bronchi (bronchial 
NO flux) and the alveoli (alveolar NO concentration) to FeNO was derived from regression 
analysis, with NO output as the dependent and exhalation flow rate as the independent factor. 
The slope and intercept of the regression line are approximate values of alveolar NO 
concentration and bronchial NO flux, respectively. 
Computed Tomography  
Volumetric whole lung scans were obtained using a standardised protocol for each scanner 
manufacturer and model to approximate to the reference scanner site (Leicester, Siemens 
Sensation 16 scanner [16 x 0.75 mm collimation, 1.5 mm pitch, 120 kVp, 40 mAs, 0.5 
seconds rotation time and scanning field of view of 500 mm]). The scans were obtained at full 
inspiration (near TLC) and at the end of expiration (near FRC). All subjects were coached in 
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the breath holding techniques, and practiced breath holding, immediately prior to scanning. 
All asthmatics were scanned within 60 minutes of receiving 400 micrograms of salbutamol 
via a spacer. Images were reconstructed with a slice thickness of 0.75 mm at a 0.5 mm 
interval using B35f kernel for the reference scanner or similar algorithm. Post processing was 
performed on semi-automated software, Apollo (VIDA Diagnostics, Iowa).   
QCT parameters obtained, with excellent inter-observer variability
10
, included morphometry, 
measured in mm
2
, Lumen Area (LA), Total Area (TA), Wall Area (WA)          and 
percentage Wall Area (%WA)        
       
  
  . Air-trapping measures were Mean Lung 
Density (MLD), the mean value of CT numbers distribution, measured upon inspiration 
(MLDI) , and upon expiration (MLDE), and MLD Expiratory to Inspiratory ratio (MLDE/I) 
measured in Hounsfield Units (HU) and Relative Voxel Change (RVC)              
                                 . The Perc15 was measured in Hounsfield 
Units (HU), i.e. the value below which the 15% of voxels with the lowest density are 
distributed. Fractal dimensions of the low attenuation clusters on inspiratory scans (LAC-D -
950) and on expiratory scans (LAC-D -856) were also measured. All morphometry measures 




 (BSA)   
                       
    
 . CT scans 
were excluded for the following reasons: i) deviations in the CT acquisition protocol, ii) lung 
density was greater in the inspiratory compared to expiratory scans and iii) CT and body 
plethysmography lung volumes were compared and for scans where the volumes were 
discrepant from the mean by > 3 SD. Density measures were corrected to account for scanner 
manufacturer and model variability. A representative example of an inspiratory and expiratory 
scan, airway reconstruction from the inspiratory scan and densitometry maps from both the 




A total of 800 subjects were considered sufficient to estimate all necessary parameters of the 
structural equation model (SEM). Assuming a Subjects-To-Variables (STV) ratio of 20:1 
11,12
 
it was possible to include up to 13 factors of influence (3 parameters per factor) into the 
model. Assuming a small variability in the parameters of interest of healthy subjects, a 
number of 100 healthy volunteers was considered sufficient. The sample size for patients 
undergoing CT-scans was calculated based on the prevalence of patients with SAD expected 
to be approximately 20%, an agreement between classification of SAD based on the SEM and 
CT-scan > 0.8 (Cohen’s kappa), a Type-I-error of 0.05 and a Power of > 80%. Following the 
algorithm given by Cantor
13
, a sample size of > 528 asthmatics valid for CT-scan and SEM 
evaluation was calculated. Moreover, Approximately 50 controls were considered sufficient 
to provide reference normal values for CT scan airways geometry and densitometry.  
Primary and secondary analyses were performed on the evaluable set. This analysis set 
comprised all enrolled subjects, independently of any possible protocol deviation, who 
underwent visit 1 with at least one study endpoint related to the primary analysis noted.  
SEM model 
Structural equation modeling was applied in asthma. As small airways dysfunction cannot be 
directly observed and measured, we inferred its unobserved or ‘’latent’’ constructs by 
modeling them from the physiological and CT data we collected on related and directly 
measurable variables, which are the “effects” of the latent constructs itself. The following 
variables reflecting Small Airways Dysfunction and both Small and Large Airways 
Dysfunction were considered in the SEM model: % fall in FVC at PC20 or PD20, R5-R20 
(small-to-mid-sized  airway resistance with IOS), X5 (resistance at 5Hz with IOS), AX 
(Airway reactance with IOS), Scond, Sacin, RV % predicted, RV/TLC % predicted, FRC 
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%predicted, Forced Expiratory Flow at 50% of FVC (FEF)50/FVC, FEF25-75/FVC, FEV1 % 
predicted, FEV1/FVC, IVC % predicted, PC20.   
The correlation matrix was computed to evaluate the correlations among observed variables. 
Summary statistics were presented. High correlations among the observed variables indicated 
the presence of underlying latent variables. An exploratory factor analysis for observed 
variables was performed in order to identify the underlying SAD factor structure. The final 
underlying SAD factor structure identified at the previous step was tested by specifying a 
confirmatory factor model. 
1. Causal model 
Once that the measurement model was set up, each causal relationship specified in the initial 
path diagram was added and tested one at time to build the final structural equation model. 
2. Small Airways Dysfunction classification 
Once the measurement model was set and fit the data properly, it was considered completed 
and it was used to classify each patient in the SAD groups, by using a model-based clustering. 
The initial assumption of two groups (based on clinical hypotheses) was compared to different 
numbers of groups, by means of posterior fit statistics such as AIC, BIC and Entropy. The 
Log-likelihood and the number of parameters were presented as well.    
3. Agreement evaluation 
A SAD classification was obtained by considering CT Scan as well. A model-based clustering 
was used to classify each asthmatic patient in two groups identifying SAD or not SAD, by 
using the CT Scan data reflecting Small Airways Dysfunction (MLD ratio, Lung Volume 
ratio, VI -856). 
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The classification and the scores derived from Clinical SAD model were compared with the 
one derived from CT-scan in order to evaluate the rate of agreement, using Cohen’s kappa 
coefficient (K) and Pearson’s correlation14. 
The detection of outliers in the SEM analysis was based on log-likelihoods of each 
observation in Full-Information Maximum-Likelihood (FIML) estimation. An individual with 
a high/extreme log-likelihood value with a disproportionate impact on the model was 
considered as outlier. 
The following identification rules and estimation procedures / methods were considered in 
this analysis. Identification constraints of the scale and measurement units were taken into 
account for the latent variables. The estimation method used for all the analysis was the 
Robust Maximum likelihood estimation method that takes properly into account the different 
nature of the observed variables (binary, continuous, ordinal, count). When it resulted 
computational unfeasible the Robust Weighted Least Square estimation method was used 
alternatively. 
Goodness of fit of the SEM model was evaluated through the following fit indices: Root 
Mean Square Error of Approximation (RMSEA), Comparative Fit Index (CFI), Tucker-Lewis 
Index (TLI).  The closer CFI and TLI are to 1 and the closer RMSEA is to 0 the better is the 
model fit. These summary statistics (with the relative p-value, if applicable), together with the 
unstandardized and standardized parameter estimates (with the relative p-value), and the R-
Square for each endogenous variable / factor if available, were computed for each part of the 
model.  
The final clinical SAD model identified with cross-sectional data (visit 1) was tested also at 
visit 2 (6 months after the baseline visit) and visit 3 (12 months after the baseline visit). The 
final model structure was confirmed at each visit and the final longitudinal SEM model was 
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estimated. The clinical SAD groups at each visit were derived through a Latent Transition 
Analysis based on the longitudinal SEM model.  
Multiple regressions 
The relationships between lung physiology variables and healthcare consumption in 
asthmatics were analyzed using a Poisson regression model for each healthcare resource 
consumption variable. Only variables with a number of missing values approximately lower 
than 50% were considered in the analysis. The model included the healthcare resource 
consumption variable as dependent variable and all the lung physiology variables as 
independent variables. The overdispersion parameter based on the deviance was considered in 
order to account for between-patient variability and standard errors were estimated allowing 
for extra-Poisson variation. The backward elimination procedure was applied to identify the 
final model.  
Predicted, Lower Limit of Normal (LLN) and Upper Limit of Normal (ULN) equations 
Continuous prediction equations and their lower limits of normal for physiologic variables 
were computed using the following prediction equations. For variables such as FEV1/FVC, 
FEV1, the Quanjer regression equations
2
 were used to derive the predicted value and the lower 
limit of normal (LLN) for each subject. For the variables such as RV, RV/TLC, FRC, IVC 
regression equations were used to derive the predicted value and the lower limit of normal 
(LLN) and upper limit of normal (ULN) for each subject. 
For IOS and MBNW variables such as R20, R5-R20, X5, AX, Scond, and Sacin and FEF50 
and % fall FVC, the regression models are presented in Supplemental Table 1. They were 
estimated with the study data from controls without airway disease in order to obtain the 




Supplemental Table 1. Summary equations for predicted values 
 
Variable Unit Regression equation for predicted value RSD 
Male 
R20 kPa/L/s 0.606347 – (Age x 0.000713) – (Height x 0.001702)   0.018575 
R5-R20 kPa/L/s 0.270439 + (Age x 0.000285) – (Height x 0.001378)   0.039838 
X5 kPa/L/s – 0.473195 – (Age x 0.000867) + (Height x 0.002408)   0.040651 
AX kPa/L/s 2.426203 + (Age x 0.004599) – (Height x 0.013162)   0.326243 
Scond VT, L
-1
 0.047168 + (Age x 0.000324) – (Height x 0.000245)                        0.018575 
Sacin VT, L
-1
 0.286222 + (Age x 0.000899) – (Height x 0.001158)                        0.047755 
FEF50 L/sec 2.168062 – (Age x 0.035548) + (Height x 0.019211)   0.775259 
Fall in FVC % – 24.93070 + (Age x 0.008664) + (Height x 0.156234)   4.424367 
    
Female 
R20 kPa/L/s 0.606347 – (Age x 0.000713) – (Height x 0.001702) + 0.040388 0.018575 
R5-R20 kPa/L/s 0.270439 + (Age x 0.000285) – (Height x 0.001378) – 0.037831 0.039838 
X5 kPa/L/s – 0.473195 – (Age x 0.000867) + (Height x 0.002408) – 0.007246   0.040651 
AX kPa/L/s 2.426203 + (Age x 0.004599) – (Height x 0.013162) – 0.088393 0.326243 
Scond*VT L
-1
 0.047168 + (Age x 0.000324) – (Height x 0.000245) + 0.001518     0.018575 
Sacin*VT  L
-1
 0.286222 + (Age x 0.000899) – (Height x 0.001158) – 0.041527      0.047755 
FEF50 L/sec 2.168062 – (Age x 0.035548) + (Height x 0.019211)   0.775259 
Fall in FVC % – 24.93070 + (Age x 0.008664) + (Height x 0.156234) +4.498172 4.424367 
 




Supplemental Table 2 shows the differential count of monocytes, basophils and 
lymphocytes and baseline pre-and post-bronchodilator physiological values and number 
and percentage of asthmatics with abnormal physiologic values ( >ULN or <LLN). 
Supplemental Table 2. Baseline physiological parameters pre- and post-bronchodilator and prevalence of 
abnormal physiological parameters based on LLN (Lower Limit of Normal) and upper Limit of normal 
(ULN, see methods) 
 
Parameter Asthma  Controls P - value 
Clinical characteristics    
WBC, 10⁹ /L 6.4 (5.4 ; 7.8) 5.8 (4.9 ; 6.0) <0.001 
Monocytes, 10⁹ /L 0.5 (0.4 ; 0.6) 0.4 (0.3 ; 0.5) <0.001 
Lymphocytes, 10⁹ /L 1.9(1.6 ; 2.3) 1.8 (1.4 ; 2.2) 0.02 
Basophils, 10⁹ /L 0.0 (0.0 ; 0.1) 0.0 (0.0 ; 0.0) 0.003 
FEV1, L 2.64 (2.10 ; 3.31) 3.51 (3.04 ; 3.89) <0.001 
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Post FEV1, L 2.94 (2.34 ; 3.62)     
% Change FEV1 9.19 (4.6 ; 16.7)   
FEV1 < LLN, N (%) 305 (40.0) 2 (2.0) <0.001 
FEV1/FVC,  % 69 (60 ; 80) 80 (80 ; 80) <0.001 
Post FEV1/FVC, % 74 (70 ; 80)   
FEV1/FVC, < LLN, N (%) 389 (51.1) 2 (2.1) <0.001 
% Fall in FVC > ULN, N (%) 365 (73.1) 2 (2.0) <0.001 
FEF50, L/sec  2.29 (1.51 ; 3.12) 3.70 (3.32 ; 4.28) <0.001 
Post FEF50, L/sec 2.95 (2.01 ; 3.90)   
FEF50 < LLN, N (%) 375 (52.4) 3 (3.4) <0.001 
IVC, L 3.65 (2.90 ; 4.54) 4.31 (3.65 ; 5.17) <0.001 
Post IVC, L 3.82 (3.13 ; 4.79)   
IVC, L < LLN, N (%) 96 (15.6) 1 (1.2) <0.001 
FEF25-75, L/sec 1.74 (1.09 ; 2.56) 3.07 (2.58 ; 4.19) <0.001 
Post FEF25-75, L/sec 2.33 (1.51 ; 3.29)   
FEF25-75 < LLN, N (%) 489 (67.6) 15 (15.5) <0.001 
FEF25-75 < LLN, N (%) 374 (51.7) 4 (4.1) <0.001 
RV, L 2.15 (1.72 ; 2.65) 1.85 (1.53 ; 2.16) <0.001 
Post RV, L 2.00 (1.61 ; 2.41)   
RV > ULN , N (%) 210 (30.3) 11 (13.3) 0.001 
TLC, L 6.03 (5.07 ; 7.16) 6.12 (5.40 ; 6.89) 0.42 
Post TLC, L 5.96 (4.98 ; 7.12)   
TLC > ULN, N (%) 134 (18.1) 13 (13.4) 0.25 
RV/TLC 0.35 (0.29 ; 0.42) 0.30 (0.25 ; 0.35) <0.001 
Post RV/TLC 0.33 (0.27 ; 0.38)   
RV/TLC > ULN , N (%) 163 (22.) 9 (9.3) 0.003 
FRC, L 3.26 (2.64 ; 3.95) 3.22 (2.85 ; 3.62) 0.76 
Post FRC , L 3.09 (2.52 ; 3.75)   
FRC > ULN, N (%) 157 (21.6) 13 (13.7) 0.07 
Raw, kPa*s/L 0.33 (0.22 ; 0.53) 0.200 (0.16 ; 0.24) <0.001 
Post Raw, 1kPa*s/L 0.23 (0.16 ; 0.37)   
Raw > ULN, N (%) 146 (21.8) 6 (6.5) <0.001 
sGaw, 1/KPa*s 1.11 (0.80 ; 1.74) 1.53 (1.18 ; 2.12) <0.001 
Post sGaw, 1/KPa*s 1.51 (1.10 ; 2.24)   
sGaw < LLN, N (%) 8 (1.4) 0 (0.0) 0.25 
R20,  kPa/L/s 0.35 (0.30 ; 0.43) 0.30 (0.25 ; 0.36) <0.001 
Post R20,  kPa/L/s 0.31 (0.26 ; 0.37)   
R20 > ULN, N (%) 145 (23.1) 9 (9.9) 0.004 
R5-R20,  kPa/L/s 0.07 (0.03 ; 0.16) 0.02 (0.00 ; 0.04) <0.001 
Post R5-R20,  kPa/L/s 0.05 (0.02 ; 0.09)   
R5-R20 > ULN, N (%) 259 (42.4) 8 (8.9) <0.001 
X5,  kPa/L/s -0.13 (-0.20 ; -0.09) -0.09 (-0.11 ; -0.08) <0.001 
Post X5,  kPa/L/s -0.11 (-0.15 ; -0.08)   
X5 < LLN, N (%) 182 (30.6) 4 (4.3) <0.001 
AX,  kPa/L/s 0.62 (0.28 ; 1.77) 0.21 (0.14 ; 0.32) <0.001 
Post AX,  kPa/L/s 0.32 (0.16 ; 0.75)   





 0.035 (0.02 ; 0.06) 0.015 (0.00 ; 0.03) <0.001 
Post Scond*VT, L
-1
 0.028 (0.02 ; 0.04)     
Scond*VT, L
-1
> ULN, N (%) 115 (30.1) 3 (4.0) <0.001 
Sacin*VT, L
-1
 0.113 (0.08 ; 0.17) 0.088 (0.06 ; 0.13) 0.002 
Post Sacin*VT, L
-1
 0.103 (0.06 ; 0.15)     
Sacin *VT, L
-1
>  ULN, N (%) 73 (19.3) 4 (5.9) 0.007 
CT Scan characteristics    
MLD Inspiratory, HU -838 (-857; -812) -840 (-854; -813) 0.65 
MLD Expiratory, HU -685 (66.9) -662 (74.0) 0.04 
Lung Volume Inspiratory,  L 5.22 (4.37; 6.22) 5.45 (4.59; 6.75) 0.30 
Lung Volume Expiratory,  L 2.62 (2.14; 3.15) 2.54 (2.21; 3.08) 0.80 
Lung Volume Ratio E/I 0.498 (0.426 ; 0.595) 0.467 (0.38 ; 0.56) 0.16 
VI 856 Expiratory 7.82 (2.5; 19.5) 7.83 (1.5; 15.5) 0.35 
VI 950 Inspiratory 3.64 (1.4 ; 7.8) 4.61(1.0 ; 8.5) 0.83 
Percentile 15 Inspiratory -921 (-935; -904) -929 (-940 ; -899) 0.46 
Median Wall Area Inspiratory 33.3 (28.5 ; 37.4) 35.4 (30.8 ; 39.8) 0.05 
Median Total Area Inspiratory 52.3 (44.8 ; 60.5) 57.7 (50.5 ; 66.0) 0.01 
Median %WA Inspiratory 63.0 (3.47) 61.7 (2.48) 0.003 
Median WA/BSA Inspiratory 17.6 (3.57) 18.7 (3.28) 0.06 
Pi10   Inspiratory 7.21 (6.59 ; 7.77) 6.70 (6.28 ; 7.84) 0.07 
Po20 %WA Inspiratory 7.41 (6.67 ; 8.50) 7.33 (6.42 ; 9.02) 0.73 
Legend to Supplemental Table 2. All parameters are presented as Mean (standard deviation), Median (Quartile1 
- Quartile 3), or N (%) as appropriate. WBC=White Blood Cell, RV= Residual Volume, FRC=Functional 
Residual Capacity, , FEV1=Forced Expiratory Volume in the 1
st
 second, FVC=Forced Vital Capacity, 
FEF50=Forced Expiratory Flow at 50% of Forced Vital Capacity, IVC=Inspiratory Vital Capacity, FEF25-
75=Forced Expiratory Flow at 25%-75% of Forced Vital Capacity, R5-R20=Peripheral Airway Resistance, 
X5=Resistance at 5 Hz, AX=Area of Reactance, PC20=Provocative Concentration of methacholine causing a 
20% fall in FEV1from baseline, PD20= Provocative Dose of methacholine causing a 20% fall in FEV1 from 
baseline ,CT= Computed tomography, MLD Ratio E/I= Mean Lung Density Expiratory to Inspiratory ratio, 
E=Expiratory, I=Inspiratory, BSA= Body Surface Area (m
2
), WA= Wall Area (mm
2
), TA= Total Area (mm
2
), 
VI=Voxel Index, Pi10= Internal perimeter of 10mm, Po20= Outer perimeter of 20mm. 
 
Baseline measures were performed in all patients, apart from MBNW and CT scans that were 
performed in a subgroup (n=382 asthmatics with and n=391 without MBNW, and n=308 with 
and n= 465 without CT scan).  Asthmatics with and without CT scan were quite similar in 
overall characteristics (Supplemental Table 3), with a significant difference between those 
with and without CT in FEV1/FVC ratio (0.69 vs 0.70 respectively), reversibility (9.8% vs 
8.7%) and IOS values, R5-R20 (0.09 vs 0.06 kPa/L/s), AX (0.81 vs 0.52 kPa/L/s) and X5 (-
0.150 and -0.120 kPa/L/s). Those with CT scan also used more frequently ICS than those 
without CT available (43 vs 19%) with a higher mean daily BDP equivalent dose (711 vs 578 




Supplemental Table 3. Demographics and physiological characteristics of asthma participants with and 
without CT scans. 
Parameter Asthma Group  
with CT Scan 
Asthma Group without 
CT Scan 
P-value 
Clinical SAD Score  -0.065 (-0.27 ; 0.30) -0.147 (-0.29 ; 0.13) 0.002 
Number of subject in Clinical SAD Group 1 167  (54.2) 285  (62.5)  
Number of subject in Clinical SAD Group 2 141  (45.8) 171  (37.5)  
Age, years 46 (34 ; 55) 46 (34 ; 54) 0.78 
Gender, female 187  (60.7) 263  (56.6) 0.25 
Race, Caucasian 270  (87.7) 410  (88.2) 0.06 
Blood pressure Systolic, mmHg 123.5 (111 ; 131) 123 (115 ; 131) 0.43 
Blood pressure Diastolic, mmHg 78 (70 ; 83) 80 (70 ; 85) 0.04 
Heart rate, beats/min 72 (64 ; 79) 71 (65 ; 78) 0.86 
Height, cm 167.55 (160.8 ; 175.7) 170 (161.0 ; 177.0) 0.13 
Weight, kg 75.15 (64.6 ; 88.0) 76 (65.0 ; 89.0) 0.90 
BMI, kg/m² 26.2 (23.4 ; 30.3) 26.04 (23.1 ; 29.6) 0.44 
Atopy (phadiatop +) 213  (82.2) 241  (79) 0.34 
FeNO (flow rate 50) 25 (17 ; 40) 24 (15 ; 37) 0.11 
SABA 259  (84.1) 412  (88.6) 0.07 
Short acting anticholinergics 4  (1.3) 5  (1.1) 0.75 
LABA 40  (13) 46  (9.9) 0.18 
ICS 105  (34.1) 79  (17) <0.001 
ICS daily dose (BDP-equivalent, mcg) 711.65 (474.6) 611.18 -401.05 0.13 
    Extra-fine ICS 43  (14) 15  (3.2) <0.001 
    Non-extra-fine ICS 62  (20.1) 65  (14) 0.02 
ICS/LABA 159  (51.6) 300  (64.5) <0.001 
ICS/LABA daily dose (BDP-equivalent, mcg) 829.85 (580.34) 912.92 -663.28 0.13 
    Extra-fine ICS/LABA 31  (10.1) 93  (20) <0.001 
    Non-extra-fine ICS/LABA 128  (41.6) 208  (44.7) 0.38 
Systemic corticosteroids 10  (3.2) 12  (2.6) 0.59 
Systemic corticosteroids mean daily dose 10 (5.0 ; 20.0) 6.25 (5.0 ; 20.0) 0.84 
Montelukast 52  (16.9) 92  (19.8) 0.31 
Lama 15  (4.9) 14  (3) 0.18 
Biologics 7  (2.3) 25  (5.4) 0.03 
GINA Step 1 47  (15.3) 88  (18.9) 0.07 
GINA Step 2 45  (14.6) 40  (8.6) 0.07 
GINA Step 3 79  (25.6) 128  (27.5) 0.07 
GINA Step 4 122  (39.6) 178  (38.3) 0.07 
GINA Step 5 15  (4.9) 31  (6.7) 0.07 
Smoker, Current Smoker, n (%) 10  (3.2) 17  (3.7) 0.95 
Smoker, Ex-smoker 63  (20.5) 93  (20) 0.95 
Number of Pack-Years 4 (1.9 ; 7.5) 4.5 (2.0 ; 7.5) 0.52 
Duration Smoking, years 12 (5.9 ; 18.1) 11.5 (7.0 ; 20.0) 0.65 
Neutrophils, 10^9/L 3.745 (2.97 ; 4.66) 3.625 (2.95 ; 4.74) 0.75 
Eosinophils, 10^9/L 0.25 (0.13 ; 0.39) 0.21 (0.13 ; 0.37) 0.31 
PC20 and PD20 category, Moderate Severe 130  (52.8) 141  (44.9) 0.003 
PC20, mg/mL 1.06 (0.4 ; 3.0) 1.47 (0.5 ; 5.9) 0.06 
15 
 
PD20, mg/mL 0.04 (0.0 ; 0.4) 0.2 (0.1 ; 0.7) <0.001 
Fall in FVC, % 17 (12.0 ; 23.0) 17 (11.0 ; 22.0) 0.44 
Fall in FVC, % predicted 351.74 (231.8 ; 629.4) 363.99 (226.3 ; 548.4) 0.39 
Fall in FVC > LLN 148  (74.7) 217  (72.1) 0.51 
FEV1, L 2.645 (2.00 ; 3.25) 2.64 (2.13 ; 3.42) 0.20 
FEV1, %predicted 82.6 (68.6 ; 93.8) 83.0 (71.0 ; 93.7) 0.52 
FEV1 < LLN 130  (42.2) 175  (38.5) 0.30 
Change FEV1, %predicted 8.1 (4.5 ; 13.1) 7.1 (3.9 ; 12.2) 0.04 
% Change FEV1 9.83 (5.3 ; 17.2) 8.67 (4.1 ; 16.3) 0.04 
FEV1/FVC, L 0.69 (0.6 ; 0.8) 0.7 (0.6 ; 0.8) 0.03 
FEV1/FVC, %predicted 84.2 (75.7 ; 92.0) 86.9 (77.3 ; 95.2) 0.007 
FEV1/FVC < LLN 175  (57) 214  (47.1) 0.008 
FEF50, L/sec 2.185 (1.45 ; 3.06) 2.39 (1.54 ; 3.28) 0.07 
FEF50, %predicted 60.0 (40.5 ; 80.3) 64.1 (44.9 ; 85.3) 0.03 
FEF50 < LLN 164  (56.6) 211  (49.5) 0.07 
FEF25-75, L/sec 1.7 (1.06 ; 2.66) 1.76 (1.11 ; 2.52) 0.70 
FEF25-75, %predicted  55.9 (36.6 ; 74.6) 56.6 (38.7 ; 76.3) 0.51 
FEF25-75  < LLN  159  (51.6) 215  (51.8) 0.96 
IVC, L 3.62 (2.85 ; 4.51) 3.65 (2.94 ; 4.56) 0.69 
IVC, %predicted 99.4 (17.93) 98.6 (18.44) 0.56 
IVC < ULN 43  (15.8) 53  (15.5) 0.92 
RV, L 2.12 (1.69 ; 2.58) 2.2 (1.77 ; 2.70) 0.09 
RV, %predicted 111.9 (95.4 ; 140.4) 119.6 (101.6 ; 138.6) 0.19 
RV, L > LLN 84  (29.8) 126  (30.7) 0.81 
TLC, L 5.95 (5.05 ; 7.02) 6.06 (5.09 ; 7.28) 0.30 
TLC, %predicted 105.7 (95.9 ; 117.3) 104.4 (95.7 ; 114.1) 0.22 
TLC > LLN 65  (22) 69  (15.6) 0.03 
RV/TLC, ratio 0.344 (0.29 ; 0.43) 0.35 (0.29 ; 0.42) 0.98 
RV/TLC, %predicted 104.7 (89.0 ; 126.6) 106.7 (93.9 ; 125.2) 0.49 
RV/TLC > LLN 72  (24.3) 91  (20.6) 0.24 
FRC, L 3.17 (2.62 ; 3.88) 3.28 (2.66 ; 3.98) 0.45 
FRC, %predicted 108.5 (93.7 ; 127.6) 109.2 (93.2 ; 125.9) 0.68 
FRC, L > LLN 66  (22.4) 91  (21) 0.63 
Raw, kPa*s/L 0.32 (0.22 ; 0.47) 0.35 (0.23 ; 0.59) 0.03 
Raw, %predicted 129.6 (90.4 ; 190.9) 151.9 (93.7 ; 263.8) 0.02 
Raw > LLN 42  (16.4) 104  (25.1) 0.008 
sGaw, 1/KPa*s 1.05 (0.79 ; 1.60) 1.16 (0.80 ; 1.87) 0.04 
sGaw, %predicted 56.7 (41.7 ; 92.0) 62.3 (43.8 ; 99.1) 0.05 
sGaw < ULN 6  (2.8) 2  (0.6) 0.06 
R20,  kPa/L/s 0.36 (0.30 ; 0.43) 0.35 (0.30 ; 0.42) 0.18 
R20, %predicted 116.4 (97.4 ; 136.2) 113.7 (97.6 ; 133.2) 0.59 
R20 > LLN 66  (24.5) 79  (21.9) 0.45 
R5-R20,  kPa/L/s 0.09 (0.03 ; 0.18) 0.06 (0.03 ; 0.14) 0.03 
R5-R20, %predicted 344.0 (95.2 ; 701.4) 227.1 (90.8 ; 619.6) 0.08 
R5-R20 > LLN 123  (47.1) 136  (38.9) 0.04 
X5,  kPa/L/s -0.15 (-0.21 ; -0.10) -0.12 (-0.18 ; -0.09) <0.001 
X5, %predicted 140.7 (101.7 ; 191.9) 126.4 (89.2 ; 179.3) 0.01 
X5 < ULN 94  (37.2) 88  (25.7) 0.003 
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AX,  kPa/L/s 0.81 (0.35 ; 1.90) 0.52 (0.23 ; 1.56) 0.002 
AX, %predicted 247.8 (113.4 ; 607.3) 175.0 (77.6 ; 417.3) <0.001 
AX > LLN 103  (47) 114  (37.4) 0.03 
Scond*VT, L
-1
 0.036 (0.019 ; 0.053) 0.0334 (0.020 ; 0.058) 0.72 
Scond*VT, %predicted 182.2 (102.8 ; 323.9) 175.3 (93.4 ; 302.3) 0.66 
Scond*VT> LLN 56  (29.5) 59  (30.7) 0.79 
Sacin*VT, L
-1
 0.1083 (0.076 ; 0.162) 0.1183 (0.082 ; 0.170) 0.11 
Sacin*VT, %predicted 106.3 (75.8 ; 144.6) 109.3 (79.6 ; 158.4) 0.28 
Sacin *VT> LLN 36  (19) 37  (19.5) 0.92 
Legend to Supplemental Table 3. For abbreviations see Supplemental Table 2. 
 
SEM models 
Supplemental Figure 2A presents the same model including hyperresponsiveness testing as 
well. The % Fall in FVC during hyperresponsiveness testing loaded to the third latent 
variable, without much change in the RMSEA, CFI and TLI parameters and the correlation 
between the baseline model without and with Fall in FVC highly correlated (r=0.99). 
Figure 2B presents the Clinical SAD model without Fall in FVC that was tested at Visit 2 
and Visit 3, and the same model structure was confirmed at the three visits. Figure 2C 
presents the CT SEM analyses of small airway function. 
Supplemental Figure 2A. Cross-Sectional Clinical SEM analysis of small airway function with fall in FVC 
during hyperresponsiveness testing 
 
 






Supplemental Figure 2C. CT SEM analyses of small airway function  
 
 
Legend to Supplemental Figure 2. RMSEA= Root Mean Square Error of Approximation, CFI= Comparative 
Fit Index, TLI= Tucker-Lewis Index. For the other abbreviations, see supplemental Table 2. Figure 2A shows 
the model of clinical SEM analysis based on small airways parameters that were available at baseline. Figure 
2B shows the model of clinical SEM analysis based on three visits of the longitudinal part of Atlantis. SAD1, 
SAD2 and SAD3, represent the assessments of SEM analysis at visits 1 ( baseline), visit 2, after 6 months, 
and visit 3 after 12 months of follow-up respectively. There is a high correlation between the three models. 
Figure 2C shows the model of clinical SEM analysis based CT parameters 
Supplemental Table 4 presents the predicted, >ULN and < LLN values of physiologic 
parameters for Clinical SAD Group1 and Clinical SAD Group2. 
 
Supplemental Table 4. Physiological parameters for the two Clinical SAD Groups including predicted 
values, >ULN and < LLN ranges  
Parameter Group 1 Group 2 P - value 
Clinical characteristics    
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WBC, 10⁹ /L 6.1 (5.4;7.5) 6.9 (5.8;8.1) <0.001 
Monocytes, 10⁹ /L 0.44 (0.37 ; 0.55) 0.50 (0.39 ; 0.60) 0.003 
Lymphocytes, 10⁹ /L 1.82 (1.53 ; 2.18) 1.94 (1.60 ; 2.33) 0.01 
Basophils, 10⁹ /L 0.03 (0.02 ; 0.05) 0.04 (0.02 ; 0.06) 0.02 
PC20, mg/mL 1.5 (0.5 ; 4.8) 0.91 (0.2 ; 4.0) 0.006 
PD20, mg 0.23 (0.1 ; 0.8) 0.04 (0.0 ; 0.2) <0.001 
PC20 and PD20 categories    
Very mild, N (%) 78 (22) 40 (20) <0.001 
Mild, N (%) 102 (29) 33 (16) <0.001 
Moderate-severe, N (%) 146 (41) 123 (61) <0.001 
Fall in FVC, % 17.0 (11.0 ; 22.0) 18.5 (14.0 ; 23.0) 0.02 
Fall in FVC > ULN, N (%) 238 (70) 126 (81) 0.01 
FEV1, L 2.96 (2.50 ; 3.61) 2.105 (1.68 ; 2.65) <0.001 
Post FEV1, L 3.23 (2.72 ; 3.89) 2.42 (1.97 ; 3.05) <0.001 
% Change FEV1 7.02 (3.9 ; 11.8) 15.17 (7.3 ; 24.2) <0.001 
FEV1 < LLN, N (%) 94 (21) 211 (68) <0.001 
FEV1/FVC, % 73 (70 ; 80) 63 (60 ; 70) <0.001 
Post FEV1/FVC, % 78 (70 ; 80) 68 (60 ; 70) <0.001 
FEV1/FVC, L < LLN, N (%) 156 (35) 233 (75) <0.001 
FEF50, L/sec 2.79 (2.13 ; 3.61) 1.53 (1.05 ; 2.13) <0.001 
Post FEF50, L/sec 3.48 (2.76 ; 4.26) 2.06 (1.51 ; 2.89) <0.001 
FEF50< LLN, N (%) 143 (34) 232 (79) <0.001 
IVC, L 4.02 (3.27 ; 4.83) 3.26 (2.55 ; 4.05) <0.001 
Post IVC, L 4.19 (3.38 ; 4.94) 3.52 (2.81 ; 4.43) <0.001 
IVC < LLN, N (%) 40 (11) 56 (0.213) <0.001 
FEF25-75, L/sec 2.28 (1.65 ; 2.98) 1.11 (0.77 ; 1.58) <0.001 
Post FEF25-75, L/sec 2.92 (2.12 ; 3.71) 1.55 (1.08 ; 2.25) <0.001 
FEF25-75 < LLN, N (%) 140 (33) 234 (0.775) <0.001 
RV, L 1.99 (1.62 ; 2.40) 2.475 (1.99 ; 3.06) <0.001 
Post RV, L 1.95 (1.54 ; 2.26) 2.1 (1.72 ; 2.61) <0.001 
RV >  ULN, N (%) 71 (17) 139 (50) <0.001 
TLC, L 6.080 (5.21 ; 7.10) 5.900 (4.88 ; 7.19) 0.08 
Post TLC, L 6.040 (5.20 ; 7.16) 5.780 (4.85 ; 7.08) 0.02 
TLC > ULN, N (%) 72 (16.3) 62 (20.8) 0.12 
RV/TLC  0.31 (0.27 ; 0.37) 0.42 (0.34 ; 0.48) <0.001 
Post RV/TLC 0.31 (0.26 ; 0.36) 0.36 (0.30 ; 0.42) <0.001 
RV/TLC >ULN, N (%) 44 (10) 119 (40) <0.001 
FRC, L 3.19 (2.64 ; 3.85) 3.325 (2.67 ; 4.01) 0.23 
Post FRC, L 3.145 (2.59 ; 3.76) 2.94 (2.42 ; 3.68) 0.06 
FRC Pleth > ULN, N (%) 79 (18.1) 78 (26.7) 0.04 
Raw, kPa*s/L 0.27 (0.20 ; 0.41) 0.46 (0.32 ; 0.69) <0.001 
Post Raw, kPa*s/L 0.2 (0.15 ; 0.29) 0.3 (0.20 ; 0.46) <0.001 
Raw > ULN, N (%) 21 (15.1) 18 (17.0) 0.70 
sGaw, 1/KPa*s 1.21 (0.87 ; 1.89) 0.89 (0.65 ; 1.40) <0.001 
Post sGaw, 1/KPa*s 1.65 (1.23 ; 2.48) 1.285 (0.88 ; 1.88) <0.001 
sGaw, (1/kPa*s) < LLN, N (%) 4 (1.0) 4 (2.2) 0.27 
R20,  kPa/L/s 0.33 (0.27 ; 0.39) 0.4 (0.34 ; 0.47) <0.001 
Post R20,  kPa/L/s 0.29 (0.24 ; 0.34) 0.35 (0.30 ; 0.43) <0.001 
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R20 > ULN, N (%) 59 (16) 86 (0.347) <0.001 
R5-R20,  kPa/L/s 0.04 (0.01 ; 0.07) 0.18 (0.12 ; 0.27) <0.001 
Post R5-R20,  kPa/L/s 0.03 (0.01 ; 0.06) 0.1 (0.05 ; 0.18) <0.001 
R5-20 > ULN, N (%) 57 (15) 202 (86) <0.001 
X5,  kPa/L/s -0.11 (-0.14 ; -0.08) -0.22 (-0.28 ; -0.17) <0.001 
Post X5,  kPa/L/s -0.09 (-0.11 ; -0.07) -0.15 (-0.21 ; -0.12) <0.001 
X5 < LLN, N (%) 28 (7) 154 (72) <0.001 
AX,  kPa/L/s 0.33 (0.19 ; 0.60) 2.14 (1.49 ; 3.16) <0.001 
Post AX,  kPa/L/s 0.22 (0.13 ; 0.34) 0.83 (0.43 ; 1.61) <0.001 
AX > ULN, N (%) 37 (12) 180 (90) <0.001 
Scond*VT, L
-1
 0.0267 (0.015 ; 0.042) 0.0491 (0.038 ; 0.075) <0.001 
Post Scond*VT, L
-1
 0.0217 (0.013 ; 0.035) 0.0397 (0.024 ; 0.058) <0.001 
Scond*VT> ULN, N (%) 49 (20) 66 (49) <0.001 
Sacin*VT, L
-1
 0.0943 (0.070 ; 0.134) 0.1533 (0.114 ; 0.197) <0.001 
Post Sacin*VT, L
-1
 0.0841 (0.059 ; 0.138) 0.1273 (0.091 ; 0.176) <0.001 
Sacin *VT> ULN, N (%) 30 (12) 43 (32) <0.001 
 
Legend to Supplemental  Table 4. For Abbreviations see supplemental Table 2. 
 
Correlations of CT SAD score with physiologic and clinical parameters  
Supplemental Figure 3 shows the correlations between the CT SAD score, based on the CT 
SEM model, and parameters measured. Correlations were much lower than those of the 
clinical SAD score that showed r-values >0.6. The highest correlations of the CT SAD score 
(>0.4 and <-0.4) existed for duration of smoking, age and RV/TLC (positively) and FEV1 
(negatively). The CT SAD score did not significantly associate with ACT (r=-0.05, p=0.367), 
but did so modestly with the number of exacerbations (r=+0.12, p=0.04). The CT SAD score 
was significanlty different across GINA severities, mean SAD score in GINA 1 being -0.747, 
GINA 2 – 0.459, GINA 3 -0.408, GINA 4 -0.166 and GINA 5 +0.088 ( ANOVA p=0.013).  
 
Model-based clustering defining CT SAD Groups  
Two groups, n=169 and n=125, were identified based on the CT SAD parameters within 
participants who underwent CT scanning (clinical characteristics: see Supplemental Tables 5 
20 
 
and 6). The two CT SAD groups demonstrated significantly different clinical SAD scores and 
CT SAD scores  and were comparable in heart rate, blood pressures, height, weight, atopy, 
FeNO levels, smoking habits, blood cell differential counts, ACT score and duration of 
disease. They used comparable asthma drugs, apart from LABA and montelukast use being 
higher in Group2 vs Group1 (17 vs 9%, 25 vs12%).  Group1 was significantly younger, and 
demonstrated, higher BMI, female prevalence and GINA stage. Sacin values were comparable 
between Group1 and controls, while Sacin was significantly different between Group2 and 
controls. Group1 and 2 had comparable values of hyperresponsiveness (severity and fall in 
FVC), Scond, R5-R20, Ax and X5 values. Overall, Group1 had otherwise fewer abnormal 
physiologic parameters. As expected, the small airway parameters of the CT-scan were 
significantly different between the two Groups; inspiratory parameters were comparable. 
Clinical SAD analysis in patients with CT scans available 
Because CT scans were available in 294 out of 739 asthma patients, we performed additional 
SEM analysis on clinical SAD parameters in this subset. The model structure and parameters 
estimates were very similar to the overall model. Including CT scan variables into the model 
(Supplemental Figure 2C) provided an additional latent variable (the CT scan). The weight of 
this latent variable in the overall measure of SAD was 0.321 (factor loading) and r
2
 was 0.1, 
showing that the low relation between CT-scan variables and non-CT clinical variables. 
 
Supplemental Figure 3 presents the correlations of all parameters measured and the CT 
SAD score.  









Supplemental Table 5.  Clinical characteristics of asthma patients in CT SAD Group1 and CT SAD 
Group2  
Parameter Group1 (n=169)  Group2 (n=125) P-value  
Clinical SAD score -0.12 (-0.28; 0.21) -0.005 (-0.24 ; 0.40) 0.04 
CT Scan SAD score -1.01 (-0.74) 0.54 (-0.76) <0.001 
Age,years  43 (31 ; 54) 50 (40 ; 56) 0.002 
Gender, female N (%) 96 (57) 82 (66 0.13 
Heart rate, bpm 72.0 (65 ; 80) 70.0 (64 ; 77) 0.20 
BP syst, mmHg 124 (114 ; 131) 121 (110 ; 130) 0.25 
BP diast, mmHg  77 (70 ; 83) 79 (70 ; 83) 0.99 
BMI, kg/m
2
 27 (24 ; 30) 25(22 ; 29) 0.008 
Atopy, N (%) 114 (81) 89 (83) 0.72 
FeNO, L/min 28 (17 ; 43) 24 (17 ; 37) 0.37 
Ex-smoking, N (%) 33 (20) 29 (23) 0.73 
Duration smoking, years 10.0 (5.0 ; 16.0) 12.2 (9.0 ; 19.0) 0.15 
GINA 1/2, N (%) 61 (37) 29(23) 0.007 
GINA 3, N (%) 50 (30) 27 (22) 0.007 
GINA 4/5, N (%) 58 (34) 69 (55) 0.007 
ICS uncombined, N(%) 52 (31) 47 (38) 0.08 
ICS/LABA, N(%) 84 (50) 68 (54) 0.43 
ICS dose, BDP equivalent, µg 627.5(415.8) 802.2(541.9) 0.10 
ICS/LABA dose, BDP equivalent, µg 724.8 (418.4) 962.1 (723.5) 0.05 
Oral corticosteroids, N (%) 3 (1.8) 7 (5.6) 0.10 
WBC, 10⁹ /L 6.6 (5.4 ; 7.7) 6.5 (5.6 ; 7.7) 0.78 
Eosinophils, 10⁹ /L 0.25 (0.15 ; 0.38) 0.24 (0.13 ; 0.40) 0.10 
Neutrophils, 10⁹ /L 3.72 (2.90 ; 4.52) 3.67 (3.00 ; 4.59) 0.67 
Monocytes, 10⁹ /L 0.46 (0.39 ; 0.59) 0.46 (0.38 ; 0.56) 0.84 
Lymphocytes, 10⁹ /L 1.90 (1.51 ; 2.24) 1.85 (1.50 ; 2.30) 0.74 
Basophils, 10⁹ /L 0.03 (0.02 ; 0.06) 0.03 (0.02 ; 0.06) 0.47 
PC20, mg/mL 1.14 (0.4 ; 3.3) 0.98 (0.3 ; 3.0) 0.55 
PD20, mg 0.03 (0.0 ; 0.3) 0.09 (0.0 ; 0.6) 0.09 
PC20 and PD20 categories    
Very mild, N (%) 23 (16.2) 20 (21.5) 0.74 
Mild, N (%) 37 (26.1) 25 (26.9) 0.74 
Moderate-severe, N (%) 78 (54.9) 46 (49.5) 0.74 
Fall in FVC, % 17.0 (13.0 ; 21.0) 17.00 (11.0 ; 23.5) 0.78 
FEV1, L 2.86 (2.21 ; 3.45) 2.27 (1.80 ; 2.91) <0.001 
Post FEV1, L 3.15 (2.45 ; 3.95) 2.69 (2.04 ; 3.21) <0.001 
% Change FEV1 9.06 (5.1 ; 16.7) 11.11 (5.4 ; 19.7) 0.24 
FEV1/FVC, % 71 (60 ; 80) 65 (60 ; 70) <0.001 
Post FEV1/FVC, % 76 (70 ; 80) 70 (60 ; 80) <0.001 
FEF50, L/sec 2.36 (1.77 ; 3.25) 1.84 (1.09 ; 2.90) <0.001 
Post FEF50, L/sec 3.23 (2.23 ; 4.09) 2.36 (1.59 ; 3.50) <0.001 
IVC, L 3.82 (3.12 ; 4.71) 3.39 (2.66 ; 4.27) 0.002 
Post IVC, L 4.10 (3.24 ; 5.02) 3.59 (2.83 ; 4.41) 0.001 
FEF25-75, L/sec 1.92 (1.32 ; 2.81) 1.38 (0.78 ; 2.32) <0.001 
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Post FEF2575, L/sec 2.64 (1.68 ; 3.53) 1.82 (1.10 ; 2.92) <0.001 
RV, L 1.95 (1.60 ; 2.47) 2.17 (1.85 ; 2.73) 0.002 
Post RV, L 1.79 (1.44 ; 2.13) 2.06 (1.66 ; 2.44) <0.001 
TLC, L 6.040 (5.04 ; 7.05) 5.86 (5.01 ; 6.99) 0.68 
Post TLC, L 5.99 (4.96 ; 7.30) 5.81 (4.96 ; 6.83) 0.45 
RV/TLC, L 0.32 (0.26 ; 0.40) 0.38 (0.32 ; 0.48) <0.001 
Post RV/TLC, L 0.26 (0.24 ; 0.34) 0.35 (0.29 ; 0.41) <0.001 
FRC, L 3.01 (2.53 ; 3.74) 3.37 (2.82 ; 4.00) 0.009 
Post FRC, L 2.90 (2.31 ; 3.57) 3.20 (2.67 ; 3.76) 0.005 
Raw, kPa*s/L 0.29 (0.21 ; 0.46) 0.33 (0.22 ; 0.47) 0.32 
Post Raw, kPa*s/L 0.20 (0.15 ; 0.28) 0.21 (0.16 ; 0.32) 0.46 
sGaw, 1/KPa*s 1.07 (0.80 ; 1.60) 1.04 (0.76 ; 1.54) 0.84 
Post sGaw, 1/KPa*s 1.59 (1.21 ; 2.10) 1.48 (1.11 ; 2.07) 0.82 
R20,  kPa/L/s 0.35 (0.31 ; 0.42) 0.37 (0.30 ; 0.46) 0.27 
Post R20,  kPa/L/s 0.31 (0.27 ; 0.36) 0.33 (0.27 ; 0.41) 0.07 
R5-R20,  kPa/L/s 0.08 (0.03 ; 0.16) 0.10 (0.03 ; 0.18) 0.31 
Post R5-R20,  kPa/L/s 0.04 (0.02 ; 0.09) 0.06 (0.02 ; 0.12) 0.07 
X5,  kPa/L/s -0.14 (-0.21 ; -0.10) -0.15 (-0.21 ; -0.11) 0.14 
Post X5,  kPa/L/s -0.10 (-0.15 ; -0.07) -0.11 (-0.17 ; -0.09) 0.04 
AX,  kPa/L/s 0.73 (0.31 ; 1.83) 0.92 (0.44 ; 1.95) 0.23 
Post AX,  kPa/L/s 0.32 (0.16 ; 0.87) 0.38 (0.22 ; 0.83) 0.17 
Scond*VT, L
-1
 0.04 (0.02 ; 0.05) 0.04 (0.020 ; 0.054) 0.71 
Post Scond*VT, L
-1
 0.02 (0.01 ; 0.04) 0.03 (0.014 ; 0.051) 0.06 
Sacin*VT, L
-1
 0.10 (0.07 ; 0.13) 0.13 (0.095 ; 0.191) 0.003 
Post Sacin*VT, L
-1
 0.082 (0.06 ; 0.13) 0.12 (0.082 ; 0.171) 0.001 
 Unscheduled consultations, N 0.27 0.38 0.80 
 No. exacerbations 0.18 0.34 0.12 
 > 1 exacerbation, N (%) 22 (13) 24 (19) 0.03 
 Duration of disease, years 19.74 (7.6 ; 29.7) 21.56 (8.0 ; 35.8) 0.12 
Age at 1
st
 Diagnosis 19 20 0.75 
Age at 1
st
 Diagnosis < 18 years, N (%) 79 (47) 58 (46) 0.88 
 ACT, total score 21 (18 ; 24) 21 (18 ; 23) 0.13 
 ACT score < 15, N (%) 24 (14.2) 19 (15.2) <0.001 
 ACQ-6, total mean score 0.67 (0.3 ; 1.7) 0.83 (0.3 ; 1.3) 0.63 
 ACQ-6 score > 1.25, N (%) 60 (35.5) 38 (30.4) <0.001 
 EQ-5D-5L: VAS score 80 (70.0 ; 90.0) 80 (70.0 ; 90.0) 0.48 
 
Legend to Supplemental Table 5. Data are presented as %, Mean (SD) and Median (interquartile ranges) as 
appropriate; for abbreviations see Supplemental Table 1 . 
Supplemental Table 5 presents the predicted, >ULN and < LLN values of physiologic 
parameters for CT SAD Group1 and CT SAD Group2. 
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Supplemental Table 6. physiological parameters for CT SAD Group1 and Group2, including predicted 
values, ULN and LLN  
Parameter Group 1 (n=169) Group 2 (n=125) P - value 
FEV1, %predicted 85.99 (73.0 ; 96.5) 75.26 (61.8 ; 90.4) <0.001 
Change FEV1, %predicted 7.93 (4.6 ; 13.2) 8.18 (4.3 ; 13.0) 0.10 
FEV1/FVC, %predicted 86.14 (79.7 ; 92.1) 80.45 (69.9 ; 90.0) <0.001 
FEV1 < LLN, N (%) 56 (33.1) 65 (52.0) 0.001 
FEV1/FVC, L < LLN , N (%) 86 (50.9) 80 (64.5) 0.02 
FEF50, %predicted 62.83 (48.2 ; 84.6) 53.16 (31.9 ; 78.8) 0.001 
FEF50 < LLN, N (%) 84 (52.2) 71 (60.7) 0.16 
IVC, %predicted 101.32 (17.13) 97.71 (18.67) 0.11 
IVC < LLN, N (%) 22 (15.1) 18 (15.9) 0.85 
FEF25-75, %predicted  50.34 (37.0 ; 69.1) 40.77 (22.1 ; 62.1) <0.001 
FEF25-75 < LLN , N (%) 108 (63.9) 91 (72.8) 0.11 
FEF25-75, %predicted  59.01 (44.3 ; 76.1) 48.63 (26.7 ; 68.8) <0.001 
FEF25-75  < LLN, N (%) 76 (45.0) 75 (60.0) 0.01 
RV, %predicted 107.14 (90.9 ; 129.5) 125.12 (102.0 ; 148.5) <0.001 
RV > ULN, N (%) 36 (22.8) 43 (38.7) 0.005 
TLC, %predicted 104.57 (95.9 ; 115.6) 107.69 (96.1 ; 120.0) 0.09 
TLC > ULN, N (%) 30 (18.2) 34 (28.8) 0.04 
RV/TLC %predicted 97.71 (82.8;115.7) 109.90 (93.6 ; 133.8) <0.001 
RV/TLC > ULN, N (%) 30 (18.2) 37 (31.4) 0.01 
FRC, %predicted 103.80 (90.2 ; 119.9) 113.85 (100.7 ; 132.3) <0.001 
FRC > ULN, N (%) 30 (18.2) 33 (28.4) 0.04 
Raw, %predicted 123.84 (86.3 ; 187.7) 137.71 (97.0 ; 211.6) 0.21 
Raw > ULN, N (%) 21 (15.1) 18 (17.0) 0.69 
sGaw, %predicted 60.09 (42.5 ; 91.6) 55.72 (41.3 ; 93.2) 0.69 
sGaw < LLN, N (%) 3 (2.4) 2 (2.4) 1.000 
R20, %predicted 113.20 (98.4 ; 131.3) 122.31 (94.5 ; 140.8) 0.30 
R20 > ULN, N (%) 28 (19.0) 36 (32.1) 0.02 
R5-R20, %predicted 320.84 (125.0 ; 728.2) 366.85 (51.2 ; 651.3) 0.94 
R5-R20 > ULN, N (%) 61 (42.7) 57 (52.3) 0.13 
X5, %predicted 141.06 (101.7 ; 190.5) 140.23 (101.5 ; 188.4) 0.75 
X5 < LLN, N (%) 52 (36.6) 36 (35.6) 0.88 
AX, %predicted 242.26 (104.5 ; 616.7) 250.06 (132.1 ; 579.6) 0.75 
AX > ULN, N (%) 55 (44.4) 45 (50.6) 0.37 
% fall in FVC > ULN, N (%) 90 (78.9) 53 (69.7) 0.15 
Scond*VT, %predicted 182.35 (110.6 ; 340.8) 178.72 (97.3 ; 277.5) 0.38 
Scond*VT> ULN, N (%) 34 (31.2) 19 (25.7) 0.42 
Sacin*VT, %predicted 93.53 (72.1 ; 129.3) 122.63 (84.3 ; 175.8) 0.007 
Sacin *VT, L
-1
> ULN, N (%) 14 (12.8) 21 (28.8) 0.008 
 
Legend to Supplemental Table 6. For abbreviations see Supplemental Table 1. 
 
















































Age, years 46 42 42 - - 44 53 45 57/54 44 
Female % 58 64 63 - - 57 50 69 49/61 61 
BMI, kg/m
2
 26 - 28 - - 26 - 24 27/30 26 
Atopy, % 81 - - - - 73 - 66 79/71 60 
Ex-smoker, % 20 ?  - - 15 - - ? 31 
Curr smoker,% 4 0 10 - - 13 - 18 0 4 






















EF ICS, % 7.5 - 9 <5% <5% - - - - - 
ICS/LABA % 54 - - 100 100 100 - 54 - - 
Exacerbation , N 0.21 - - - - 1.2 - - 1.0/3.5 - 
Emergency vis, N 0.1 - - - - 0.1 - - - - 
ACT/ACQ6 21/0.8 - - - 20/- 20/- 23/- 22/- 1.0/1.8 21/0.8 
(ACQ) 
FEV1, %pred 83 86 86 80 64 98 76 100 91/87 88 
FEV1/FVC,%  69  74  74 68 81 66 - 73/68 73 
MEF50,%pred 62 - - - - - - - - 62 
FEF25-75,  %pred 57 60 60 60 43 78 44 62 - - 
FEF25-75 <LLN 68   26 - - - - - - 
 FEF25-75 
<60%pred, % 
57 54 +50 - - - - - - - 
FEV1%>80 and    
FEV1/FVC>0.7, 
% 




96 - - - 41 - - - - - 
R20, kPa/L/s 0.35 - - - - - - 0.31 0.31/0.
39 
0.37  
R20, %pred 114 - 133 
132 
137 
- - - - - - - 
R20>ULN 23.1 - - - - - - - - 30 
R5-R20, kPa/L/s 0.07 0.07 0.09 0.08 
0.12  
- - - 0.06 0.06 0.05/0.
05 
0.09 
R5-R20>ULN, % 42 - - - - - - - - 31 
R5-R20 >0.10, % 37 43                                                                                                                                - - - - - - - - 
R5-R20 =0.03, % 70 - 65 
64 
70 
- - - - - - - 
R5-R20>0.075, 
% 
33 - - - - - - 66 - - 
AX, kPa/L/s 0.62  - - - - - - - 0.41/0.
47 
0.34  
AX>LLN, % 41 - - - - - - - - 33 
X5, kPa/L/s -0.13 - - - - - -0.10 -0.11 -0.13/-
0.15 
- 
X5<LLN, % 31 - - - - - - - - - 
FRC, %pred 109             - - - 120 109 - - - - 
FRC>LLN, % 22 - - -       
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FRC>120%pred 16 - - - 37 26 - - - - 
RV, %pred 117 - - - 133 122 - - - - 
RV>LLN, % 30 - - - 43 31 - - - - 
FEV1<60%pred,
% 








15 - - -  31 - - - - 















9 - - - - 24 - - - - 
FEV1>35%pred, 
% 
49 - - - - - 52 - - - 
FEV1<60%pred 71 - - - - -  - - - 
Scond*Vt, L
-1
 0.035 - - - - - ? - 0.051/ 
0.038 
0.027 
Scond*VT,%pred 181 - - - - - 137 - - - 
Scond*VT 
>LLN, % 
30 - - - - - - - - 47 
Sacin*VT, L
-1
 0.113 - - - - - ? - 0.175/ 
0.184 
0.097 
Sacin*VT, %pred 107 - - - - - 162 - - - 
Sacin*VT >LLN, 
% 
19 - - - - - - - - 42 
Sacin*VT >0.12 45 - - - - - 100 - - - 
Legend to Supplemental Table 7. Comparison of the findings in ATLANTIS with those reported in the literature. 
*, inclusion criterion added , since this is not asthma-wide, but selected on Sacin (ref 18), or Moderate-severe 
asthma (ref 20) Ref number in top of Table refers to article results in Reference number in the Supplement. 
WO=Without, PAO= peripheral airway obstruction; M-MS= Mild to moderate severe asthma; Sev= severe 
asthma; Pred= predicted; EF=extra-fine; RSD= residual standard deviation; ICS dose = BDP equivalents per 
day, -= data not available in publication; Ref number 15 has British Thoracic Society data from BTS stage 2,3, 
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Reviewer #4: Thank you for your responses and changes to the manuscript, and apologies 
for any conflicting recommendations with the journal. Thank you for clarifying my 
understanding of these parameters. I have only a few additional points to help clarify points 
in your manuscript. 
Answer to Reviewer #4: We thank the reviewer for these suggestions and have answered 
them point-by-point below. 
 
Minor comments: 
1. Abstract: Findings: Sent 5: just say MBNW Sacin here, instead of defining it again after 
sent 2. 
Answer to comment 1: We have adjusted this as follows (crossed words were deleted): 
“Clinical-SAD Group1 (n=452) had “milder“ SAD, i.e. comparable ventilation heterogeneity 
in pre-acinar/acinar airways values (MBNW Sacin) with controls. Group2 (n=312) had more 
abnormal physiologic SAD measures than Group1, particularly IOS and spirometry, and more 
severe asthma (asthma control, treatments, exacerbations, quality of life).” 
 
2. Abstract: Interpretation: I wouldn't say these parameters contribute to SAD. For Sent 1, 
please try or edit "SAD is a complex feature of asthma, with multiple physiologic measures 
likely reflecting different disease components." I would drop the "further work is needed." I 
think it is, but I was thinking you would expand on the sentence and I agree there isn't room in 
the abstract. 
 
Answer to comment 2: We now have changed the abstract. However, we do not study 
asthma heterogeneity, but the complexity of small airway dysfunction (SAD) in asthma. It is 
impossible to get a specific regional signal from the silent zone of the lungs unfortunately. 
SAD cannot be captured by one measurement. Thus it  was the main aim of the ATLANTIS 
study to assess many physiologic measurements. Putting together all the available 
measurements we performed, we provide information about the relevant effect of small 
airway dysfunction (SAD) as assessed by IOS, MBNW, body plethysmography and 
spirometry. We have changed the sentence as follows (crossed words that were deleted and 
underlined changes), and in addition followed the comment of the Editor (please see below for 
final result): 
“SAD is a complex and silent signature of asthma, which is likely to be directly or indirectly 
captured  by combinations of physiologic tests: spirometry, body plethysmography, IOS, and 
MBNW. SAD is present across all asthma severity and particularly in severe disease. The 
clinical classification of SAD in two groups, i.e. a “milder” and “more severe” SAD group, by 
the easy-to-conduct measures IOS and spirometry, is meaningful given its association with 
GINA asthma severity stages, asthma control, quality of life, and exacerbations. Further work 
is needed 
 
3. Table 1. I think this table is great and adds a lot. I suggest adding a heading for column 2, 
such as "Interpretation".  
*Reply to Reviewers Comments
2 
 
Answer to comment 3: We now have changed the Table according to suggestions in 
the Reviewer’s Comment numbers 3-7 and added the abbreviations used in the Legend 
to the  Table 1 see Table 1 at Answer to Comment 6 from  reviewer #4  
 
4. Table 1. Would help to have a subheadings under physiologic (or instead of physiologic) 
for the clinical test the measure is from (i.e. spirometry, MBNW, IOS, methacholine 
challenge, etc.). 
Answer to comment 4; We have added these subheadings (please see Table below) 
5. Table 1. Could you add sGaw, as it is a parameter in table 4? 
Answer to comment 5: Table 4 shows the independent predictors of exacerbations in the 
Poisson Regression model and in the Supplement we wrote:   
“The relationships between lung physiology variables and healthcare consumption in 
asthmatics were analyzed using a Poisson regression model for each healthcare resource 
consumption variable. Only variables with a number of missing values approximately lower 
than 50% were considered in the analysis. The model included the healthcare resource 
consumption variable as dependent variable and all the lung physiology variables as 
independent variables. “ 
Here we thus included ALL lung physiology variables. We now have added this to the Legend 
of the Table as follows:  
“All lung physiology parameters were included in the Poisson Regression model.” 
 
6. Table 1. I think the interpretations could be more clear (most of them seem to be for small-
to-mid-sized airways), but perhaps these are just overlapping measures. Can you clarify 
whether X5 and R5-20 reflect the same level of airways (small-mid)? And AX overlaps with 
X5 (distensibility of small-mid sized airways)? 
Answer to comment 6: Thank you for pointing this out. Actually, measurements are 
overlapping as far as the regional location inside the respiratory system is concerned. 
However, each single measurement reflects different aspects or different functional effects of 
small-mid sized and / or peripheral airways physiology. For instance the mentioned 
parameters R5-R20, X5 and AX are all derived from the oscillation technique (IOS) that 
reflect SAD by different mechanism. Thus R5-R20 presents Respiratory System Resistance of 
small-to-mid-sized conductive and peripheral airways resistance, while X5 presents 
Respiratory System Reactance reflecting inertance and elasticity (capacitance) of the whole 
respiratory system including small peripheral airways; finally AX represents the distensibility 
of the peripheral lungs (parenchyma + small peripheral airways). Thus, though all show 
evidence of Small Airways Dysfunction, the mechanisms underlying this are different.  
We now have updated Table 1 to depict these aspects even more extensively: 
Physiologic parameters Interpretation 
Spirometry  
FEF25-75 (corrected for FVC), L/s/L
 13




FEF50 (corrected for FVC), L/s/L
 13
 
volumes are measurements of airflow obstruction in 
small-to-mid-caliber airways taken at low/mid 
expiratory lung volumes. 
When corrected for FVC, they are surrogate 
measures of the sizes of small-to-mid caliber airways 
relative to lung size, called dysanapsis. Dysanapsis is 
a characteristic favoring airways 
hyperresponsiveness. 
Body plethysmography  
RV/TLC ratio, L/L 
14
 Air trapping due to obstruction in both conducting 
small and peripheral airways 
FRC, L 
14
 Respiratory system resting volume as main 





 Respiratory Resistance of small-to-mid-sized 
conductive and peripheral airways  
X5, kPa/L/s 
15
 Respiratory System Reactance reflecting inertance 




 Distensibility of the peripheral lungs (parenchyma + 
small peripheral airways) 
MBNW  
Scond*VT, L
-1   16
 Index of convectional ventilation heterogeneity in 
peripheral conducting airways 
Sacin*VT, L
-1   17
 Index of diffusive ventilation heterogeneity in most 
peripheral pre-acinar/acinar airways 
Hyperresponsiveness  
Fall in FVC at PC20 or PD20, %
18,19
 Air trapping due to excessive bronchoconstriction or 
closure of small airways 
CT scan parameters  
MLD ratio, I/E 
25
 Ratio of mean lung density for inspiratory versus 
expiratory scans- a measure of air-trapping due to 
lung parenchyma inspiratory distension in the supine 
position 




 Ratio of CT-derived lung volume for inspiratory 
versus expiratory scans- a measure of air-trapping 
due to obstruction in both conducting small and 
peripheral airways in the supine position 
VI-856, HU 
21
 The voxel index < -856 Hounsfield Units from the 
expiratory scans, an index of expiratory air trapping 
 Legend to Table 1. Numbers in superscript refer to references used. IOS= impulse 
oscillometry; MBNW= Multiple breath nitrogen washout; CT= computed tomography, 
HU=Hounsfield Units 
 
7. Table 1. What are at the units for FEF25-75 units when you correct for FVC? Is it the 
proportion of exhalation spent in the mid-exhalation? These should be interpretable enough 
for others to use.  
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Answer to comment 7:  The FEF25/75 values were corrected for level of FVC in statistical 
analyses, since this impacts on the FEF25-75 values. The unit of FEF25-75 is  L/min. The 
FEF25/75 values were corrected for level of FVC in the statistical analyses, since this reflect 
the disproportionate growth between airway size and lung parenchyma that affect lung 
mechanics and airway reactivity. The FEF25-75 unit is L/s/L
 
, see Table I, where the relevant 
unit was added to each measurement according to SI unit symbols. 
 
8. Table 4. I would include at the bottom of this table that the coefficients are per 1 unit 
increase in each parameter.   
Answer to comment 8: We have added this to the Table, as the Reviewer suggested. 
9. Table 4. FEF25-75 units are really important here too, since it is per unit change 
Answer to comment 9: We now have also added units for this variable 
 
10. Table 4. Do all of these results make sense to you? More exacerbations with higher R5-
R20, higher RV/TLC ratio, lower FEF, lower Raw, lower height and females seems ok. What 
about the PC20 categories, I interpret the findings as very mild (and each category) has fewer 
exacerbations compared to normal. Are those results switched around? And in the second 
panel of results, are there really more consultations with a higher FEV1? Same comment for 
PC20 categories, they seem switched around here too.  
Answer to comment 10: When one measures hyperresponsiveness with PC20 or PD20 
values, it means that  a higher PD 20 reflects less severe hyperresponsiveness. Normal means 
that there was no hyperresponsiveness, so a very high value for PC20 or PD20.  
Individuals with a higher PC20 or PD20 have less frequent exacerbations, and conversely 
patients with lower PC20 or PD20, and thus more severe hyperresponsiveness have more 
frequent exacerbations.  
To help interpretation we now have added the following to the Legend of the Table as follows: 
“The coefficients are per 1 unit increase in each parameter. As example: the estimate of R5-
R20 (kPa/L/s) for exacerbations is 2.894, one needs to calculate exp(2.894) = 18.065 and this 
means that for 1-unit increase of R5-R20 the mean number of exacerbations will increase by a 
factor of 18.07, holding other variables constant. Mild hyperresponsiveness means a higher 
PD20 or PC20 value. Patients with more severe hyperresponsiveness have more frequent 
exacerbations and unscheduled consultations. For abbreviations see Table 2 
 
Specific comments from the editor: 
 
1* The introduction is still slightly unclear as to what is being presented in this paper, and 
what else will be covered elsewhere in the future. There also seems to be some repetition with 
the methods section. I have suggested at the end of this email a possible revised introduction 
(that could be pasted in to the article). I have moved pieces of text from the current version 
and earlier rebuttal. This is just a suggestion to attempt to clarify the project, and would need 
to be checked for accuracy, so please amend as appropriate. 
5 
 
Answer to Editor’s suggestion number 1: We thank the Editor for this suggestion and 
changing to more alike we had proposed in an earlier version. We have adjusted the 




Asthma is a prevalent obstructive airway disease that affects the entire bronchial tree. The 
small airways, defined by a diameter <2 mm and referred to as the "silent zone" of the lungs, 
contribute to the resistance in the airways of patients with obstructive airways disease
1
. This is 
of clinical importance since small airways can be inflamed in asthma and hence narrowed
2-4
. 
Small airway narrowing can also occur due to smooth muscle contraction after inhaling 
allergic and non-allergic irritants. Moreover, remodeling can affect small airway wall 




Small airways dysfunction (SAD) has been postulated to exist at all severities of asthma, 
whereas some studies suggest that the prevalence increases with asthma severity 
6,1
. However, 
it is still not clear what proportion of asthma patients suffers from SAD, and which tests or 
combination of tests best defines it. Lack of best practice is due to the fact that published 
studies investigating the small airways in asthma included only small-sized and/or relatively 





The ATLANTIS (AssessmenT of smalL Airways involvemeNT In aSthma) study is a 
multinational 1-year prospective cohort study, including people with asthma of all severities 
and controls without airway disease. In this paper we present the baseline, cross-sectional data 
from ATLANTIS, with the aiming to identify which combination of biomarkers, physiologic 
testing and imaging approaches best measures the presence and extent of SAD in asthma, and 
their relationship with features of asthma. We assess SAD through a series of all available, 
clinically applicable, potential SAD tests, both for physiological and CT measures. The 
physiological tests may reflect abnormalities in different parts of the bronchial tree or 
different aspects of small airways dysfunction, providing different perspectives on SAD
9,10
. 
Lung imaging by CT scan can provide additional insight regarding SAD, but the relationship 
with physiologic measures of SAD in asthma has not been studied extensively and only in 
small groups; here we test both physiological and CT scan measures in a large cohort. In 
addition, we develop a score defining to what extent SAD is present in each individual patient 
and assess its usefulness for prediction of asthma severity, control, quality of life and history 
of exacerbations. In future papers (not presented here), we will report the longitudinal data 
from ATLANTIS and aim to validate the SAD score over time, we will develop and validate a 
Small Airways Dysfunction Tool (SADT), a questionnaire as an easy measure to suggest 
SAD, and we will assess which direct and indirect measures of inflammation best 
discriminate between the large and small airways' compartments, with bronchial and 
transbronchial biopsies, in a smaller subset of participants.” 
 
 
2* At the last round of review, one of the reviewers requested that the strengths and 
6 
 
limitations weren't at the beginning of the section, and we would prefer this information 
comes later in the discussion. Although we use the STROBE checklist to ensure that all 
components are included, in our guidance for authors 
(http://www.thelancet.com/pb/assets/raw/Lancet/authors/tlrm-info-for-authors.pdf) we 
indicate "The Discussion section should contain a full description and discussion of the 
context." We would suggest starting with a summary of the main findings as you have done, 
followed by a section relating results to earlier work (moving text from later in the 
discussion). 
Answer to Editor’s suggestion number 2: We have followed the Editor’s suggestion and 
rearranged the Discussion as was suggested.  
 
3* A minor point, but in the first round of review, reviewer 3 raised the issue of racial 
differences. Although there are insufficient data for analyses by race, could the main 
manuscript note (in the results section describing patient characteristics), that the large 
majority of people included were white (88% and 96% in asthmatic and the control groups). 
Although this is mentioned in the supplement, it could be of interest to readers of just the 
main paper. 
Answer to Editor’s suggestion number 3: We have added the percentages as the Editor has 
suggested as follows (changes underlined):  
“Participants  
Baseline characteristics are shown in Table 2, Table 3 (asthma only) and Supplemental Table 
2. Gender, age and smoking habits were comparable between asthma and control participants; 
the large majority of people included were of Caucasian descent (88% and 96% in asthma and 
control participants respectively).  
 
General editorial comments: 
 
* Our research articles (that are not RCTs) are usually up to 3500 words with up to 30 
references, and your article is currently 4462 words with 49 references. Although we can be 
slightly flexible, and we appreciate that additions have been made to the article during the 
peer-review process as requested by reviewers, please consider these limits when making your 
final revisions before acceptance. If there is text that could be shortened, or references that 
could be removed, please change at this stage. I have suggested some cuts to the introduction 
below, and the discussion could also be an area to trim. 
 
Answer to Editor’s General comment 1: We have reduced the length of the manuscript an 
tried to reduce also the number of References. However, given the questions and suggestions 
by the reviewers, and particularly Reviewer 4 we had to add quite a few references and 
especially to Table1.  We have rewritten the Discussion, and now have reduced the number of 




* The study title should include a descriptor—ie, randomised trial, case-control study, 
prospective analysis, population-based study etc… In this case the ATLANTIS study is a 
prospective cohort study, but in this paper baseline data are being reported. Could we suggest 
a revision to the title something along the lines of: "Exploring the relevance and extent of 
small airways dysfunction in asthma: baseline data from the AssessmenT of smalL Airways 
involvemeNT In aSthma (ATLANTIS) prospective cohort study"  
 
Answer to Editor’s General comment 2: We have rephrased the Title of the manuscript as 
follows to capture the prospective cohort study as follows: 
"Exploring the relevance and extent of small airways dysfunction in asthma: baseline data 
from the AssessmenT of smalL Airways involvemeNT In aSthma (ATLANTIS) prospective 
cohort study" 
 
3* Please check with your co-authors, and confirm, that all names are spelt correctly, and 
affiliations listed correctly. We will not correct names and affiliations after publication of 
your article. 
Answer to Editor’s General comment 3: All author’s names have been spelt correctly  
 
4* Please supply (after author names on the title page) one preferred degree per author and 
indicate in the authorship if any authors are full professors. 
Answer to Editor’s General comment 4: We now have below added one preferred degree per 




, MD Prof, Brightling C
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, MD Prof,  Baldi S
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, MD Prof, Gagnatelli A
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, MD Prof, Nicolini G
5
, PhD,  Kraft M
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, MD Prof, and the ATLANTIS study group* 
5* Please give full first names for all authors:  
Answer to Editor’s General comment 5: The first names of authors are as follows:  
Postma Dirkje S
1













, Van der Molen Thys
7











 and the ATLANTIS 
study group* 
6 * Summary: We have requested additions to the abstract below. At this stage, please do not 
worry about the word length of the abstract - accuracy and completeness here are key: 
 
-Background: Please include the aim of this study in this section. 




-Interpretation: We suggest replacing 'Further work is needed' with information about the 
follow-up of the ATLANTIS study. 
 
Answer to Editor’s General comment 6: Here we have followed your suggestions and those 
of Reviewer #4 and changed the abstract as follows (changes underlined). This consequently 




Small airways dysfunction (SAD) is well-recognized in asthma, yet its role in asthma severity 
and asthma control is unclear. Our study aimed to assess which (combination of) biomarkers, 
physiological testing and imaging markers best measures the presence and extent of SAD in 
asthma. 
Methods 
This multinational observational study investigated participants without and with asthma 
(GINA severity stage 1-5). Asthma inclusion criteria were: 1) age 18-65 years; 2) clinical 
asthma diagnosis  > 6 months, confirmed by a chest physician 2, supported by objective 
evidence of any of the following at the baseline visit or in the previous 5 years: a) positive 
airway hyperresponsiveness to methacholine, or b) positive reversibility (ΔFEV1≥ 12% and ≥ 
200 mL within 30 minutes after 400 μg of salbutamol pMDI with or without a spacer or c) 
PEF variability >20%, measured during 7 days or d) documented reversibility after a cycle 
(e.g. 4 weeks) of maintenance anti-asthma treatment; 3) stable asthma on any previous regular 
asthma treatment (“rescue” β2-agonists alone included) at a stable dose for > 8 weeks before 
baseline; 4) lifetime smoking ≤ 10 pack-years. They underwent spirometry, body 
plethysmography, impulse oscillometry (IOS), Multiple Breath Nitrogen Washout (MBNW), 
computed tomography (CT) and questionnaires. Structural equation modeling (SEM) was 
applied in asthma to assess the contribution of all physiological and CT parameters to SAD. 
With SEM, we  defined a clinical-SAD and CT-SAD score. Asthma subjects were classified 
in SAD groups using model-based clustering. Asthma severity, control and health care 
utilization in the past year were compared with the SAD scores and SAD groups.  
Findings  
We investigated 773 asthma and 99 control participants (median [interquartiles] age 46 [34, 
54] and 41 [29, 52] years, 58% and 57% females, respectively). All physiologic measures 
contributed to the clinical SAD model with SEM analysis. The prevalence of SAD in asthma 
was dependent on the measure used and lowest with MBNW Sacin that reflects ventilation 
heterogeneity in the most peripheral, pre-acinar/acinar airways. IOS and spirometry, reflecting 
dysfunction of small-to-mid-sized airways, contributed most to the Clinical-SAD score and 
differentiated the two SAD Groups. Clinical-SAD Group1 (n=452) had “milder“ SAD, i.e. 
comparable ventilation heterogeneity in pre-acinar/acinar airways values (MBNW Sacin) with 
controls. Group2 (n=312) had more abnormal physiologic SAD measures than Group1, 
particularly IOS and spirometry, and more severe asthma (asthma control, treatments, 
exacerbations, quality of life). Clinical-SAD scores were higher in Group2 (“more severe” 
SAD) and related to asthma control, severity, and exacerbations. Clinical-SAD and CT-SAD 




SAD is a complex and silent signature of asthma, which is likely to be directly or indirectly 
captured  by combinations of physiologic tests: spirometry, body plethysmography, IOS, and 
MBNW. SAD is present across all asthma severity and particularly in severe disease. The 
clinical classification of SAD in two groups, i.e. a “milder” and “more severe” SAD group, by 
the easy-to-conduct measures IOS and spirometry, is meaningful given its association with 
GINA asthma severity stages, asthma control, quality of life, and exacerbations. The 
longitudinal part of ATLANTIS will show the relevance of the SAD score for future risks in 
asthma, and additionally which parameter best associates with future asthma control. 
Moreover, we will report on development of a Small Airways Dysfunction Tool (SADT), a 
questionnaire as an easy measure to suggest SAD, and on the measures of inflammation that 
best discriminate between the large and small airways’ compartments, with bronchial and 
transbronchial biopsies, in a smaller subset of participants. 
 
7 * You've noted in your rebuttal that your article confirms to the STROBE guidance, and we 
ask authors to complete this checklist and submit it with their revised article. Please complete 
the checklist, available here:  
STROBE - Observational studies — 
http://www.thelancet.com/journals/lancet/article/PIIS0140-6736(07)61602-X/fulltext 
For more info: http://www.equator-network.org/ 
Answer to Editor’s General comment 7:  We have inserted the Strobe table below and have 
added all pages. NA means Not Applicable 
Table The STROBE statement—checklist of items that should be addressed in reports of 
observational studies  
 




Title and abstract  
   
 
1 
(a) Indicate the study's design with 
a commonly used term in the title 
or the abstract 
Page1  
  
(b) Provide in the abstract an 
informative and balanced 
summary of what was done and 
what was found  
Page 3 
Introduction  
   








and rationale for the investigation 
being reported 
Objectives 3 
State specific objectives, including 
any prespecified hypotheses 
Pages 7-8 
Methods  
   
Study design 4 
Present key elements of study 
design early in the paper 
Pages 7-8  
Setting 5 
Describe the setting, locations, and 
relevant dates, including periods 
of recruitment, exposure, follow-
up, and data collection  
Page 9 
Participants 6 
(a) Cohort study—give the 
eligibility criteria, and the sources 
and methods of selection of 




Case-control study—give the 
eligibility criteria, and the sources 
and methods of case ascertainment 
and control selection. Give the 
rationale for the choice of cases 
and controls  
NA 
  
Cross-sectional study—give the 
eligibility criteria, and the sources 












studies, give matching criteria and 
number of exposed and unexposed  
  
Case-control study—for matched 
studies, give matching criteria and 
the number of controls per case  
NA 
Variables 7 
Clearly define all outcomes, 
exposures, predictors, potential 
confounders, and effect modifiers. 
Give diagnostic criteria, if 
applicable  







For each variable of interest give 
sources of data and details of 
methods of assessment 
(measurement). Describe 
comparability of assessment 
methods if there is more than one 
group  
Pages 9,10 and 
supplement 
Bias 9 
Describe any efforts to address 
potential sources of bias 
Page 9 
Study size 10 
Explain how the study size was 
arrived at 
Supplement 
Quantitative variables 11 
Explain how quantitative variables 
were handled in the analyses. If 
applicable, describe which 
groupings were chosen, and why  
Page 11 and 
Supplement 
Statistical methods 12 
(a) Describe all statistical 
methods, including those used to 
control for confounding 










(b) Describe any methods used to 
examine subgroups and 
interactions 
Page 11 and 
Supplement 
  
(c) Explain how missing data were 
addressed 
Reference 25, 
and Page 11, and 
Page 9 of 
Supplement 
  
(d) Cohort study—if applicable, 




Case-control study—if applicable, 
explain how matching of cases and 




applicable, describe analytical 
methods taking account of 
sampling strategy  
All data were 
used at baseline, 
Supplement 
  








(a) Report the numbers of 
individuals at each stage of the 
study—eg, numbers potentially 
eligible, examined for eligibility, 
confirmed eligible, included in the 











(b) Give reasons for non-
participation at each stage 
Figure 1 
  
(c) Consider use of a flow diagram 
 
Descriptive data 14 
*
  
(a) Give characteristics of study 
participants (eg, demographic, 
clinical, social) and information on 
exposures and potential 
confounders  
Page 12, Tables 




(b) Indicate the number of 
participants with missing data for 
each variable of interest 
Figures 2 and 5, 
and Supplement 
  
(c) Cohort study—summarise 
follow-up time (eg, average and 
total amount)  
NA 
Outcome data 15 
*
  
Cohort study—report numbers of 
outcome events or summary 




numbers in each exposure 





numbers of outcome events or 
summary measures  
Figures 2 and 5 
and Supplement 
Main results 16 
(a) Give unadjusted estimates and, 
if applicable, confounder-adjusted 
estimates and their precision (eg, 









95% confidence interval). Make 
clear which confounders were 
adjusted for and why they were 
included  
  
(b) Report category boundaries 




(c) If relevant, consider translating 
estimates of relative risk into 
absolute risk for a meaningful time 
period  
NA 
Other analyses 17 
Report other analyses done—eg, 
analyses of subgroups and 
interactions, and sensitivity 
analyses  
Page 11, Page 15 
Discussion  
   
Key results 18 
Summarise key results with 
reference to study objectives 
Page 17 
Limitations 19 
Discuss limitations of the study, 
taking into account sources of 
potential bias or imprecision. 
Discuss both direction and 
magnitude of any potential bias  
Pages 18 and 19 
Interpretation 20 
Give a cautious overall 
interpretation of results 
considering objectives, limitations, 
multiplicity of analyses, results 
from similar studies, and other 










Discuss the generalisability 
(external validity) of the study 
results 
Page 17 
Other information  
   
Funding 22 
Give the source of funding and the 
role of the funders for the present 
study and, if applicable, for the 
original study on which the 
present article is based  
Page 12 
* Give such information separately for cases and controls in case-control studies, and, if 
applicable, for exposed and unexposed groups in cohort and cross-sectional studies. An 
explanation and elaboration article discusses each checklist item and gives 
methodological background and published examples of transparent reporting. The 
STROBE checklist is best used in conjunction with this article (freely available on the 
websites of PLoS Medicine, Annals of Internal Medicine, and Epidemiology). Separate 
versions of the checklist for cohort, case-control, and cross-sectional studies are 
available on the STROBE website.  
 
8 * Please report means with SDs (e.g. mean SAD score, mean age in discussion). 
 
Answer to Editor’s General comment 8: We now have adjusted the Discussion and report 
means accompanied by SD values and medians with interquartile ranges. 
 
9* Lancet style is to provide p values to two significant figures, unless p<0.0001 (if this is the 
case, then please revise to the latter). You need only give the p-value to 2 decimal places for 
non-significant results (ie p=0.87). 
Answer to Editor’s General comment 9: We have followed the suggestions of the Editor. 
However, when reading Lancet Respiratory Medicine articles, we noted that many of them 
show figures with three significant numbers, being 0.057 for instance . We wondered whether 
the p<0.0001 instead was p< 0.001? It is important to know if significances are extremely 
significant or borderline. And we agree that hence it is sufficient to have two significant 
numbers. Thus, we changed accordingly 0.057 into 0.06, and 0.029 in 0.03. However, this is 
not the case for values like  0.001 and 0.002. We now have adjusted throughout the 
manuscript all Tables and changed all other numbers to two significant values if < 0.001.  
We have also changed this in the Supplemental Tables.  
16 
 
We hope that this is what Lancet Respiratory Medicine wishes and so the readers can 
interpret our data.  
10 * As I am sure you are aware, the Lancet group are very supportive of protocol-based 
research and so encourage authors to post the protocol document on a publicly accessible 
website; a margin link to the website will then be put in the paper. Would you like to do this 
for your protocol? Perhaps the link to the ERJ paper? If so, please send us the protocol link 
with your final corrections. Please note that if you do wish to do this then the weblink should 
not be temporary. 
Answer to Editor’s General comment 10: 
We hereby provide a link to the paper in the ERJ. 
https://www.ncbi.nlm.nih.gov/pubmed/26028618, and we had already provided a Link to the 
full study, as follows 
 https://clinicaltrials.gov/ct2/show/NCT02123667?term=NCT02123667&rank=1 
We hope this is what Lancet Respiratory Medicine is needing 
 
* Lancet style is to have a 'Role of the funding source' at the end of the methods. The 
following points need to be addressed in the "Role of the funding source" statement: 
 
* The role of the sponsors in the study design. 
 
* The role of the sponsors in the collection, analysis, or interpretation of the data. 
 
* The role of the sponsors in the writing of the report. 
 
* Those who had access to the raw data (by author initials). If the funding source had no role 
then this should be stated. Please also add to this section (if true): "The corresponding author 
had full access to all of the data and the final responsibility to submit for publication." 
 Answer to Editor’s General comment 10: 
We now have added the following after the Methods section:  
Role of the Funding source   
Chiesi Farmaceutici SpA financed the study, contributed to the set-up of the study which was 
designed by DP, MK, CB, MvdB, LF, AP, TvdM, KR, SS and DS. Chiesi Farmaceutici SpA 
contributed to interpretation of the study and approved the submitted manuscript. Data 
collection and management was done by Cromsource and data were analysed by CROS NT. 
All co-authors discussed and interpreted the data. The first draft of the report was written by 
DP, CB and MK; DP collated input from all co-authors. DP and MK had access to raw data. 
The corresponding author had full access to all of the data and the final responsibility to 
submit the initial and revised manuscript. 
 
11* At the beginning of the methods section, please give the exact dates here (if known)—ie, 
day, month, year.  
Answer to Editor’s General comment 11: We now have added this as follows: 
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“Participants were recruited (first patient in June 30, 2014 and last patient out March 3, 2017) 
from general practitioners, chest physician’s databases and by advertisements in 29 centers 
across 9 countries worldwide.” 
12* In the Research in context section, 'Evidence before this study', please include a 
description of all the evidence that the authors considered before undertaking this study. 
Authors should state: the sources (databases, journal or book reference lists, etc) searched; the 
criteria used to include or exclude studies (including the exact start and end dates of the 
search), which should not be limited to English language publications; the search terms used; 
the quality (risk of bias) of that evidence; and the pooled estimate derived from meta-analysis 
of the evidence, if appropriate. 
 
Answer to Editor’s General comment 12: We now have added the following to the Research 
in Context section: 
“We searched PubMed for studies in asthma, including the terms asthma, adult, and small 
airways, and published between database inception and April 2018, using spirometry and any 
combination of body plethysmography, impulse oscillometry (IOS; including R5-R20 values) 
and Multiple Breath Nitrogen Washout (MBNW) measures, and similar terms in addition to 
CT scans.” 
 
13 * ICMJE Conflicts of Interest form: We have received all forms except from Dr Siddiqui. 
Answer to Editor’s General comment 13: We now have added the form with the name on it. 
 
14* Please ensure there is a conflict of interest statement to the end of your paper, as per 
Lancet style. These statements should exactly match those given on your signed conflict of 
interest forms. If there are none then please state "The authors declared no conflicts of 
interest" or "The other authors declared no conflicts of interest." 
Answer to Editor’s General comment 14: We have now added the following text after the 
Discussion section as follows: 
Declaration of interest 
D.P. reports that the University of Groningen has received money regarding a research grant 
from Astra Zeneca, Chiesi, Genentec, GSK and Roche, regarding consultancies from Astra 
Zeneca, Chiesi, and GSK, outside the submitted work. CB reports grants and personal fees 
from Chiesi, grants from AirPROM,  during the conduct of the study; grants and personal fees 
from GlaxoSmithKline, AstraZeneca/Medimmune, Boehringer Ingelheim, Novartis, Chiesi, 
Roche/Genentech, personal fees from Vectura, Theravance, PreP, Gilead, Sanofi/Regeneron 
Teva, grants from Pfizer and Mologic, personal fees from Gossamer and 4DPharma,  outside 
the submitted work. SB reports personal fees from Chiesi SAS FRANCE,  during the conduct 
of the study; personal fees from employment, outside the submitted work.  MvdB reports 
research grants paid to University from Chiesi, Teva Pharma, GlaxoSmithKline,  outside the 
submitted work. LF reports personal fees, non-financial support and other from Chiesi 
Farmaceutici,  during the conduct of the study; grants, personal fees and non-financial support 
from Boehringer Ingelheim, Chiesi Farmaceutici, GlaxoSmithKline, Merck Sharp & Dohme, 
Takeda, AstraZeneca, Novartis,Menarini; personal fees and non-financial support from Pearl 
Therapeutics and Mundipharma ,personal fees from Zambon,  outside the submitted work. 
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AG and GN report employment by Chiesi Farmaceutici S.p.A. which sponsored the study. AP 
reports grants and personal fees from Chiesi Pharmaceuticals, during the conduct of the study; 
grants, personal fees, non-financial support and other from Chiesi, Astrazeneca, 
GlaxoSmithKline, Boehringer Ingelheim, Mundipharma and personal fees and non-financial 
support from Menarini, Pfizer, Novartis, Zambon, outside the submitted work. TvdM reports 
grants and personal fees from Astra Zeneca, TEVA, GSK, personal fees from Boehringer 
Ingelheim, outside the submitted work;  and From 1 June 2017 T van der Molen is a part-time 
employee of GSK. KR reports personal fees from AstraZeneca, Boehringer Ingelheim, 
Novartis, Sanofi, Teva, Intermune, Chiesi Pharmaceuticals, Berlin Chemie and grants from 
Ministry of Education and Science, Germany outside the submitted work. SS reports grants 
from Chiesi onulus foundation, Sir Jule Thorne Trust, Medical Research Council/EPSRC 
NAPP, NIHR UK, and personal fees from AZ, GSK, Boehringer Ingelheim, Novartis, 
Mundipharma, Owlstone,  outside the submitted work. D Singh reports grants and personal 
fees from Chiesi, AstraZeneca, Boehringer Ingleheim, GlaxoSmithKline, Glenmark, Merck, 
Menarini, Mundipharma, Novartis, Peptinnovate, Pfizer , Pulmatrix,  and personal fees from 
Cipla, Apellis, Genentech, Skyepharma, Teva, Therevance, and Verona,  outside the 
submitted work. MK reports grants from NIH, Chiesi, Sanofi, personal fees from Elsevier, 
during the conduct of the study. 
 
 
15 * Authorship forms: We have received all forms except from Dr Siddiqui. 
Answer to Editor’s General comment 15: We now have added the form with the appropriate 
name. 
 
16 * Please ensure there is an Author contributions section to the end of your paper before the 
references, as per Lancet style. These statements should exactly match those given on your 
signed forms. Authors should be referred to by their initials in this section 
Answer to Editor’s General comment 16: We now have added the following:  
“Contributors  
DP, MK, CB, MvdB, LF, AP, TvdM, KR, SS and DS designed the study. DP, MK, CB, 
MvdB, LF, GA, AP, TvdM, KR, SS, NG and DS discussed and interpreted the data. The first 
draft of the paper was written by DP, CB and MK; DP collated input from all co-authors who 
reviewed all versions of the manuscript. DP and MK had access to raw data. The 
corresponding author had full access to all of the data and the final responsibility to submit 
the initial and revised manuscript.” 
17 * All web references should have the date they were last accessed (e.g. ref 11). 
Answer to Editor’s General comment 17: We have added the date of last access to references 
with web sites. 
 
18* Please supply figures in an editable format, such as high-resolution EPS format. Where 
applicable please export directly from your statistical package if possible. 
Answer to Editor’s General comment 18: we have submitted all figures as appropriate.  
 
19 * It is not Lancet policy to edit or style supplementary material for the web; however, this 
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material will still be hosted on our website as a pdf of the author supplied file. Please style 
your supplementary material as per the guidelines found at 
http://www.thelancet.com/pb/assets/raw/Lancet/authors/tlrm-info-for-authors.pdf. Please note 
that we will be unable to correct any errors in the webappendix following publication; as 
such, please check carefully when submitting. Please supply the webappendix as a single PDF 
file, with the pages paginated. 
Answer to Editor’s General comment 19: We have provided an accurate Supplemental file 
with pages numbered.  
 
20 * It is not TLRM policy to include investigator lists in the main paper; instead, these will 
be published in an online appendix that is linked to the paper. Please move the list to the 
appendix. 
Answer to Editor’s General comment 20:  We have deleted the list of investigators from the 
main paper as requested and added it in the Supplement.  
21 * If you would like the contributors from the ATLANTIS study group to be included in 
PubMed, we're now required to supply a separate list of the group members in a specific 
format if we want these names to be shown on PubMed. (This is in addition to the list of 
names and affiliations required by the journal to be listed at the end of the paper or in the 
appendix.) If relevant, to ensure that the information we supply to PubMed is accurate and 
complete, please upload with your revision a list of all study group members whose names 
should appear on PubMed, presented as a two-column table in Word. First and middle names 
or initials should be placed in the first column, and surnames in the second column. Names 
should be ordered as you wish them to appear on PubMed. The table will not be included in 
the paper itself - it's simply used to make sure that PubMed adds the names correctly. 
 
Answer to Editor’s General comment 21: The list of collaborators for PubMed is as 
follows: 
name surname 
Emilio  Pizzichini 
Alberto Cukier 
Rafael  Stelmach 
Ronald Olivenstein 
Qingling  Zhang 
Philipp  Badorrek 
Christian Gessner 
Nicola  Scichilone 
Alfredo   Chetta 
Pierluigi   Paggiaro 
Stefano   Milleri 
Mariella  D'Amato 
Antonio  Spanevello 
Maria Pia  Foschino 
Willem Germen  Boersma 
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Marielle  Broeders 
J.Sebastiaan  Vroegop 
Vicente  Plaza Moral 
Ratko  Djukanovic 
Omar  Usmani 
Robert  Schilz 
Richard Martin 
Nicola Hanania 
  Answer to Suggested edits to the introduction: 
We have changed the introduction as little as possible and only changed where clarity was 
needed. The changes from the text provided have been underlined.  
 
“Asthma is a prevalent obstructive airway disease that affects the entire bronchial tree. The 
small airways, defined by a diameter <2 mm and referred to as the "silent zone" of the lungs, 
contribute to the resistance in the airways of patients with obstructive airways disease
1
. This is 
of clinical importance since small airways can be inflamed in asthma and hence narrowed
2-4
. 
Small airway narrowing can also occur due to smooth muscle contraction after inhaling 
allergic and non-allergic irritants. Moreover, remodeling can affect small airway wall 




Small airways dysfunction (SAD) has been postulated to exist at all severities of asthma, 
whereas some studies suggest that the prevalence increases with asthma severity 
6,1
. However, 
it is still not clear what proportion of asthma patients suffers from SAD, and which tests or 
combination of tests best defines it. Lack of best practice is due to the fact that published 
studies investigating the small airways in asthma included only small-sized and/or relatively 





The ATLANTIS (AssessmenT of smalL Airways involvemeNT In aSthma) study is a 
multinational 1-year prospective cohort study, including people with asthma of all severities 
and healthy controls without airway disease. In this paper we present the baseline, cross-
sectional data from ATLANTIS, aiming to identify which combination of biomarkers, 
physiologic testing and imaging approaches best measures the presence and extent of SAD in 
asthma, and their relationship with features of asthma. We assess SAD through a series of all 
available, clinically applicable, potential SAD tests, both for physiological and CT measures. 
The physiological tests may reflect abnormalities in different parts of the bronchial tree or 
different aspects of small airways dysfunction, providing different perspectives on SAD
9,10
. 
Lung imaging by CT scan can provide additional insight regarding SAD, but the relationship 
with physiologic measures of SAD in asthma has not been studied extensively and only in 
small groups; here we test both physiological and CT scan measures in a large cohort. 
In addition, we develop a score defining to what extent SAD is present in each individual 
patient and assess its usefulness for prediction of asthma severity, control, quality of life and 
history of exacerbations. In future papers (not presented here), we will report the longitudinal 
data from ATLANTIS and aim to validate the SAD score over time, we will develop and 
21 
 
validate a Small Airways Dysfunction Tool (SADT), a questionnaire as an easy measure to 
suggest SAD, and we will assess which direct and indirect measures of inflammation best 
discriminate between the large and small airways' compartments, with bronchial and 
transbronchial biopsies, in a smaller subset of participants
9.“ 
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